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ABSTRACT 
Natalie S. Holman: Investigating the role of hepatocyte-derived exosomes in drug-induced 
liver injury 
(Under the direction of Edward LeCluyse and Paul Watkins) 
 
 Drug-induced liver injury (DILI) is the primary cause of acute liver failure in the 
United States and is responsible for a substantial number of drug failures both pre- and post-
market.  Over 1,000 drugs have been associated with DILI and as a result, understanding the 
mechanisms of toxicity has proved extremely difficult.  A common theme across 
mechanisms is the involvement of the immune system in the etiology, exacerbation, or 
resolution of DILI.  It has become apparent that events at the hepatocyte level prior to cell 
death may influence immune responses and mediate the outcome of DILI.  Hepatocyte-
derived exosomes (HDE) may constitute one such immunomodulatory signal.  HDE are 
constitutively released lipid-bound particles that have the unique ability to pass through 
fenestrations in the sinusoidal endothelium and enter the systemic circulation, potentially 
delivering stress signals to local and distal immune cells.  The current research sought to 
establish HDE as mediators of early immune responses in the absence of overt DILI.  We 
present a comprehensive analysis of the kinetics, content, and immunologic activity of HDE 
from primary hepatocytes stressed by sub-toxic drug exposures.  To our knowledge, this is 
the first report of content profiling and functional analysis using primary human HDE in the 
context of DILI.  Studies in rats, rat hepatocytes, and human hepatocytes exposed to the 
prototypical hepatotoxicant acetaminophen (APAP) verified changes in the RNA content of 
HDE prior to overt injury.  Next, HDE from control- and APAP-treated primary human 
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hepatocytes were collected for content profiling and functional analysis.  The global profiles 
of mRNA and miRNA in HDE shifted as a result of drug exposure.  Lastly, the immunologic 
activity of HDE was examined by exposing monocytes to HDE from control- and APAP-
treated primary human hepatocytes.  Differential gene expression in pathways related to 
immune cell function and cholesterol metabolism were observed.  Functionally, APAP HDE 
exposure resulted in sensitization of monocytes to LPS stimulation.  miRNA profiles in 
APAP HDE suggested that monocyte gene expression may have been mediated directly by 
exosomal miRNA.  These results demonstrate that HDE influence immune cells before overt 
hepatotoxicity and highlight the mechanistic relevance of HDE in mediating DILI outcomes.
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CHAPTER 1.   
 
INTRODUCTION 
 
 
1.1  Overview 
Drug-induced liver injury (DILI) is the primary cause of acute liver failure in the 
United States and Europe (Bernal et al., 2010; Ostapowicz et al., 2002; Wilke et al., 
2007).  It remains a major problem in drug safety, impacting patients, physicians and the 
pharmaceutical industry.  Many of the most serious clinical DILI reactions are 
idiosyncratic and poorly understood. To prevent DILI and reduce patient harm, a greater 
understanding of the pharmacological mechanisms that underlie DILI is needed.  
Growing evidence suggests that while an initial response begins at the hepatocyte level, 
communication with the immune system is essential for propagating both dose-dependent 
(intrinsic) and idiosyncratic DILI (I-DILI) reactions.  We hypothesize that extracellular 
vesicles (EVs) called exosomes carry signals from stressed hepatocytes that modulate 
these early immune reactions.  Exosomes are small (<150 nm) lipid bilayer-bound 
particles formed and secreted via the endolysosomal pathway as a means of cell-cell 
communication.  Hepatocyte-derived exosomes (HDE) are capable of signaling locally 
and systemically, as they are small enough to diffuse into the circulation through 
fenestrations unique to the sinusoidal endothelium.  HDE are constitutively released and 
thus present in biofluids such as plasma under basal conditions, but their abundance and 
 2 
 
content are altered in overt DILI (Wetmore et al., 2010).  HDE contents include proteins 
and lipids, but the most well-studied alterations are those of HDE RNAs.  The possible 
mechanisms of exosomal communication are vast, and include antigen presentation, 
receptor-mediated signaling, and the transfer of functional genetic material such as 
mRNA and miRNA (McKelvey et al., 2015).   
Studies have recently shown that HDE directly regulate innate and adaptive 
immune cell responses during liver disease.  HDE influence adaptive immunity in the 
content of hepatitis C (HCV) infection (Dreux et al., 2012; Harwood et al., 2016), while 
models of non-alcoholic steatohepatitis (NASH) and alcoholic liver injury have identified 
a role for HDE in promoting innate immune cell responses (Hirsova et al., 2016; Kakazu 
et al., 2015; Momen-Heravi et al., 2015a; Verma et al., 2016).  Based on the 
immunomodulatory activity of HDE in other contexts and the plasticity of their content, 
we hypothesize that HDE carry signals of drug-induced hepatocellular stress to the 
immune system prior to overt hepatotoxicity, and that this communication may 
ultimately influence the outcome of DILI.   
The field of exosome research is relatively new, and as a result, little has been 
done to investigate the role of HDE in DILI.  The majority of studies have focused on 
HDE as biomarkers of liver injury.  The present research addressed a novel subject and 
required considerable optimization of methods for HDE analysis.  Therefore, it was 
necessary to select a model hepatotoxic drug with well-defined and reproducible toxicity 
profiles in rats, rat hepatocytes, and human hepatocytes.  To induce hepatocellular stress 
for the purposes of studying HDE release, the prototypical intrinsic hepatotoxicant 
acetaminophen (APAP) was selected.   
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To substantiate the role of HDE in early DILI events, three Specific Aims were 
pursued.  In Aim 1, we sought to establish whether HDE could signal to the immune 
system prior to overt cytotoxicity by defining alterations in HDE following APAP-
induced hepatocellular stress.  The effects of APAP on specific RNA content and 
quantity of HDE were determined in vivo and in vitro using rats, primary rat hepatocytes, 
and primary human hepatocytes.  Aim 2 incorporated next-generation sequencing 
techniques for global mRNA and miRNA profiling on primary human HDE to define 
differential RNA enrichment in APAP HDE across multiple donors.  In Aim 3, the 
immunomodulatory effects of HDE from control- and APAP-treated primary human 
hepatocytes on THP-1 monocytes were examined by cytokine release and gene 
expression analysis.  Differential gene expression in monocytes was correlated to 
increases in specific HDE miRNAs in an effort to identify miRNAs that could potentially 
be responsible for the biological effects of HDE. 
These data provide the first report of immunomodulation by primary human HDE 
and define for the first time their mRNA and miRNA content under control and APAP-
stressed conditions.  By informing the human relevance of HDE in intrinsic DILI, this 
work will facilitate evaluation of HDE as a means to predict and explain mechanisms of 
I-DILI. 
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1.2  Drug-induced liver injury 
DILI is the primary cause of liver failure in the United States and Europe (Bernal 
et al., 2010; Ostapowicz et al., 2002; Wilke et al., 2007).  It is a common adverse effect 
caused by drugs, due largely to the first-pass metabolism of orally administered 
compounds and the high metabolic activity of the liver.  DILI is categorized as direct or 
intrinsic when the toxicity is dose-dependent and readily reproduced pre-clinically (Bass 
and Ockner, 1996).  These reactions are often identified early in development and 
frequently result in abandonment of the drug candidate.  However, the most problematic 
clinically relevant adverse liver reactions are idiosyncratic in nature, occurring on the 
order of 1 in 10,000 patients taking a drug within the therapeutic range (Fontana, 2014).  
Symptoms may not manifest for months and may still occur following cessation of 
treatment (Fontana, 2014).  I-DILI reactions are often severe, and may result in liver or 
multi-organ failure, cerebral edema, and even death (Ostapowicz et al., 2002; Ulrich, 
2007).  Such rare cases can lead to the withdrawal of approved drugs, making beneficial 
treatments unavailable to patients.  As a result, DILI is responsible for a significant 
number of pre-and post-market drug failures. 
Identification of underlying mechanisms has proved especially difficult as DILI 
has been associated with hundreds of drugs that elicit a broad spectrum of injuries (Bass 
and Ockner, 1996; Hussaini and Farrington, 2014).  Differential diagnosis is hampered by 
the fact that DILI patients often remain asymptomatic until injury is extensive, and 
pathologic presentation of DILI is often indistinguishable from other liver diseases (Bass 
and Ockner, 1996; FDA CDER, 2009).  In order to prevent DILI, a greater understanding 
of the cellular mechanisms that underlie intrinsic and idiosyncratic DILI is imperative. 
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1.3  Exosomes and extracellular vesicles 
 EVs are defined as sub-micron sized membrane-bound particles released from 
cells both actively and passively under various conditions.  EVs were first discovered in 
1946 in a study of clotting disorders (Chargaff and West, 1946) and were, for decades to 
follow, dismissed as cellular debris or “platelet dust” (Siekevitz, 1972; Wolf, 1967).  It is 
not surprising that EVs were discovered in coagulation and platelet studies, because 
platelets are the most abundant source of circulating EVs in plasma (Aryani and Denecke, 
2016).  Although once classified as debris, EVs are now recognized as critical 
participants in intercellular communication.   EVs play a role in paracrine and juxtacrine 
signaling by transporting cell-specific contents including protein, microRNA, and mRNA 
to recipient cells locally and systemically.  EVs are separated into three classes: 
exosomes, microvesicles, and apoptotic bodies, based upon cellular biogenesis, size, and 
molecular content (Table 1.1) (Andaloussi et al., 2013; Gyorgy et al., 2011; Raposo and 
Stoorvogel, 2013).  The relatively new field of EV research is plagued with 
inconsistencies in EV definition and nomenclature.  For the purposes of this dissertation, 
exosomes are defined as small EVs (< 150 nm in diameter) secreted through the 
endolysosomal pathway that are enriched for proteins involved in formation of 
multivesicular bodies and exocytosis (Table 1.1).  Exosomes are considered the most 
homogeneous class of EVs based on their size and enrichment profile.  Microvesicles are 
a relatively heterogeneous class of EV that range from approximately 100 to 1,000 nm 
and are produced by outward blebbing of the plasma membrane (Table 1.1).  Lastly, 
apoptotic bodies are those cellular fractions produced during apoptosis ranging from 1-5 
µm and containing organelles as well as DNA (Table 1.1).
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Table 1.1 Classes of extracellular vesicles.  Approximate size, origin, and enriched molecule data were obtained from multiple 
publications to present a field consensus (Andaloussi et al., 2013; Gyorgy et al., 2011; Raposo and Stoorvogel, 2013).    
 
 
 
 
  
 
EV Class Approximate Size (nm) Subcellular Origin Enriched Markers Typical Contents
Exosomes 40-150
(relatively homogeneous)
Endolysosomal pathway/multivesicular 
bodies
Tetraspanins
ESCRT  components
Flotillin
mRNA, microRNA, non-
coding RNA, ctyoplasmic and 
membrane proteins, MHC 
molecules
Microvesicles 100-1,000
(heterogeneous)
Membrane budding Integrins
External 
phosphatidylserine
mRNA, microRNA, non-
coding RNA, proteins, surface 
receptors
Apoptotic Bodies 1,000-5,000 Apoptotic cell membrane blebbing DNA DNA, subcellular fractions, 
organelles
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In vivo and in vitro research demonstrates that EVs are released from most 
mammalian cell types, including those of the human airway (Kesimer et al., 2009), 
immune system (Wahlgren et al., 2012), central nervous system (Faure et al., 2006), stem 
cells (Ratajczak et al., 2006), and tumor cells (Harris et al., 2015).  As such, EVs have 
been detected in virtually all biofluids including blood (Caby et al., 2005), semen 
(Vojtech et al., 2014), urine (Pisitkun et al., 2004), breast milk (Admyre et al., 2007), 
saliva (Ogawa et al., 2011), ascites (Andre et al., 2002), amniotic fluid (Asea et al., 
2008), bile (Masyuk et al., 2010), bronchoalveolar lavage fluid (Torregrosa Paredes et 
al., 2012), and cerebrospinal fluid (Vella et al., 2007). 
While exosomes and microvesicles are released constitutively, their content is 
highly regulated by the status of the parent cell.  It follows that research has uncovered 
their ability to mediate myriad physiological and pathological processes, including tissue 
repair (Gatti et al., 2011), cell fate and phenotype (Aliotta et al., 2007), coagulopathy 
(Hisada et al., 2016), metastasis (Bigagli et al., 2016), viral transmission (Bukong et al., 
2014), and immune function (Dreux et al., 2012).  Their biological activity is attributed to 
receptor-mediated signaling (Taylor et al., 2003), antigen presentation (Raposo et al., 
1996), and the ability to horizontally transfer cargo including mRNA and microRNA 
(Valadi et al., 2007), protein (Ratajczak et al., 2006), viral particles (Izquierdo-Useros et 
al., 2009), and receptors (Al-Nedawi et al., 2008) to recipient cells via fusion or 
endocytic mechanisms (McKelvey et al., 2015; Mulcahy et al., 2014) (Figure 1.1).  The 
current research tests the hypothesis that HDE carry signals of drug-induced stress to 
immune cells, promoting immune response prior to overt cytotoxicity, and that the 
transfer of exosomal miRNA is in part responsible for these biological effects. 
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Figure 1.1.  Mechanisms of exosome formation and uptake. Exosome biogenesis in source 
cell (blue) via multivesicular bodies and the endolysosomal pathway. This process can produce 
exosomes carrying receptors with the same outward orientation as in the plasma membrane. 
Exosomes can exert biological effects on recipient cells (green) through numerous molecular 
mechanisms, including endocytosis, fusion, and receptor-mediated signaling. Figure modified 
from (McKelvey et al., 2015). 
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1.3.1  Exosomes mediate heterotypic hepatocellular communication 
The liver is a structurally complex and physiologically diverse organ comprised of 
many cell types that fall into 2 categories: parenchymal (hepatocytes) and non-parenchymal 
cells (NPCs).  Hepatic NPCs include sinusoidal endothelial cells (SECs; specialized high-
permeability capillary lining), Kupffer cells (KCs; resident macrophages), cholangiocytes 
(biliary epithelial cells), stellate cells (pericytes), and various stem cell compartments.  While 
much exosome research to date has focused on the biomarker potential of EVs and exosomes 
in various liver diseases, EVs and exosomes are now recognized as key mediators of 
interactions between hepatic and extra-hepatic cells.  For example, in hepatitis C (HCV) and 
B (HBV) viral infection, SECs secrete exosomes that impart protective anti-viral activity to 
hepatocytes (Giugliano et al., 2015; Li et al., 2013).  These SEC exosomes also help to 
control viral replication following interferon (IFN) stimulation.  SECs themselves may be 
activated by stellate cell- and cholangiocyte-derived EVs after bile duct ligation, suggesting a 
potential role for EVs in the mechanisms of vasculopathy (Witek et al., 2009).  In turn, 
stellate cells are activated by HDE (Royo et al., 2013) and cholangiocyte proliferation is 
promoted by the heterogeneous population of exosomes in bile (Masyuk et al., 2010).  
Human adult liver stem cells produce EVs that enhance hepatic regeneration in rats following 
partial hepatectomy (Herrera et al., 2010) and conversely inhibit growth of the hepatoma cell 
line HepG2 and ectopic murine tumors (Fonsato et al., 2012). 
1.3.2  HDE mediate communication between the liver and immune cells 
HDE regulation of immune signaling in non-infectious liver disease has been best 
studied in models of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver 
disease (NAFLD).  Broadly, these diseases are characterized by lipid-induced hepatocyte 
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toxicity, chronic inflammation, and compensatory wound healing leading to fibrosis.  
Evidence suggests that hepatocellular lipotoxicity is mediated by inflammatory signaling 
which has led to investigation of the link between hepatocyte lipoapoptosis and inflammatory 
response (Hirsova and Gores, 2015).  In a recent study by Hirsova et al, murine bone marrow 
derived macrophages (BMDMϕ) were exposed to EV from mice with or without a high-fat 
diet as well as EV from mouse hepatocytes with or without toxic lipid treatment.  EVs from 
mice on a high-fat diet and from lipoapoptotic hepatocytes induced expression of the 
interleukins IL-6 and IL-1β in BMDMϕ relative to control EVs (Hirsova et al., 2016).  A 
similar study found that palmitate exposure caused a mouse hepatocyte cell line to increase 
the production of ceramide-enriched EVs.  These ceramide-loaded EVs chemotactically 
recruited more BMDMϕ than EVs from control-treated hepatocytes (Kakazu et al., 2015).  
Far less research has focused on the role of HDE in xenobiotic-induced liver injury.  
The most encouraging evidence has been observed in models of alcoholic liver disease.  A 
comparison of the immunomodulatory effects of control- versus ethanol (EtOH)-treated 
Huh7.5 cells revealed that EtOH EVs synergize with lipopolysaccharide (LPS) to promote 
increased production of pro-inflammatory mediators tumor necrosis factor alpha (TNF-α), 
IL-1β, and monocyte chemoattractant protein 1 (MCP-1) in THP-1 monocytes (Momen-
Heravi et al., 2015a).  To our knowledge, a direct relationship between drug-stressed primary 
human HDE and monocytes has not been established. 
1.4  Immune-mediated DILI mechanisms 
Immune responses in DILI are generally believed to initiate the injury (as in adaptive 
immune attack) or exacerbate existing injury (as with inflammation).  A brief description of 
select canonical immune-mediated DILI reactions is provided below, with a summary in 
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Figure 1.2.  These mechanisms do an excellent job of explaining how serious hepatotoxicity 
develops.  We do not have a sufficient understanding of how the immune system participates 
in the events that precede fulminant hepatotoxicity, but it is likely that the first interaction 
between an injured cell and the immune system occurs prior to overt cytotoxicity.  In a 2010 
review, Adams and colleagues aptly summarized the issue: “…the direct effects of drugs on 
liver cells may be the initiating event for an immune response, which determines the extent 
of liver damage” (Adams et al., 2010). The present research addresses the hypothesis that 
HDE facilitate that initiating event, forming a connection between drug-stressed 
hepatocytes and the immune system that ultimately mediates the outcome of DILI. 
 
  
 
1
3
 
 
 
Figure 1.2.  The links between inflammatory stress and modern DILI mechanisms. This figure is intended to orient the reader to 
current opinions regarding the role of inflammation in DILI, but also to highlight the potential downstream consequences of immune 
mediation by HDE. Reproduced from (Shaw et al., 2010). 
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Adaptive immune attack 
 Increasing evidence suggests that intrinsic and idiosyncratic drug-induced 
hepatocellular death may often be mediated by adaptive immune responses (Adams et al., 
2010; Ju and Reilly, 2012; Russmann et al., 2009).  For example, human leukocyte antigen 
(HLA) genotype is a strong risk factor for DILI associated with a wide range of drugs, 
suggesting a role for the adaptive immune system in drug-mediated hepatotoxicity (Urban et 
al., 2014).  I-DILI may manifest as an adaptive immune attack on the liver as part of an 
allergic hypersensitivity response.  However, it is rare that I-DILI cases present with 
symptoms indicative of allergic reactions such as rash, fever, and eosinophilia (Andrade et 
al., 2005).  As such, evidence of an adaptive immune I-DILI reaction may not be obtained 
until the patient recovers following treatment cessation and a “rechallenge” can be 
performed.  In a rechallenge, the patient is re-exposed to the implicated I-DILI drug and 
monitored closely for signs of hepatotoxicity and a secondary immune reaction, known as a 
positive rechallenge (Tujios and Fontana, 2011).  Typically, liver injury reappears quickly, 
which is consistent with adaptive immune memory.  However, not all I-DILI events show 
recurrent injury upon rechallenge.  It is difficult to determine whether negative rechallenge 
results are due to the lack of an adaptive immune mechanism, or whether these results 
indicate that some form of immune adaptation has occurred between the first drug regimen 
and rechallenge (Hunt, 2010; Tahaoglu et al., 2001; Tujios and Fontana, 2011).  For these 
reasons, earlier indicators of immune system involvement in DILI are needed. 
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Reactive metabolite formation and the hapten hypothesis 
 The liver’s capacity to process xenobiotics and many endogenous substances is based 
largely on high levels of phase I oxidative metabolic enzymes which are designed to yield 
reactive metabolites for phase II conjugation and subsequent elimination.  Many hepatotoxic 
drugs are bioactivated by phase I enzymes such as cytochrome P450s (CYPs) to produce 
highly reactive drug metabolites (Kaplowitz, 2005; Uetrecht, 2008).  In fact, 62% of I-DILI 
drugs have been associated with reactive metabolites (Walgren et al., 2005).  These 
metabolites are electrophiles or free radicals that may bind to cellular targets before phase II 
enzymes can stabilize them.  Consequences include glutathione depletion, covalent protein or 
DNA adduct formation, and redox-cycling to generate excess reactive oxygen species (Han 
et al., 2006; Hanawa et al., 2008; Jollow et al., 1973; Kaplowitz, 2005).  When reactive 
metabolites bind to mitochondrial proteins, the result can be electron transport chain 
interference or membrane permeability transition, resulting in adenosine triphosphate (ATP) 
depletion.  It is believed that drug or metabolite protein binding may promote immune 
activation.  While the molecular mechanisms that underlie this relationship are unclear, a 
popular hypothesis is that binding of a drug or its metabolite to hepatic proteins leads to 
formation of new antigens called haptens.  These “neoantigens” or haptens may be presented 
on cell surface HLA molecules and recognized as foreign by adaptive immune cells.  
However, this process alone is often insufficient to cause an attack on the liver; it is believed 
that immune cell activation is also required to produce co-stimulatory signals and 
chemokines which recruit adaptive immune cells to the liver.  
  
 16 
 
Inflammation and innate immunity 
DILI is often accompanied by elevations in biomarkers that trigger an innate immune 
response such as high mobility group box 1 (HMGB1), and those that are suggestive of 
immune cell activation including miR-155 and acetylated HMGB1 (Antoine et al., 2014; 
Bala et al., 2012; Fontana, 2014).  Intrinsic DILI often involves an immune cascade that 
follows overt cytotoxicity, as is the case with APAP.  In APAP DILI, it is believed that 
infiltrating monocytes and resident liver macrophages (KCs) are stimulated by hepatocellular 
necrosis to produce pro-inflammatory cytokines.  These cytokines may themselves be 
sufficient to exacerbate hepatocyte injury (Maiuri et al., 2015; Shaw et al., 2010), and such 
mechanisms are best modeled in a dynamic co-culture environment (Rose et al., 2016) 
(Appendix).  Cytokines and chemokines in turn recruit additional immune cells (i.e. 
neutrophils, lymphocytes, NK cells, monocytes), thus forming a link to the adaptive immune 
system.  Whether immune cell recruitment promotes enhanced inflammation or encourages 
regeneration is dependent upon many factors including the tissue microenvironment.  For 
example, infiltrating monocytes may differentiate into pro-inflammatory dendritic cells or 
reparative monocyte-derived macrophages (Shi and Pamer, 2011; Zigmond et al., 2014).    
1.5  Acetaminophen 
To stimulate and characterize sub-toxic HDE release, this research utilized the 
prototypical intrinsic hepatotoxicant N-acetyl-p-aminophenol (APAP).   While the ultimate 
application of this research is to understand the role of HDE in mediating immune responses 
in I-DILI, it was necessary to first substantiate our hypothesis using a drug with well-defined 
mechanisms and established toxicity profiles across multiple experimental platforms. 
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APAP is an analgesic and antipyretic that has been in use since the 1800’s (Hinson et 
al., 2010).  It is the active ingredient in Tylenol® and has become a ubiquitous additive in 
hundreds of over-the-counter and prescription medications for allergies, pain, cold, flu, 
cough, and fatigue (FDA, 2016).   As a result, many consumers receive APAP in multiple 
products at once, but if taken appropriately, as 95% of consumers do, APAP is considered an 
extremely safe drug (Kaufman et al., 2012).   
APAP-induced liver injury was first reported in 1966 (Davidson and Eastham, 1966) 
and is now a widespread concern as a growing number of patients intentionally or 
accidentally exceed the maximum daily dose of 4 g APAP (CHPA, 2014).  While there are 
known susceptibility factors including alcohol use (Larson et al., 2005) and genetic 
polymorphisms (Harrill et al., 2009b), APAP is a prototypical dose-dependent toxicant and 
can cause DILI in anyone who ingests a high enough dose.  In fact, APAP overdose is 
responsible for 80,000 emergency room visits and hospitalizations annually (Serper et al., 
2016).  It follows that APAP is the leading cause of acute liver failure in the United States 
(Larson et al., 2005).   
APAP, ingested orally, is quickly absorbed in the gut and reaches maximum plasma 
concentration (Cmax) within 1.5 h (Hodgman and Garrard, 2012).  The drug is subject to 
hepatic first-pass metabolism and is mostly glucuronidated or sulfated by phase II 
detoxifying enzymes in humans (Mazaleuskaya et al., 2015).  A fraction of APAP is 
metabolized by CYP enzymes including CYP3A4, CYP2E1, CYP1A2, and CYP2D6 (Laine 
et al., 2009).  The principal CYP enzymes involved vary depending on APAP dose, but 
CYP34 and CYP2E1 are generally considered the primary metabolizers of APAP in humans.  
The CYPs oxidize APAP in a process that bioactivates it to a toxic intermediate known as N-
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acetyl-p-benzoquinone imine (NAPQI) (Hinson et al., 2010).  NAPQI is highly reactive and 
is neutralized by binding to glutathione (GSH) under normal conditions (Jollow et al., 1974).  
At intermediate and high APAP doses, the sulfation and glucuronidation pathways, 
respectively, become saturated (Mazaleuskaya et al., 2015).  When these processes are 
overwhelmed, greater proportions of APAP are available for CYP bioactivation, leading to 
increased production of the toxic metabolite, NAPQI.   Eventually GSH stores are exhausted 
and NAPQI is free to bind cellular macromolecules, including those critical for energy 
production, leading to oxidative stress and impaired homeostasis that result in cytotoxicity 
(Bessems and Vermeulen, 2001; James et al., 2003; Prescott, 1981).  APAP exhibits a 
centrilobular zonal toxicity, which can be explained by the higher CYP2E1 expression and 
smaller stores of GSH in centrilobular hepatocytes (Jaeschke, 2008).  The most effective 
treatment for APAP overdose, N-acetylcysteine (NAC), works by restoring GSH levels and 
is highly efficient if administered 8-10 h following overdose (Prescott, 1981).  APAP also 
causes kidney injury via similar bioactivation mechanisms. 
The severity of APAP DILI is linked to innate immune activation in rodent models 
and humans, but there is significant conflict regarding whether immune activity is deleterious 
or advantageous.  Evidence for the benefit of innate immune cells in APAP DILI includes 
mechanistic findings that these cells support resolution or, at best, do not actively promote 
toxicity.  For instance, mice treated with the KC depleting compound clodronate showed 
lower IL-6 and IL-10 gene expression, which was associated with enhanced APAP 
susceptibility (Ju et al., 2002).  Similarly, humans with APAP-induced liver failure have high 
concentrations of proliferating KCs at sites of hepatic regeneration (Antoniades et al., 2012; 
Widmann and Fahimi, 1975).  Despite increased KC activity, anti-inflammatory cytokines 
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predominated, suggesting that KC activation was not patently detrimental following APAP 
overdose.  Another mouse model of APAP injury showed that monocytes infiltrating the liver 
negatively regulated neutrophil activation while supporting tissue regeneration and 
angiogenesis (Zigmond et al., 2014).  Recruited monocytes have also been shown to 
differentiate into hepatic macrophages that assist in clearing dead cells and promoting the 
pro-restorative activity of neutrophils (Holt et al., 2008).  With regard to neutrophils, mouse 
and human APAP overdose cases show sustained neutrophil activation in the aftermath of 
acute injury, suggesting that these cells were not actively promoting the toxicity (Williams et 
al., 2014).  In contrast, other reports indicate that immune cell infiltration is associated with 
increased APAP hepatotoxicity.  In liver-specific HMGB1 knockout mice, neutrophil 
accumulation was positively correlated with enhanced liver injury (Huebener et al., 2015).  
In an MCP-1 receptor (CCL2R) knockout mouse model, monocyte recruitment to the liver 
corresponded to increased APAP DILI (Mossanen et al., 2016).  It is important to note, 
however, that these results were observed in models of APAP overdose, leaving the role of 
innate immunity in early stages of injury largely unknown. 
The current research does not address the beneficial or detrimental nature of immune 
activation in APAP DILI.  Here, APAP is used to stress hepatocytes for the purpose of 
studying sub-toxic HDE responses; the mechanisms of APAP overdose are not the focus of 
these investigations.  Recent evidence suggests that immune responses after sub-toxic APAP 
exposure manifest prior to overt hepatocellular injury in healthy volunteers (Fannin et al., 
2015), a process that we believe likely involves the release of hepatocellular stress signals 
contained in HDE.   
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1.6  Summary and dissertation content 
The purpose of the current research was to characterize the role of HDE in directly 
mediating early immune events in DILI (Figure 1.3).  When we began this work, a single 
method to generate HDE from rat hepatocytes had been published and the number of 
hepatocytes required was prohibitively high (Conde-Vancells et al., 2008; Royo et al., 2013).  
There were no reports on the isolation, content, or function of HDE from primary human 
hepatocytes.  Therefore, it was necessary to develop fit-for-purpose methods for the harvest 
and analysis of HDE from primary rat and human hepatocytes.  In Chapter 2, HDE 
enrichment and RNA content analysis techniques were extensively validated and optimized.  
Using these methods, we evaluated the kinetics of APAP-induced HDE release to assess the 
likelihood that HDE were altered before overt hepatocellular death.  In Chapter 3, 
translationally relevant sub-toxic HDE alterations were observed following APAP exposure 
in rats, primary rat hepatocytes, and primary human hepatocytes (Aim 1).  These results 
confirmed that HDE content is affected by drug-induced stress in both species, and may 
serve as a signaling mechanism to immune cells prior to the onset of hepatocyte death.  We 
provide novel evidence of HDE alterations in the absence of overt APAP-induced toxicity.  
Also presented is the first characterization of baseline mRNA levels in primary human HDE, 
which may be related to body mass index (BMI).  We then applied next-generation 
sequencing techniques to comprehensively profile the mRNA and miRNA content of HDE 
from control- and APAP-treated primary human hepatocytes (n=5) (Aim 2).  HDE from the 
same hepatocytes were incubated with THP-1 human monocytes to address the hypothesis 
that exosomes from drug-stressed hepatocytes are capable of immunomodulation in the 
absence of toxicity (Aim 3).  Gene expression profiling of THP-1 monocytes revealed that 
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exposure to APAP HDE altered genes related to cholesterol metabolism and lipid 
homeostasis.  Cytokine release from monocytes exposed to HDE and then stimulated with 
LPS revealed differences in the effects of control HDE and APAP HDE.  HDE from control-
treated human hepatocytes suppressed LPS-induced cytokine secretion.  However, APAP 
HDE did not demonstrate cytokine suppression, perhaps suggesting monocyte predisposition 
to LPS activation.  Many of the significant differentially expressed genes in APAP HDE-
treated monocytes have been associated with increased pro-inflammatory mediator 
production in the literature, and may explain this effect.  In addition, genes involved in 
immune cell trafficking and lymphoid development were also differentially expressed as a 
result of APAP HDE.  The findings of Aims 2 and 3 are presented in Chapter 4, including the 
correlation of exosomal miRNA content with the biological effects of HDE.  We observed 
biologically plausible associations between the miRNAs differentially enriched in APAP 
HDE and down-regulation of their target genes in monocytes treated with APAP HDE.  
These observations support the hypothesis that HDE may transfer miRNAs that are 
potentially responsible for pro-inflammatory priming effects of APAP HDE on immune cells.  
Conclusions, limitations, and future directions of this work are discussed in Chapter 5. 
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In summary, this research highlights HDE as a critical means of communication 
between hepatocytes and immune cells following drug-induced hepatocellular stress.  These 
findings validate application of the approaches developed here to understanding the role of 
HDE in I-DILI. We have shown: 
 
1. The liver-specific RNA contents of HDE in rat and human model systems are 
altered prior to overt hepatotoxicity 
 
2. Global mRNA and miRNA profiles within primary human HDE are altered in 
response to drug-induced stress and may reflect changes in hepatocyte gene 
expression  
 
3. Primary human HDE from control- and APAP-treated hepatocytes directly 
influence monocyte gene expression and subsequent cytokine response to LPS, 
which may ultimately result in modulation of DILI 
 
4. Delivery of specific miRNA via HDE may be responsible for the 
immunomodulatory activity of HDE, including sensitization of monocytes to 
inflammatory stimuli 
  
 
2
3
 
 
Figure 1.3.  Schematic representation of the current hypothesis. Hepatocyte stress may be communicated to the immune system in 
the absence of cytotoxicity via danger signals such as HDE.  The immune response to HDE may ultimately impact the outcome or extent 
of DILI. We believe that the process of early HDE-mediated interactions with the immune system is conserved across DILI mechanisms 
and types.  
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CHAPTER 2. 
 
OPTIMIZATION OF METHODS FOR THE STUDY OF PRIMARY HEPATOCYTE-
DERIVED EXOSOMES 
 
2.1  Introduction 
In the last decade, extracellular vesicles (EVs) have received enormous attention in 
the research community for their value as mechanistic mediators, biomarkers, drug delivery 
vehicles, and drug targets.  It follows that methods of EV analysis continue to evolve at a 
rapid pace, and due to the infancy of this field, no standardized methods exist.  In such a new 
and emerging field, the means by which EVs like exosomes are isolated and studied is widely 
regarded, even among professional EV-focused societies, as specific to the goal of the 
research (Witwer et al., 2013).  This chapter describes the optimization and validation of 
project-specific methods for the study of exosomes released by primary rat and human 
hepatocytes.  
To date, the two most widely used methods for exosome isolation are 
ultracentrifugation (UC) and polymer precipitation.  Alternative methods include size-
exclusion column chromatography and immuno-affinity isolation including modified flow 
cytometry protocols and immunoprecipitation (Taylor and Shah, 2015).  Most protocols 
introduce some form of size-exclusion either by filtration or other means.  Many methods are 
a hybrid of two or more approaches. 
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It is important to note that while the term “isolation” is commonly employed, no 
currently available technique offers complete separation and purification of different vesicle 
types.  All methods use either size or molecular markers to separate exosomes from other 
vesicles, but size, buoyant density, content, and exterior molecular tags may overlap across 
classes (Witwer et al., 2013).  To be technically correct, current approaches may “enrich” for 
exosomes, but cannot fully isolate them.   
 The selection of an enrichment method also influences the outcome of downstream 
analyses including microRNA, mRNA, and protein profiles (Alvarez et al., 2012; Taylor and 
Shah, 2015; Taylor et al., 2011; Van Deun et al., 2014).  Therefore, method(s) must be 
validated for each new research inquiry, cell type, sample source, and endpoint.  
Ultracentrifugation (UC) 
UC utilizes differential sedimentation and high speed (100,000-120,000 x g) 
centrifugation to enrich for the smallest class of EVs.  While sequential spins may improve 
separation, UC is subject to several limitations.  For instance, sedimentation is influenced by 
particle density, which is not consistent across exosomes.  UC will also pellet contaminants 
such as protein aggregates and lipoproteins (Witwer et al., 2013; Yuana et al., 2014).  In 
addition, aggregation-prone EVs may form larger complexes that could be removed 
erroneously in the supernatant (Witwer et al., 2013). 
Gradient-based UC or “buoyant velocity separation” is the most time consuming and 
technically challenging protocol; however, it is considered very stringent and is often 
employed as a means of “cleaning up” preparations produced by other methods (Witwer et 
al., 2013).  Unfortunately, this approach is low-throughput and results in vastly decreased 
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exosomal protein and RNA yields relative to polymer precipitation or UC without a density 
gradient (Van Deun et al., 2014).  While the addition of a density gradient does separate a 
number of contaminants, particles with the same density as EVs, such as high-density 
lipoproteins (HDL), which also carry RNA, will segregate with EVs (Vickers et al., 2011; 
Witwer et al., 2013).  The EV product of gradient-based UC is heavily influenced by such 
details as tube length, rotor type, speed, and centrifugation time, making it the least replicable 
approach (Cvjetkovic et al., 2014; Witwer et al., 2013). 
Polymer precipitation 
Commercially available polymer precipitation reagents such as ExoQuick™ (SBI) or 
the Total Exosome Isolation Kit (Thermo Fisher) can be used on culture medium, urine, 
plasma, serum, and other biofluids.  Once samples are cleared of cellular debris, the reagent 
is added for an incubation period ranging from 30 min to 24 h, depending on sample type and 
precipitation kit.  The reagent’s polymers form a mesh-like network that traps exosome-sized 
vesicles while leaving larger particles in solution.  This exosome “trapping” facilitates 
precipitation of an exosome pellet with relatively low centrifugal forces (System Biosciences, 
2013).  While polymer precipitation does not require laborious sample handling, it may co-
precipitate non-exosomal material as with most other methods.  Exosomes isolated by 
ExoQuick-TC™ (EQ), the version of ExoQuick™ (SBI) designed for tissue culture 
supernatants, demonstrate biological activity (Kaur et al., 2014; Koeck et al., 2014) and 
functional RNA transfer (Giugliano et al., 2015; Momen-Heravi et al., 2015a).  Therefore, 
this method represents a reliable, fast, and non-destructive technique for exosome enrichment 
and downstream functional studies.  
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2.2  Exosome enrichment method validation 
2.2.1 Initial proof of concept for studying primary human hepatocyte-derived exosomes 
(HDE) 
At the time this work was initiated, no group had published research on primary 
human HDE.  A handful of studies had been conducted using primary rat hepatocytes 
(Conde-Vancells et al., 2008; Royo et al., 2013), but the majority of hepatic exosome 
research employed hepatocyte-like cell lines.  The paucity of manuscripts addressing primary 
HDE was likely due to the difficulty of culturing primary hepatocytes and the availability of 
primary human hepatocytes.  As an initial proof of concept, we sought to empirically 
determine whether HDE could be detected in the media supernatant of primary human 
hepatocytes cultured on a small scale relative to primary rat hepatocyte studies (Royo et al., 
2013).  
Freshly isolated primary human hepatocytes were obtained from Triangle Research 
Labs (Research Triangle Park, NC).  Hepatocytes were cultured on a rigid collagen I 
substratum in 6-well plates (Corning) at 1.5e6 or 2.25e6 cells per well.  Given that primary 
human hepatocytes had not yet been utilized for exosomal RNA experiments, the cell and 
medium requirements to achieve sufficient exosome material by UC were not known.  To 
induce stress and promote exosome accumulation, cultures were starved for 120 h following 
a 24 h acclimation period.  Media samples were collected from single wells of 1.5e6 
hepatocytes, single wells of 2.25e6 hepatocytes, and two wells of 1.5e6 hepatocytes pooled 
(3e6 cells total).  Exosomes were isolated from cell culture medium using UC.  Cell debris 
was removed by clarification at 1,300 x g for 10 min at 4 ºC.  The resulting supernatant was 
transferred to a new tube and clarified at 16,000 x g for 10 min at 4 ºC to remove large 
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microparticles.  Supernatants were transferred to autoclaved polycarbonate ultracentrifuge 
tubes (Beckman) and balanced with sterile phosphate-buffered saline (PBS) (Gibco).  
Exosomes were enriched by centrifugation at 100,000 x g for 60 min at 4 ºC.  The pellet was 
washed with PBS and centrifuged again under the same conditions as described previously 
(Taylor et al., 2011).  
Immediately following UC, RNA was isolated from exosomes using the miRCURY 
Cell & Plant RNA Isolation Kit (Exiqon), which was selected for its superior performance in 
isolating high quality microRNA and mRNA from exosomes (Eldh et al., 2012).  The 
manufacturer’s protocol for mammalian cells was followed.  Total RNA concentration was 
analyzed using a NanoDrop 1000 spectrophotometer (Thermo).  Exosomal RNA yield was 
compared across hepatocyte densities (Figure 2.1).  Results confirmed that UC-based 
enrichment of primary human HDE produces detectable quantities of RNA, and that there is 
a linear relationship between exosomal RNA quantity and the number of hepatocytes 
producing exosomes in vitro.    
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Figure 2.1. Human hepatocyte-derived exosomes isolated by ultracentrifugation on a 
small scale contain detectable quantities of RNA that are proportionate to the number of 
cultured hepatocytes. Data were collected from exosomes produced by primary human 
hepatocytes cultured without media change for 120 h to stimulate cell stress and exosome 
accumulation. 
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With the knowledge that EQ-based polymer precipitation usually produces higher 
quantities of exosomal RNA than UC (Pisitkun et al., 2004; Taylor et al., 2011), we were 
confident using EQ for the study of primary human HDE going forward.  Using EQ, we were 
able to detect highly abundant exosomal RNAs such as albumin mRNA and miR-122, in 
HDE from as little as 1 ml of primary human hepatocyte culture supernatant (data not 
shown).  When performing experiments for publication (Chapter 3), the optimal media 
volume for HDE enrichment was determined to be 2 ml. 
2.2.2  Enrichment method comparison using primary rat HDE 
Freshly isolated primary male Sprague-Dawley rat hepatocytes were obtained from 
The Hamner Institutes for Health Sciences (Research Triangle Park, NC).  Hepatocytes were 
cultured on a rigid collagen I substratum in 6-well plates (Corning) at 1.5e6 cells per well.  
Following a 24 h acclimation period and second media change, media was not replaced for 
120 h to promote stress-related exosome release and accumulation.  Cell starvation was 
intentional in order to maximize the release of exosomes, as this experimental design 
represented a 10-20-fold reduction in rat hepatocytes relative to previously published 
exosome studies (Royo et al., 2013).  Media samples were collected from single wells of 
1.5e6 hepatocytes and two pooled wells of 1.5e6 hepatocytes per well.  Exosomes were 
isolated from equal volumes of cell culture medium (2 ml from 1.5e6 cells and 4 ml from 3e6 
cells) using UC or EQ polymer precipitation. UC was performed as previously described, 
using UC tubes treated with RNase inhibitor to reduce RNA degradation.  Polymer 
precipitation samples were prepared using EQ reagent according to the manufacturer’s 
instructions for cell culture supernatant, with an overnight incubation.  
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Immediately following enrichment, exosome pellets were processed for RNA or 
protein yield.  Exosomal RNA from both methods was isolated and quantified according to 
hepatocellular input as previously described.  Aliquots of RNA were converted to 
complementary DNA (cDNA) for quantitative real-time polymerase chain reaction (qRT-
PCR) analysis using a High Capacity cDNA Reverse Transcription Kit (Applied Biosytems) 
according to the manufacturer’s instructions, using equal volumes of exosomal RNA across 
samples (Eldh et al., 2012).  RT-PCR was performed on a 7900HT Fast RT-PCR System 
(Applied Biosystems) using the rat albumin TaqMan Gene Expression Assay 
(Rn00592480_m1) and Fast Advanced Master Mix.  Absolute quantities of mRNAs were 
calculated using a rat albumin cDNA standard curve generated from bacterial plasmids. 
Exosomal protein was extracted from exosomes by lysis with RIPA Lysis and 
Extraction buffer with protease inhibitors (Thermo).  Samples were mixed thoroughly and 
incubated at 4 ºC for 30 min with agitation.  Following lysis, protein was separated from 
nucleic acids by centrifugation at 10,000 x g for 2 min at 4 ºC.  Supernatants were stored at -
80 ºC until protein quantification with a BCA Protein Assay Kit (Thermo) according to the 
manufacturer’s instructions.   
Across all endpoints, EQ enrichment produced higher yields of exosomal protein, 
RNA, and albumin (Figure 2.2).  These metrics of exosomal material increased with 
hepatocyte density in the EQ preparations while total RNA, protein, and albumin copy 
number in HDE enriched by UC did not increase with cell number.  From this work, we 
determined that EQ is a reliable means of exosome enrichment from primary rat hepatocytes 
cultured on a small scale.  
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Figure 2.2. ExoQuick-TC precipitation produces superior exosome yields relative to 
ultracentrifugation. Comparison of total exosomal protein (A), RNA (B), and albumin copy 
number (C) between exosomes isolated from equal volumes of rat hepatocyte conditioned 
medium.  
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2.2.3  Enrichment method comparison using rat plasma 
The purpose of this work was to select an appropriate exosome enrichment method 
for future processing of in vivo samples.  When isolating exosomes from biofluids such as 
blood, there are arguably more variables to be aware of that can influence exosome status and 
therefore data quality.  For instance, thought must be given to the type of anticoagulant and 
the gauge of needle used for blood collection.  EDTA is largely preferred as an anticoagulant 
over heparin because it interferes less with downstream PCR reactions, including qRT-PCR 
on both mRNA and microRNA (Beutler et al., 1990; Johnson et al., 2003; Kim et al., 2012).  
Interference with RNA content analysis is a critical consideration when handling small 
quantities of RNA such as those within EVs.  Similarly, care must be taken to avoid shear 
forces when collecting blood by using a large-bore needle.  This consideration is driven by 
platelets and their sensitivity to activation, as platelet activation induced by handling may 
result in massive EV release and skewing of the true EV population within a sample (Witwer 
et al., 2013). 
Whole blood was collected from adult male, Sprague-Dawley rats following 
euthanasia by CO2 inhalation and subsequent exsanguination.  Blood was collected by 
cardiac puncture with an 18-gauge needle and transferred to K2EDTA Vacutainer tubes 
(Beckton Dickinson).  The anticoagulant and needle gauge were selected to minimize platelet 
activation according to previously published methods used to study liver-derived EVs 
(Brodsky et al., 2008).  Tubes were immediately inverted and incubated for 5 min on ice 
prior to plasma isolation by centrifugation at 1,300 x g for 10 min at 4 ºC.  To generate 
platelet-poor plasma (PPP), the resulting supernatant was centrifuged at 16,000 x g for 10 
min at 4 ºC, conditions which represent a harmonization of previously published methods 
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(Cattaneo et al., 2007; Yuana et al., 2011).  Supernatants were removed and separated into 
250 µl aliquots for exosome enrichment by UC or EQ precipitation.  UC was conducted as 
described previously.  Polymer precipitation was carried out using EQ reagent according to 
the manufacturer’s protocol for serum.  Albumin mRNA copy number analysis and protein 
isolation were performed on exosomes as described prevoiusly. 
From the same volume of plasma, exosomes prepared via EQ have a higher protein 
concentration compared to exosomes from UC (Figure 2.3).  However, the copies of albumin 
mRNA detected by qRT-PCR were similar across methods (Figure 2.3).  Albumin mRNA 
quantity is often used to approximate HDE number, and if this assumption is made, these 
qPCR data may indicate that UC and EQ enrichment produce a similar exosome yield.  If 
true, this finding would indicate that the higher protein concentration observed with EQ was 
due to extra-exosomal protein precipitation.  However, following incubation with EQ, the 
plasma exosome pellet could not be fully resuspended due to dense, insoluble material in the 
tube.  Further investigation revealed that the insoluble material was likely fibrin protein 
aggregates, and that plasma should be pre-treated with thrombin to defibrinate, producing a 
more “serum-like” form that is compatible with EQ (System Biosciences, 2013).  Given that 
exosomal protein concentration and albumin copy number showed similar trends in vitro 
(Figure 2.2), we hypothesize that the addition of thrombin to the EQ plasma samples would 
likely have increased the albumin mRNA yields, and that this method is suitable for future in 
vivo studies (Chapter 3). 
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Figure 2.3. Plasma-derived exosome enrichment by ultracentrifugation and ExoQuick. 
By exosomal protein (A), EQ produces more material but, by qRT-PCR for the HDE marker 
albumin (B), no difference was observed. 
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2.3  Methods for exosomal RNA isolation and analysis 
2.3.1  RNA elution volume 
Given that our experiments utilize a significantly reduced culture medium input to 
generate HDE, a primary concern was the yield and quality of exosomal RNA that could be 
isolated for analysis.  Based on a rigorous comparison of exosomal RNA isolation kits, the 
miRCURY™ Cell & Plant kit (Exiqon) was selected as it produces the highest exosomal 
RNA yield, wide size distribution (allowing for enrichment of miRNA), and sufficient 
quality for qPCR analysis (Eldh et al., 2012).  In their work, Eldh and colleagues isolated 
exosomes from a large volume of cell culture supernatant (85 ml) and obtained an average of 
11 µg exosomal RNA from all methods.  Using 1-2 ml of primary hepatocyte culture 
supernatant, we obtain 0.2-1 µg exosomal RNA eluting in the same volume (50 µl).  To 
increase the concentration of exosomal RNA for downstream analysis, we examined the 
effect of decreasing the elution volume using the miRCURY kit. 
We validated this method modification by preparing 9 samples of 2e6 fresh primary 
human hepatocytes from the same donor.  The isolation process was the same for all samples 
and was conducted according to the manufacturer’s instructions.  At the elution step, samples 
were separated into 3 groups: single 50 µl elution, single 25 µl elution, and a group in which 
12.5 µl of elution buffer was added to the column and eluted (n=3/group).  For the 12.5 µl 
group, a second aliquot of 12.5 µl was added to the column and eluted into the same tube, 
resulting in a final volume of 25 µl.  This condition was included to examine whether 
washing of the column increased or decreased total yield.  The concentration of RNA in each 
sample was measured in triplicate on a NanoDrop 1000 spectrophotometer.  
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The concentration of RNA eluted in 50 µl was roughly half that of the samples eluted 
in 25 µl, with a yield of 36.9 and 35.5 µg, respectively.  The lack of significant difference (p 
= 0.76 by Student’s t-test) between the yield in these samples indicates that eluting in 25 µl 
was a viable option to concentrate RNA without loss of yield.  However, samples generated 
by two consecutive 12.5 µl elutions had highly variable RNA yields (17.5 ± 7.7 µg) that were 
lower than a single 25 µl elution, likely because such a small volume cannot adequately or 
reliably saturate the surface area of the column.  Exosomal RNA was eluted in a single 
aliquot of 25 µl for all remaining miRCURY kit isolations.  
2.3.2  Exosome-specific optimization of qRT-PCR 
 A common challenge for exosome researchers is the absence of housekeeping 
molecules that are reliably detected at consistent levels across samples.  Exosome 
constituents, including lipid, protein and RNA, are largely specific to the parent cell type and 
are very sensitive to changes in the cellular environment.  Therefore, it has been very 
difficult to identify exosome components that are suitable for normalization (i.e., that are not 
altered by treatment or experimental conditions) (Witwer et al., 2013; Yang et al., 2014).  As 
the quantification of HDE RNA is a primary metric proposed here, we have chosen absolute 
qRT-PCR to circumvent the need for a housekeeping gene.  The data product of absolute 
quantification is the definitive copy number of a given target based upon a dilution series of 
known target cDNA copy number.  
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Generation of cDNA standard curves via bacterial cloning 
Initially, standard curves for each mRNA analyte were generated by bacterial cloning 
as previously described (Wetmore et al., 2010).  Bacteria transformed to express the DNAs 
of interest were obtained as glycerol stocks, either from Dr. Barbara Wetmore or purchased 
from Dharmacon (Table 2.1).  For both human and rat constructs, DNAs were cloned by 
culturing the transformed bacteria in sterile Miller’s Luria Bertani broth (LB; Fisher 
Scientific) prepared with the appropriate concentration of selective antibiotic (Table 2.1).  
Starter cultures were generated by inoculating 5 ml of the antibiotic-containing LB with a 
pipette tip that had been pressed into a tube of frozen bacterial stock and were incubated with 
shaking (300 rpm) for approximately 8 h at 37 ºC.  When the starter cultures became turbid, 
suggesting log-phase growth, the cultures were expanded for bulk cDNA production.  Based 
on the turbidity of starter culture, 250-500 µl was transferred into a sterile vented flask 
containing 250 ml of fresh LB broth.  Flasks were incubated with shaking (300 rpm) 
overnight (approximately 16 h) at 37 ºC.  The remaining starter culture was used to create 
frozen glycerol stocks for future use.  Briefly, bacteria were pelleted by centrifugation at 
3,500 x g for 5 min and resuspended in 950 µl of antibiotic-containing LB.  This solution was 
combined with an equal volume of 60% glycerol (Fisher Scientific) to give a final 
concentration of 30% glycerol.  Stocks were stored at -80 ºC.  Following the overnight 
incubation, bacteria were spun out of the bulk cultures at 3,500 x g for 5 min at 4 ºC.  Pellets 
were frozen at -20 ºC until processing or were used directly for DNA isolation.  Plasmid 
DNA (pDNA) was isolated from each batch of bacteria (clone) using a HiSpeed Plasmid 
Purification Kit (Qiagen) according to the manufacturer’s protocol. 
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Upon elution, the pDNA concentration was obtained using a NanoDrop 1000 
spectrophotometer (Thermo).  Based on the size and weight of each individual vector (Table 
2.1) and the concentration of plasmid DNA produced by that clone, the number of cDNA 
copies per preparation was calculated.  With this information, each pDNA was diluted to 
1e12 and 1e9 copies per microliter and stored as concentrated stocks.  A standard curve 
consisting of 10-fold serial dilutions with final copy numbers ranging from 1e6 to 10 was 
prepared fresh in nuclease-free water immediately prior to each qRT-PCR reaction. 
Absolute qRT-PCR copy number calculation 
The cycle threshold (Ct) values for each standard dilution were plotted against the log 
of the copy number to produce a linear regression formula y = mx + b where y is the Ct 
value, m is the slope, and b is the y-intercept.  Solving this equation for x facilitates 
quantification of copy number for each unknown exosomal cDNA sample.  Linearity of the 
curve was also utilized to characterize individual assay reaction or amplification efficiency 
such that E = [10(-1-slope) – 1], where E is efficiency.  Efficiency is considered optimal 
between 0.90 and 1.05. 
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Table 2.1. Plasmid DNA vector information for preparation of qRT-PCR standard curves by bacterial cloning. Rat (A) and 
human (B) constructs are described. Amp: ampicillin; Chlor: chloramphenicol. * indicates custom TaqMan Gene Expression Assay 
primers were designed to avoid known SNPs. 
 
 
 
 
 
A
cDNA Amplicon Entrez Gene ID IMAGE Consortium Clone ID Plasmid Vector Coding Sequence Length (bp) Total Vector Size (bp) Antibiotic Resistance TaqMan Gene Expression Assay
Albumin 24186 7303856 pExpress-1 2020 6137 Amp (100 µg/ml) Rn00592480_m1 (a)
Rn01413927_g1 (b)
Fibrinogen β-chain polypeptide 24366 7371665 pExpress-1 1604 5721 Amp (100 µg/ml) Rn01459028_m1
Haptoglobin 24464 7321960 pExpress-1 1239 5356 Amp (100 µg/ml) Rn00561393_m1
α-1-microglobulin/bikunin precursor 25377 7368246 pExpress-1 1180 5297 Amp (100 µg/ml) Rn01458278_m1
Apolipoprotein H 287774 7364928 pExpress-1 1175 5292 Amp (100 µg/ml) Rn01467588_m1
Group-specific component 24384 7130137 pExpress-1 1684 5801 Amp (100 µg/ml) Rn01414180_m1
Retinol binding protein 4 25703 7369314 pExpress-1 939 5056 Amp (100 µg/ml) Rn01451315_g1
Transferrin 24825 7132382 pExpress-1 2323 6440 Amp (100 µg/ml) Rn01445479_m1
Serpin peptidase inhibitor A1 24648 7131535 pExpress-1 1603 5720 Amp (100 µg/ml) Rn00574670_m1
B
cDNA Amplicon Entrez Gene ID IMAGE Consortium Clone ID Plasmid Vector Coding Sequence Length (bp) Total Vector Size (bp) Antibiotic Resistance TaqMan Gene Expression Assay
Albumin* 213 4734617 pDNR-LIB 2068 6229 Chlor (25 µg/ml) Forward: TACTCTGTCGTGCTGCTGCT
Reverse: CAGGGCATTCTTTTTGCTTC
Fibrinogen β-chain polypeptide 2244 4734415 pDNR-LIB 1948 6109 Chlor (25 µg/ml) Hs00905942_m1
Haptoglobin 3240 4716454 pDNR-LIB 1139 5300 Chlor (25 µg/ml) Hs00605928_g1
α-1-microglobulin/bikunin precursor 259 5433460 pOTB7 1413 3228 Chlor (25 µg/ml) Hs01089670_m1
Apolipoprotein H 350 4734357 pDNR-LIB 1201 5362 Chlor (25 µg/ml) Hs00979400_m1
Group-specific component 2638 4767205 pDNR-LIB 1720 5881 Chlor (25 µg/ml) Hs00167096_m1
Retinol binding protein 4 5950 4767481 pDNR-LIB 950 5111 Chlor (25 µg/ml) Hs00928627_g1 
Transferrin 7018 5264299 pBluescriptR 2330 5320 Amp (100 µg/ml) Hs01067774_m1
Serpin peptidase inhibitor A1 5265 3859644 pCMV-SPORT6 1584 5980 Amp (100 µg/ml) Hs01097800_m1
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Performance of plasmid-based standard curves 
Validating the rat albumin mRNA qPCR assay (Rn00592480_m1) for HDE content 
analysis was the focus of early efforts.  The assay performed well in preliminary experiments 
(Figure 2.4), but efficiency declined over time.  A fresh rat albumin pDNA standard curve 
was generated, and 5 and 20 µl qRT-PCR reaction volumes were tested on two different 
qPCR instruments (7900 HT Fast RT-PCR System and 7900 HT Sequence Detection 
System; ABI) in an attempt to improve amplification efficiency.  Regardless of reaction 
volume, the efficiencies were closer to acceptable limits and the standard deviations were 
lower with the 7900 Fast RT-PCR System (data not shown).  Despite improved instrument 
performance, standard curve results remained inconsistent across multiple qPCR plates.  
The predominant form of albumin pDNA was presumably circular given that the 
construct had not been gel-purified.  We hypothesized that the standard curve could be 
affected negatively by contaminants, including alternate forms of pDNA.  It has also been 
shown that the conformation of DNA cloned via cellular methods can significantly bias 
quantification and alter efficiency due to differential primer binding, with circular pDNA 
resulting in drastic copy number over-estimations in both SYBR Green and TaqMan 
platforms (Hou et al., 2010; Lin et al., 2011).  While efficiency differences depend on the 
target being quantified, linearized pDNA curves generate more accurate copy number 
extrapolations and therefore, were the conformation of choice for future standard curves 
(Hou et al., 2010).   
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Figure 2.4. Representative rat albumin standard curve generated from uncut pDNA. Data 
represent an average of triplicate qPCR wells fitted with a linear regression model. Initial 
amplification efficiency (E) is within the ideal range (0.90-1.05).    
 
  
15
20
25
30
35
40
Linear Regression of Alb pDNA Curve
Log (copy number)
A
v
e
ra
g
e
 C
t 
V
a
lu
e
1 2 3 4 5 6
y = -3.4972x + 42.04
R
2
 = 0.9957
E = 0.93
 43 
 
Linearization of pDNA standard curves 
Focusing on the rat albumin construct, pDNA was linearized via restriction digest 
using an enzyme with a single cut site, XhoI (Figure 2.5).  Digests were prepared in a 50 µl 
reaction volume with 2 µg circular DNA, 20 units XhoI (New England Biolabs; NEB), 
Buffer 2 (NEB), and nuclease-free water.  Following a 16 h incubation at 37 ºC, digests were 
combined with Track-It Cyan/Orange gel loading buffer (Invitrogen), and electrophoresed in 
parallel with 2 µg uncut plasmid and Track-It 100 bp DNA ladder (Thermo) in a horizontal 
mini 1% agarose gel (Sigma) containing 1.5 µg/ml ethidium bromide (EtBr) with 1x 
tris/borate/EDTA (TBE) buffer (Sigma) at 100 V constant for 90 min.  Migration was 
visualized with an ultraviolet (UV) transilluminator (Figure 2.5) and the linearized band was 
excised from the gel with a scalpel.  The linear albumin DNA fragment was purified from the 
agarose using a QIAquick Gel Extraction Kit (Qiagen) pursuant to the manufacturer’s “Quick 
Start” protocol.  Upon elution of the purified linear albumin, the eluate concentration was 
determined using a NanoDrop 1000 spectrophotometer and the copy number was determined 
as outlined in an earlier section. Concentrated stocks were stored in aliquots at -80 ºC.  The 
same procedure was followed to generate linearized human standards from constructs 
described in Table 2.1.  
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Figure 2.5. Linearization of pDNA carrying insert for qPCR standard curve. Illustration 
of rat albumin DNA vector and restriction site targeted to linearize plasmid (A). Representative 
gel of uncut and linearized pDNA for rat Ambp standard curve (B). Image demonstrates 
differential gel migration of various pDNA conformations. For all pDNA standards, the 
linearized band represented in the “Digest” lane was excised for purification. Image of pDNA 
forms (right portion of panel B was adapted from (Hegyi et al., 2013)). 
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Comparison of circular vs. linear pDNA curves 
Rat Albumin 
Freshly diluted circular and linearized standard curves were prepared with copy 
numbers ranging from 1e6 to e10 in 10-fold serial dilutions.  These curves were assayed in 
parallel using the rat albumin TaqMan Gene Expression Assay (Rn00592480_m1) with 5 and 
20 µl total reaction volumes.  For both reaction sizes, the linearized pDNA curve 
demonstrated much lower Ct values relative to the circular pDNA curve with the same copy 
numbers (Table 2.2).  These findings agree with existing evidence that circularized plasmid-
based qPCR standard curves generate inflated copy number estimations (Hou et al., 2010).  
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Table 2.2. Linearized pDNA standard curve for rat albumin shows universally lower 
average Ct values than circular pDNA. 
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Human Constructs 
Freshly diluted circular and linearized pDNA standard curves for all human TaqMan 
assays (Table 2.1) were prepared with copy numbers ranging from 1e6 to 10 in 10-fold serial 
dilutions, as described above.  These curves were assayed in parallel using 5 µl total reaction 
volumes.  For 6 out of 8 constructs, the linearized plasmid DNA curve demonstrated much 
lower Ct values relative to the same copy number using the circular plasmid curve (Figure 
2.6).  While 2 linearized curves (Gc and ApoH) were not detected at lower Cts than the 
corresponding circular standards, these linearized standards had superior linearity and 
reaction efficiency.  For human ApoH, the uncut standard curve yielded R2 = 0.9808 and E = 
1.23 while the linearized curve showed R2 = 0.9979 and E = 0.985.  The human Gc curve had 
R2 = 0.9711 in the circular form versus 0.9984 in the linear form and E = 1.13 versus 0.903.  
The linearized standard curves were used for qPCR analyses of human HDE content 
described in Chapter 3. 
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Figure 2.6.  Linear versus circular pDNA standard curves for human exosome qRT-PCR 
assays. All 8 human constructs are represented with open circles indicating curves generated 
from uncut pDNA and the closed circles representing curves from linearized pDNA. In all 
cases, the linearized standard curves were detected at lower Ct values and/or showed better 
linearity and amplification efficiency than the corresponding circular pDNA curves. 
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Optimization of rat exosomal albumin qRT-PCR 
While the linearized conformation of pDNA was superior to the circular form, within 
a month of generation, Ct values for the standard curve in 5 µl albumin qPCR reactions had 
increased from 16.8 (Table 2.2) to 19.2, despite storage in aliquots to prevent multiple 
freeze/thaw cycles (data not shown).  We next investigated an alternative TaqMan Gene 
Expression Assay in addition to molecular cloning for stable standard curve generation.  
Validation of an alternative qPCR assay for detection of albumin in rat HDE 
To detect exosomal albumin in rat HDE, we initially used the TaqMan Gene 
Expression Assay Rn00592480_m1 (Table 2.1) because it had been used in earlier EV 
studies (Wetmore et al., 2010) and was found to identify the most rat albumin transcripts by 
the manufacturer.  However, underperformance of the assay was a concern, as this 
primer/probe set targets the 5’ end of rat albumin cDNA.  Therefore, we selected an 
alternative assay, Rn01413927_g1 (Table 2.1), which targets the 3’ region and had also been 
validated in EV samples (Wetmore et al., 2010).  Using the same linearized pDNA standard 
curve and qPCR plate, these two assays were compared in 5 µl qPCR reactions.  The new 
assay (Rn01413927_g1) had superior linearity and lower Ct values for the same standard 
curve, allowing all six standards to be detected relative to only five standards with the 
original assay (Figure 2.7).  All further analyses of albumin mRNA quantity in rat HDE were 
conducted using this new qPCR assay. 
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Figure 2.7.  Side-by-side performance of two qRT-PCR assays for rat albumin. Lines 
represent linear regression analyses with respective R2 values next to each curve. The 
alternative assay (Rn01413927_g1) shows lower Ct values for the same standards and detects 
as few as to 10 copies, while the original assay (Rn00592480_m1) detection limit is 100 copies. 
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Primer design 
Prior to designing PCR primers, the mRNA/cDNA sequence for the target of interest 
must be known.  Given that the PCR amplicon will be measured in a qPCR assay, the region 
within the PCR amplicon targeted by the qPCR assay must be preserved.  While TaqMan 
Gene Expression Assay primer sequences are proprietary, the start position and size of the rat 
albumin TaqMan amplicon were known.  Using this information, flanking forward and 
reverse PCR primers were selected to generate a PCR amplicon of approximately 500 bp, 
which is generally considered the optimal amplicon size for traditional PCR (New England 
Biolabs; Premier Biosoft) (Figure 2.8).  Primers were designed to be roughly 18-22 bp in 
length with a GC percentage between 40 and 60% and melting temperature (Tm) between 42 
and 65 ºC (New England Biolabs; Premier Biosoft).  Custom primers were synthesized by 
Invitrogen and provided as lyophilized stocks.  
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Figure 2.8. Rat albumin mRNA sequence (NCBI Reference Sequence NM_134326.2) used 
for custom PCR primer design. TaqMan assay (Rn01413927_g1) amplicon of 76 bp in size 
(1734-1874 bp) is highlighted in yellow and the binding sites of the flanking forward and 
reverse primers are indicated by a red underline. The embedded table shows the sequences of 
the forward primer (top) and the reverse primer (bottom).  
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Polymerase chain reactions 
Rat liver cDNA (1 µg) was used as the template in 25 µl PCR reactions.  Reaction 
components included GC Enhancer and AmpliTaq Gold polymerase from an AmpliTaq Gold 
360 Master Mix kit (Thermo), as well as forward and reverse primers at a final concentration 
of 0.2 µM. The volume was adjusted to 25 µl with nuclease-free water.  No template control 
reactions were also prepared with water in place of the cDNA template.  Using a thermal 
cycler, PCR reactions were run under the following conditions: 95 ºC for 10 min (Taq 
polymerase activation); 35 cycles of 95 ºC for 30 sec (denaturation), 60 ºC for 30 sec 
(annealing) and 72 ºC for 30 sec (extension); 72 ºC for 7 min (final extension); and held at 4 
ºC.   
The PCR product was subjected to gel electrophoresis to confirm appropriate 
amplicon size (~500 bp) and purity (Figure 2.9).  Electrophoresis was performed as 
previously described with the exception of voltage (200 V constant) and time (70 min).  Gel 
purification of the PCR product was conducted as described and the eluate concentration was 
measured by NanoDrop for copy number calculations. 
Assessing performance of PCR-based standard curve by qPCR 
The gel-purified PCR product was diluted in a series of six 10-fold dilutions to 
generate the qRT-PCR standard curve for rat albumin.  Using the newly validated TaqMan 
Gene Expression Assay, linearity and amplification efficiency of the PCR-based standard 
curve were determined.  All standards down to 10 copies were detected (E = 0.940; R2 = 
0.9999).   Concentrated stocks of this curve were stored at -80 ºC.  The Ct signals for each 
standard remained stable for the duration of our qRT-PCR experiments.  
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Figure 2.9. Gel electrophoresis of rat albumin PCR product confirming amplicon size. 
No template control indicates a PCR reaction that was carried out with water instead of 
template DNA. The lack of a band in this lane demonstrates an absence of non-specific PCR 
amplification. 
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Assessing performance of PCR-based standard curve by qRT-PCR 
The gel-purified PCR product was diluted in a series of six 10-fold dilutions to 
generate the qRT-PCR standard curve for rat albumin.  Using the newly validated TaqMan 
Gene Expression Assay, linearity and amplification efficiency of the PCR-based standard 
curve were determined.  All standards down to 10 copies were detected (E = 0.940; R2 = 
0.9999).   Concentrated stocks of this curve were stored at -80 ºC.  The Ct signals for each 
standard remained stable for the duration of our qRT-PCR experiments.  
Generation of a standard qRT-PCR curve for miR-122  
As with albumin mRNA, we sought to quantify the copy number of hepatocyte-
specific microRNA miR-122 within rat and human HDE using TaqMan qRT-PCR.  
Fortunately, miRNA sequences are highly conserved across species, and the TaqMan assay 
for miR-122 (hsa-miR-122-5p; Applied Biosystems) detects both rat and human miR-122, 
among other species.  We generated a universal miR-122 standard curve of known copy 
number for qRT-PCR of human and rat exosomal miR-122 using a miScript miRNA Mimic 
(Qiagen).  A lyophilized stock of synthetic miR-122 was reconstituted with nuclease-free 
water to a concentration of 1.2e13 copies/µl.  Given the high quantities of miR-122 within 
hepatocytes and HDE, an 8-point standard curve was preferred.  From the stock, an 
intermediate dilution of 2e10 copies/µl was prepared to facilitate generation of the highest 
standard at 2.5e8 copies/µl.  Six serial 10-fold dilutions of the highest standard were 
generated with the final standard being a zero copy blank (also serving as a no template 
control for the RT reactions).  
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 The standard curve of synthetic miR-122 was reverse-transcribed using a TaqMan 
miRNA Reverse Transcription Kit (Applied Biosystems) with miR-122-specific primers in a 
5 µl total reaction volume scaled according to the manufacturer’s instructions.  The resultant 
cDNA was diluted to produce a set of standards whose final concentrations in a qPCR 
reaction would be 1e7 copies to 10 copies (Table 2.3).  This standard curve remained stable 
through the completion of exosomal miR-122 quantification experiments. 
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Table 2.3. Preparation of the miR-122 qRT-PCR standard curve. Schematic shows how 
copy numbers were tracked and adjusted during standard preparation from stock dilution to 
qRT-PCR input.   
 
 
 
 
  
miRNA Concentrations Total Copy Number in RT Concentration in RT
copies/µ l copies copies/µ l
2.50E+08 5.00E+08 1.00E+08
2.50E+07 5.00E+07 1.00E+07
2.50E+06 5.00E+06 1.00E+06
2.50E+05 5.00E+05 1.00E+05
2.50E+04 5.00E+04 1.00E+04
2.50E+03 5.00E+03 1.00E+03
2.50E+02 5.00E+02 1.00E+02
0.00E+00 0.00E+00 0.00E+00
qRT-PCR reaction Concentration in cDNA
input following 20x dilution
Std # copies copies/µ l
1 1.00E+07 5.00E+06
2 1.00E+06 5.00E+05
3 1.00E+05 5.00E+04
4 1.00E+04 5.00E+03
5 1.00E+03 5.00E+02
6 1.00E+02 5.00E+01
7 1.00E+01 5.00E+00
8 0.00E+00 0.00E+00
Add 2 µl to
RT reaction
Divide by RT 
volume
Dilute 
cDNA 
to 100 
µl 
Transfer 2 
µl to qPCR
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2.3.3  Exogenous mRNA spike-in control 
In addition to standardizing qRT-PCR results across plates with the use of absolute 
quantification, we wanted to normalize for slight differences in RNA isolation efficiency 
across exosome samples and batches.  Since no endogenous reference or housekeeping genes 
have yet been identified in exosomes, we selected an exogenous non-mammalian spike-in to 
serve as a pseudo-housekeeping marker.  An exogenous reference mRNA control was spiked 
in to all samples at an equal quantity prior to RNA extraction.  The recovery of this mRNA 
was assessed in parallel with target mRNAs of interest during qRT-PCR and used to adjust 
Ct values for the gene of interest. 
Preparation and addition of mRNA spike-in 
The addition of exogenous mRNA reference controls for qRT-PCR is a well-
established practice (Johnston et al., 2012; Revilla-Fernandez et al., 2005; Smith et al., 2003) 
deemed useful for cellular applications since traditional internal housekeeping genes such as 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or hypoxanthine phosphoribosyl-
transferase 1 (HPRT) are often subject to endogenous transcription changes.  Exogenous 
RNA introduced at a known concentration for the purposes of normalizing qRT-PCR data 
from exosomal samples is highly desirable because exosomes do not currently have 
housekeeping genes that remain constant across experimental conditions.  We selected 
synthetic luciferase mRNA Luciferase Control RNA (Promega) as a validated exogenous 
reference gene (Johnston et al., 2012). 
The copy number of stock Luciferase Control RNA was calculated based on construct 
size as described in an earlier section.  To test the spike-in using actual exosomes, various 
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concentrations of luciferase were spiked in to human HDE (2 µl per sample) prior to RNA 
isolation, immediately following addition of miRCURY Lysis Buffer.  Linear acrylamide 
carrier was added to each sample and RNA isolation was performed according to our 
established protocol with elution in 25 µl.  A High Capacity cDNA Reverse Transcription Kit 
(Applied Biosytems) was used to generate cDNA from all samples.  This kit uses random 
primers, allowing for reverse transcription of exosomal mRNA and exogenous luciferase 
mRNA to occur in the same reaction. 
Based on the multiplexed qPCR data shown below, we selected a working spike-in 
concentration of 1.6e8 copies/µl to be added to all subsequent exosome samples (2 µl per 
sample). 
Validation of exosomal albumin and exogenous luciferase multiplexed qRT-PCR 
The most value would be gained from a reference gene (endogenous or exogenous) 
that is measured in the same qPCR reaction as the target, eliminating a number of 
confounding variables.  We wished to combine qPCR assays for albumin and luciferase. 
With multiplexing in mind, we selected a TaqMan gene expression assay for luciferase that 
was “primer-limited” because of the over-abundance of luciferase relative to albumin in our 
samples  (Applied Biosystems, 2010; Henegariu et al., 1997).  Choosing a primer-limited 
assay for the more abundant target helps ensure that luciferase does not out-compete albumin 
for reagents and does not confound albumin Ct values.  The TaqMan qPCR master mix we 
used was optimized for multiplexing (Applied Biosystems, 2010), and the combined assays 
had distinct reporter dyes (albumin = FAM, luciferase = VIC).  
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To validate this duplex approach, the performance of individual assays was compared 
to their performance when multiplexed in an effort to identify possible interference.  Human 
HDE prepared with increasing concentrations of luciferase spike-in were analyzed by qPCR 
using the luciferase assay alone and in combination with albumin (Figure 2.10).  The Ct 
values of luciferase were not affected by the addition of the albumin assay.  We also 
compared the Ct values from human and rat albumin standard curves using the albumin assay 
alone and multiplexed with luciferase (Figure 2.10).  No changes in the Ct values of either 
albumin standard curve were detected using the albumin assay alone versus in conjunction 
with luciferase.  This work confirmed that the exogenous normalization gene luciferase can 
be measured in the same qPCR reaction as human or rat albumin.  
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Figure 2.10. Validation of qRT-PCR multiplexed assays for albumin and exogenous 
luciferase reference mRNA. Addition of the luciferase TaqMan assay does not interfere with 
detection of the human (A) or rat (B) albumin standard curves (both A and B share the same 
graph legend). Detection of luciferase across a range of concentrations is not affected by the 
albumin assay (C). Data points represent the mean Ct value for triplicate qPCR reaction wells 
and are fit with linear regression models. 
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Normalization of qRT-PCR data using exogenous mRNA 
Multiplexed qPCR for albumin and luciferase produced Ct values for both genes.  
Normalization to luciferase as a reference gene was performed by the following process.  
First, luciferase Ct values were averaged across triplicate wells of each sample.  The median 
of these averages was calculated.  On a per-sample basis, the average luciferase Ct was 
subtracted from the median of all luciferase averages.  The result is a normalization factor for 
each sample.  This sample-specific normalization factor was added to the corresponding 
albumin Ct values for a given sample.  The sum represents a normalized albumin Ct that can 
be used to calculate copy number in the unknown samples as previously described in the 
copy number calculation section.  The luciferase normalization factor was also applied to 
other mRNAs in those samples that were run on the same qPCR plate. 
2.4  Initial acetaminophen exposures and concentration selection for in vitro HDE 
studies 
2.4.1  Rat hepatocytes 
Freshly isolated primary Sprague-Dawley (SD) rat hepatocytes were obtained from 
the Hamner Institutes for Health Sciences (Research Triangle Park, NC).  Hepatocytes were 
seeded in culture plates coated with collagen type I (Corning) at a density of 1.5 x 106 cells 
per well in plating medium (high-glucose Dulbecco’s modified Eagle’s medium [DMEM], 
penicillin-streptomycin, sodium pyruvate, fetal bovine serum [Thermo Fisher Scientific], 
insulin, and dexamethasone [Sigma-Aldrich]).  Culture plates were incubated at 37ºC with 
5% CO2.  After attachment, non-adherent cells were removed and fresh plating medium was 
added.  Cultures were transitioned to serum-free hepatocyte maintenance medium (Modified 
Chee’s Medium, custom formulation) 4 h after plating.  Following a 24 h acclimation period, 
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hepatocyte cultures were exposed to acetaminophen (APAP; 0, 0.37, 1.1, 3.3, 10, or 30 mM) 
in medium for 72 h.  Treatment-induced effects on cell health were determined by measuring 
alanine aminotransferase (ALT) in the medium with an Infinity ALT/GPT Reagent kit 
(Thermo) modified for platereader format.  Reagent was warmed to 37 ºC and 200 µl were 
added to each well containing 20 µl of sample, media blank, or high and low controls.  The 
assay plate was incubated for 30 sec at 37 ºC before data collection.  The change in 
absorbance at 340 nm was measured every 60 sec for 8 min total on a SpectraMax M3 
microplate reader (Molecular Devices) in kinetic mode.  
After 72 h APAP exposure, the levels of ALT in culture medium as a function of 
APAP concentration demonstrated a pattern indicative of cell health at low concentrations, 
slight toxicity at intermediate concentrations, and overt necrosis at high concentrations 
(Figure 2.11).  However, the assay had a narrow dynamic range and was deemed 
inappropriate for in vitro hepatocellular toxicity approximation.  Morphologically, toxicity 
was apparent at 10 and 30 mM APAP.   
HDE and exosomal RNA were isolated as previously described.  Increases in 
exosomal albumin mRNA relative to untreated controls were observed at sub-toxic 
concentrations as low as 1.1 mM (Figure 2.11) and became statistically significant at 3.3 mM 
(p < 0.05, one-way ANOVA with Bonferonni’s multiple comparison test).  We selected this 
concentration range for acute 24 h exposures in vitro to study the early, sub-toxic responses 
of HDE to APAP.  
To examine the toxicity of a range of APAP concentrations in rat hepatocytes over 24 
h, we exposed primary rat hepatocytes to 0, 5, 10, or 20 mM APAP and measured lactate 
dehydrogenase (LDH) in the medium as described elsewhere (Holman et al., 2016).  We 
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empirically determined that overt APAP cytotoxicity after 24 h does not occur below 20 mM 
in rat hepatocytes (Figure 2.12) and that these concentrations were suitable to induce low to 
high levels of sub-toxic hepatocyte stress.  
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Figure 2.11. Primary rat hepatocyte responses following a range of APAP exposures for 
72 h. Exosomal albumin mRNA (A) increased consistently with APAP exposure, while ALT 
was significantly decreased prior to elevations (B). * p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001; one-way ANOVA with Bonferroni’s multiple test correction. 
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Figure 2.12. Overt cytotoxicity in primary rat hepatocytes is statistically significant 
following 24 h exposure to 20 mM APAP. Data are presented as the mean + SEM across 3 
biological replicates assayed in triplicate. ** p < 0.01; one-way ANOVA with Dunnett’s post-
test relative to vehicle. 
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2.4.2  Human hepatocytes 
We next sought to establish the appropriate concentration of APAP to stress primary 
human hepatocytes in vitro within 24 h.  Freshly isolated primary hepatocytes were cultured 
as previously described and exposed to 5 mM APAP for 24 h.  Cytotoxicity was determined 
by LDH leakage into medium and cellular ATP content using methods described in Holman 
et al 2016 (Figure 2.13). 
The average fold change in LDH measured in culture medium following APAP 
exposure was 1.4 (representing an increase from 9 to 13% of total LDH in the system) and 
the average fold change in cellular ATP was 0.95 relative to controls.  These alterations were 
minor and deemed to be biologically insignificant because in overt APAP hepatotoxicity, 
ATP, which is indicative of mitochondrial stress and energy imbalance, would be greatly 
decreased prior to the necrotic cell death indicated by increased LDH leakage.  The lack of 
significant APAP cytotoxicity was supported by the fact that no changes in exosomal 
albumin mRNA were detected.  We concluded that to induce biologically relevant 
hepatocellular stress in human hepatocytes within 24 h for the study of exosomal alterations, 
a concentration of 10 mM APAP would be required.  Our results agree with published data 
from primary human hepatocytes which revealed that within 24 h, APAP does not cause 
significant LDH elevations until 30 mM (Kia et al., 2015). Therefore, 10 mM APAP was 
used for subsequent primary human hepatocyte exposures. 
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Figure 2.13. Overt cytotoxicity is not observed in primary human hepatocytes following 
24 h exposure to 5 mM APAP. Data are presented as the mean + SEM across 3 biological 
replicates assayed in triplicate. ** p < 0.01, *** p < 0.001; one-way ANOVA with Dunnett’s 
post-test relative to vehicle. 
Control APAP
Exosomal Albumin
mRNA
LDH
Leakage
ATP
Content
0
20000
40000
60000
80000
0.0
0.5
1.0
1.5
C
o
p
y
 N
u
m
b
e
r F
o
ld
 C
h
a
n
g
e
***
**
 70 
 
 
CHAPTER 3. 
 
SUBTOXIC ALTERATIONS IN THE RNA CONTENT OF HEPATOCYTE-
DERIVED EXOSOMES FROM HUMAN AND RAT MODELS OF DRUG-INDUCED 
LIVER INJURY1  
 
3.1  Introduction 
Drug-induced liver injury (DILI) is responsible for significant pre- and post-market 
drug failures and is the primary cause of acute liver failure in the United States and Europe 
(Bernal et al., 2010; Ostapowicz et al., 2002; Wilke et al., 2007).  DILI, therefore, represents 
a major economic and clinical challenge for patients, healthcare providers, and 
pharmaceutical companies.  Identification of underlying mechanisms has proved especially 
difficult as DILI has been associated with hundreds of drugs that elicit a broad spectrum of 
injuries (Hornby et al., 2014; Hussaini and Farrington, 2014).  However, increasing evidence 
suggests that drug-induced hepatocellular death may often be mediated by immune responses 
(Adams et al., 2010; Ju and Reilly, 2012; Russmann et al., 2009).  For example, human 
leukocyte antigen (HLA) genotype is a strong risk factor for DILI associated with a wide 
range of drugs, suggesting a role for the adaptive immune system in drug-mediated 
hepatotoxicity (Urban et al., 2014).  In addition, elevations in biomarkers that trigger an 
                                                 
1 This chapter has been published as an original research article in Toxicological Sciences and is presented 
according to journal convention. The original citation is as follows: Holman et al. 2016. Sub-toxic alterations in 
hepatocyte-derived exosomes: an early step in drug-induced liver injury?, Toxicological Sciences, 151(2):365-
375; Epub 2016 Mar 8.   
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innate immune response such as high mobility group box 1 (HMGB1), and those that are 
suggestive of immune cell activation including miR-155 and acetylated HMGB1, have been 
associated with DILI (Antoine et al., 2014; Bala et al., 2012; Fontana, 2014).  Furthermore, 
immune reactions are triggered by hepatocellular danger signals, which can be released in the 
absence of hepatocyte death and communicate to other cell types as part of a stress response 
(Uetrecht and Naisbitt, 2013).  
Extracellular vesicles released by hepatocytes, principally hepatocyte-derived 
exosomes (HDE), may constitute one such danger signal (Conde-Vancells et al., 2008; De 
Maio, 2011; Royo and Falcon-Perez, 2012; Royo et al., 2013).  By virtue of their small size 
(<150 nm), HDE can readily cross through fenestrations in the sinusoidal endothelium and 
enter the bloodstream (Conde-Vancells et al., 2008), carrying liver-specific contents that are 
modified during DILI (Wetmore et al., 2010).  Clinically relevant alterations in HDE content 
and quantity have been detected in multiple models of liver injury including viral hepatitis 
(Zhang et al., 2014), alcoholic hepatitis (Momen-Heravi et al., 2015b), non-alcoholic 
steatohepatitis (Hirsova et al., 2016), cirrhosis, and hepatocellular carcinoma (Bernal et al., 
2010).  Moreover, exosomes are immunomodulatory and can carry damage-associated 
molecular patterns (DAMPs), antigens, and cytokines to recipient cells (Beninson and 
Fleshner, 2014; De Maio, 2011; Liu et al., 2006; Robbins and Morelli, 2014).  In the liver, 
HDE released by hepatitis C-infected hepatocytes activate dendritic cells and those released 
during lipotoxicity influence macrophage phenotype (Dreux et al., 2012; Hirsova et al., 
2016).  Recent experiments have demonstrated that one means by which HDE evoke immune 
responses is the delivery of functional genetic material such as microRNA (miRNA) and 
messenger RNA (mRNA).  For example, HDE-based RNA species miR-122 and albumin 
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mRNA (ALB) have been shown to activate recipient monocytes and fibroblasts, respectively 
(Momen-Heravi et al., 2015a; Royo et al., 2013).   
HDE may play a critical role in the initiation of and response to DILI by transmitting 
signals of hepatocellular stress that directly or indirectly stimulate an immune response.  For 
HDE to mediate early DILI events, we hypothesized that significant alterations in HDE 
content and/or number must occur prior to, or in the absence of, overt hepatocellular injury.  
To better understand the potential of HDE to modulate early immune-driven DILI events, we 
sought to establish that sub-toxic drug-induced HDE alterations were consistent in vivo and 
in vitro, and relevant in human DILI.  Acetaminophen (APAP) was selected as the model 
hepatotoxicant due to its well-defined in vivo and in vitro toxicity profiles.  We utilized this 
prototypical intrinsic hepatotoxicant for verification that the exosomes released by 
hepatocytes following drug exposure were altered in the absence of overt injury.  Although 
the role of immune reactions in APAP-induced liver injury is controversial, there is recent 
evidence of induction of immune tolerance in healthy adults that do not develop ALT 
elevations after recurrent therapeutic doses of APAP (Fannin et al., 2015), further supporting 
selection of APAP as our model toxicant.  This finding also suggests that some stress-
induced HDE alterations may promote an adaptive response to toxicity rather than an 
exacerbation of injury. 
We therefore evaluated the dose- and time-dependent effects of APAP on HDE-
associated RNAs in rats, primary rat hepatocytes, and primary human hepatocytes.  Because 
exosomes in the blood are derived from multiple cell types, exosome-associated liver-
enriched ALB mRNA and liver-specific miR-122 were assayed as a means to confirm the 
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presence of, and track alterations in, HDE across platforms (Bandiera et al., 2015; Miyamoto 
et al., 2008). 
3.2  Materials and Methods  
3.2.1  Animal exposures 
 Male Sprague-Dawley rats (Crl:SD), 7-9 weeks of age, were purchased from Charles 
River Laboratories and allowed to acclimate in-house for 7-10 days prior to study initiation.  
Water and food (pelleted PicoLab Rodent Diet 20 [Lab Diet]) were available ad libitum 
during this time.  Food was removed during an 18 h fasting period immediately prior to 
compound administration.  APAP (Sigma-Aldrich) was administered in 0.5% (w/v) 
methylcellulose (Sigma-Aldrich) at 0, 500, or 1400 mg/kg by oral gavage.  After dosing, 
food was provided ad libitum until necropsy.  Studies were conducted in accordance with the 
Guide for the Care and Use of Laboratory Animals, and were approved by the Mispro 
Institutional Animal Care and Use Committee (Mispro Biotech Services Inc.).   
3.2.2  Necropsy and histology 
 Rats were euthanized by CO2 inhalation and subsequent exsanguination at 0, 1, 2, 4, 
8, 12, and 24 h post-dose (n=6 per group).  Blood was collected in K2EDTA Vacutainer® 
tubes (Becton Dickinson).  Portions of the liver (median lobe) were minced and placed in 
RNAlater® Stabilization Solution (Applied Biosystems) for gene expression analysis.  
Sections from the left and median lobes were fixed in 10% neutral buffered formalin 
followed by 70% ethanol.  Paraffin-embedded blocks were sectioned (5 µm) and stained with 
hematoxylin and eosin (H&E).  Histopathological examination was performed by a board-
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certified veterinary pathologist.  Severity scores were assigned for centrilobular degeneration 
and necrosis (+1, minimal; +2, mild; +3, moderate; +4, marked).  Degeneration was defined 
as pre-necrotic hepatocellular change in centrilobular areas, including cytoplasmic 
hypereosinophilia, nuclear condensation and cellular dissociation.   Degeneration is assumed 
to precede fulminant necrosis such that, if given more time, degenerating cells likely would 
have progressed to necrosis.  Necrosis was marked by areas of complete hepatocellular 
destruction and neutrophil infiltration.  
3.2.3  Plasma isolation and plasma-derived exosome enrichment 
 Within 15 min of collection, blood was centrifuged to obtain cell-free plasma.  
Alanine aminotransferase (ALT) activity in fresh plasma was determined using a CLC 720 
clinical chemistry analyzer (Carolina Liquid Chemistries).  Additional aliquots of plasma 
were frozen at -80ºC until exosome isolation.  Thawed plasma was treated with Purified 
Thrombin Plasma Reagent and exosomes were isolated with ExoQuick™ Exosome 
Precipitation Solution (System Biosciences) according to the manufacturer’s instructions.  
The post-ExoQuick supernatant was reserved for RNA isolation to analyze liver-specific 
RNAs in the extra-exosomal, protein-rich plasma fraction. 
3.2.4  Primary hepatocyte culture and medium-derived exosome enrichment 
 Freshly isolated primary hepatocytes from human donors (n=7; Table 3.1) and male 
Sprague-Dawley rats (n=3) were obtained from commercial sources (QPS Hepatic 
Biosciences and Triangle Research Labs).  Individual batches of fresh hepatocytes were 
seeded into 12-well plates coated with collagen type I (Corning) at a density of 0.9 x 106 cells 
per well in hepatocyte plating medium (William’s E medium, penicillin-streptomycin, 
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GlutaMax™, HEPES, sodium pyruvate, fetal bovine serum [Thermo Fisher Scientific], 
insulin, and dexamethasone [Sigma-Aldrich]).  Culture plates were incubated at 37ºC with 
5% CO2.  After attachment, non-adherent cells were removed and fresh plating medium was 
added.  Cultures were transitioned to hepatocyte maintenance medium without fetal bovine 
serum after 3-4 h.  Following a 24 h acclimation period, hepatocyte cultures were exposed to 
APAP or a medium control (vehicle) for 24 h.  All conditions were tested in triplicate culture 
wells for each rat or human donor.  
Hepatocyte-conditioned medium (1-2 ml) was collected after 24 h and clarified by 
centrifugation at 3000g for 15 min.  Exosomes were precipitated from medium with 
ExoQuick-TC™ (System Biosciences) following the protocol for this sample type.  LDH 
activity was assayed with a Cytotoxicity Detection Kit (Roche) as described previously (Kia 
et al., 2015).  Cellular ATP content was measured with CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega) according to the manufacturer’s instructions.  Data were collected 
using a SpectraMax® M3 microplate reader (Molecular Devices). 
  
 76 
 
Table 3.1  Characteristics of primary human hepatocyte donors. 
 
 
  
Age (yr) BMI Sex Race
<1 15 M African-American
3 17 M Caucasian 
14 24 F Caucasian 
26 32 M Caucasian 
30 33 F African-American
48 24 F Caucasian 
74 23 F Caucasian 
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3.2.5  Extracellular vesicle characterization and validation of exosome enrichment 
Nanoparticle tracking analysis 
Nanoparticle tracking analysis was performed on exosomes produced in vitro using a 
NanoSight NS500 (Malvern Instruments).  The instrument was calibrated using polystyrene 
bead standards (100 nm) before each use (Malvern Instruments).  Diluted samples were 
advanced through the detection chamber to obtain 5 readings per sample, each with a capture 
period of 60 sec.  Particle concentration and size were determined using NTA software 
version 3.0 (Malvern Instruments). 
Electron microscopy  
Exosomes were precipitated from filtered (0.2 µm PES) hepatocyte-conditioned 
culture medium using ExoQuick-TC.  Exosome preparations were diluted 1:1000 in 
Dulbecco’s phosphate buffered saline (DPBS) to start the assembly reaction.  At 10 min, 
samples were applied to glow-discharged 200 mesh Quantifoil R 2/1 grids (Electron 
Microscopy Sciences), blotted briefly, and plunged into liquid ethane as described previously 
(Dokland, 2006).  The frozen grids were transferred to a Gatan 622 cryo-holder and imaged 
using an FEI Tecnai™ F20 transmission electron microscope, operated at 200 kV with 
magnifications from 5,000x to 29,000x and defocus settings of -6.0 to -10.0 μm.  Images 
were collected on a Gatan Ultrascan™ 4000 CCD camera. 
Immunoblot analysis 
Protein extracts were prepared from hepatocyte monolayers or exosomes using RIPA 
Lysis and Extraction Buffer (Thermo) with Halt Protease Inhibitor Single-Use Cocktail 
(Thermo) and Triton X-100 (hepatocytes only).  Protein concentration was determined using 
the BCA Protein Assay Kit (Thermo).  Equal protein quantities of each sample were 
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separated on 4-12% NuPAGE Bis-Tris gels (Life Technologies) and transferred to 
Immobilon®-FL PVDF membranes (Millipore).  Membranes were blocked with either 5% 
(w/v) non-fat dry milk in PBS or Odyssey PBS Blocking Buffer (Licor Biosciences).  The 
following primary antibodies were used for immunoblotting: Flotillin-1 (BD Transduction 
Laboratories), CD63 (Abcam), CD81 (AbD Serotech), Prohibitin-1 (Santa Cruz 
Biotechnology Inc.), and Grp78 (BD Transduction Laboratories).  Proteins were detected 
using IRDye secondary antibodies (Licor Biosciences) or Alexa Fluor® 680-conjugated 
AffiniPure IgG (Jackson Immunoresearch Laboratories).  Blots were imaged using an 
Odyssey® Classic Imaging System (Licor Biosciences).  
3.2.6  Total RNA isolation and analysis by absolute qRT-PCR 
 Total RNA was isolated from plasma- and culture medium-derived exosomes using 
the miRCURY Cell & Plant Isolation Kit (Exiqon) according to the manufacturer’s 
instructions for RNA isolation from blood.  To analyze extracellular RNA in the protein-rich 
compartment of culture medium and plasma, total RNA was isolated from culture medium 
samples or post-ExoQuick plasma supernatants, respectively, using the miRNeasy 
Serum/Plasma Kit (Qiagen) and manufacturer’s protocol.  Total RNA from rat liver, rat 
hepatocytes, and human hepatocytes was isolated with the miRNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions.  For all RNA isolations, a spike-in cocktail 
consisting of linear acrylamide carrier (Applied Biosystems) and exogenous RNA controls, 
Luciferase mRNA mimic (Promega) and C. elegans miR-39 (Qiagen), was added.  
Synthesis of cDNA for mRNA analysis was performed with equal volumes of RNA 
using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  Quantitative 
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real-time PCR (qRT-PCR) was performed on a 7900HT Fast Real-Time PCR System 
(Applied Biosystems) using TaqMan® Gene Expression Assays and Fast Advanced Master 
Mix.  Absolute quantities of mRNAs were calculated using a species-matched standard curve 
generated from bacterial plasmids or PCR amplification of liver cDNA.  Synthesis of cDNA 
for analysis of miR-122 copy number was performed using a TaqMan® miRNA Reverse 
Transcription Kit (Applied Biosystems).  Absolute qRT-PCR was performed on a 7900HT 
Fast Real-Time PCR System (Applied Biosystems) using TaqMan® MicroRNA Assays (hsa-
mir-122-5p) and Universal Master Mix II (no UNG).  Absolute quantities of miR-122 in 
cells, exosomes, and the protein-rich fraction were computed from a standard curve of 
synthetic miR-122 cDNA. 
3.2.7  Statistical analysis 
Analyses were conducted using GraphPad Prism 6 (GraphPad Software, Inc.) unless 
otherwise noted.  For all tests, p<0.05 was considered statistically significant.  Mean values 
from plasma-based endpoints (i.e. exosomal RNA and ALT activity) were analyzed using a 
two-way analysis of variance (ANOVA).  Results from APAP-treated animals were 
compared to time-matched control groups with Fisher’s Least Significant Difference 
(Fisher’s LSD) test.  In vitro data from rat hepatocytes were averaged across triplicate wells 
and a fold change relative to control was calculated for each rat.  Fold changes across rats 
(n=3) were averaged and compared by one-way ANOVA.  Results from each APAP 
concentration were compared to controls using Dunnett’s test for multiple comparisons.  In 
vitro data from each human hepatocyte batch were averaged across triplicate wells and a fold 
change relative to donor-matched controls was calculated.  From individual fold changes, a 
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mean across all donors was obtained.  Mean fold changes of control and APAP-treated 
groups were compared by Student’s two-tailed t-test. 
3.3  Results 
3.3.1  Exosomal albumin transcript quantities are significantly elevated prior to APAP-
induced hepatic necrosis in rats 
 Adult male Sprague-Dawley rats were administered a low (500 mg/kg) or high (1400 
mg/kg) dose of APAP or a vehicle control and were sacrificed at 0, 1, 2, 4, 8, 12, or 24 h 
post-dose.  Liver injury was determined by histology and plasma ALT activity.  Liver-
specific RNAs isolated from circulating exosomes were quantified to determine the 
relationship between hepatocyte-derived exosome (HDE) alterations and liver injury.  
Histological findings of necrosis (Figure 3.1; Table 3.2) and elevated plasma ALT activity 
(Figures 3.2, 3.3) were observed only in rats treated with the high dose of APAP at 24 h post-
exposure.  Exosomal albumin transcript (ALB) quantity, however, was significantly elevated 
in APAP-treated animals (relative to time-matched, vehicle-treated controls) prior to 
histological observations of necrosis or increases in plasma ALT (Figures 3.2, 3.3).  Drug-
induced elevations in mean exosomal ALB quantity were detected as early as 4 h post-dose; 
these elevations became dose-dependent at 8 h post-dose.  By 12 h, mean exosomal ALB 
mRNA had increased 30- and 50-fold in the low- and high-dose groups, respectively (Figure 
3.2).  Increases in exosomal ALB reached statistical significance in the high dose group at 12 
h and in the low dose group at 24 h, without signs of liver injury (Figures 3.2, 3.3).  
Together, these data suggest that changes in HDE release occur as a result of sub-toxic APAP 
exposure in vivo.   
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Figure 3.1. Histopathology of rat liver sections 24 h after APAP treatment. Representative 
photomicrographs of H&E stained liver sections from rats 24 h after administration of (A) 
0.5% methylcellulose vehicle, (B) 500 mg/kg APAP, or 1400 mg/kg APAP with (C) moderate 
or (D) marked centrilobular necrosis. Bars indicate 200 µm. 
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Table 3.2. Histopathological scoring of APAP-treated rat livers stained with H&E. Scoring: +1, minimal; +2, mild; +3, moderate; 
+4, marked. *, indicates outlier removed from data set. 
 
 
 
 
 
 
 
No findings
Time (h) Score: 0 +1 +2 +3 +4 +1 +2 +3 +4
0 4 6 0 0 0 0 0 0 0 0
500 4 6 0 0 0 0 0 0 0 0
1400 4 0 6 0 0 0 0 0 0 0
0 8 6 0 0 0 0 0 0 0 0
500 8 5 0 0 0 0 0 0 0 1*
1400 8 1 4 1 0 0 0 0 0 0
0 12 6 0 0 0 0 0 0 0 0
500 12 6 0 0 0 0 0 0 0 0
1400 12 1 2 3 0 0 0 0 0 0
0 24 6 0 0 0 0 0 0 0 0
500 24 2 2 0 1 0 0 0 1 0
1400 24 0 1 0 0 0 1 1 2 1
Number of animals
Treatment 
(mg/kg)
Centrilobular degeneration Centrilobular necrosis
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Figure 3.2. In vivo elevations in ALT activity and exosomal ALB as a function of APAP 
dose and exposure time. APAP-induced elevations in (A) plasma ALT activity and (B) 
exosomal ALB mRNA. Data are presented as mean + SEM of fold change over time-matched 
controls (n=5-6 rats/group). * p < 0.05, **** p < 0.0001; two-way ANOVA with Fisher’s LSD.  
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Figure 3.3. Absolute values of ALT activity and circulating liver-specific RNAs as a 
function of APAP dose and exposure time in vivo. APAP-induced elevations in (A) plasma 
ALT activity, (B) exosomal ALB mRNA copy number, (C) exosomal miR-122 copy number, 
and (D) protein-rich miR-122 copy number. Data are presented as mean + SEM (n=5-6 
rats/group). * p < 0.05, **** p < 0.0001; two-way ANOVA with Fisher’s LSD.  
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3.3.2  Quantity and distribution of extracellular miR-122 are altered by sub-toxic APAP 
exposure in vivo 
Unlike ALB mRNA which was not detected outside of the exosomal plasma fraction 
(data not shown), circulating miR-122 is stable in exosomes and in a “protein-rich” 
Argonaute-bound form (Arroyo et al., 2011; Hornby et al., 2014).  In order to determine if 
miR-122 followed a similar trend as exosomal ALB upon in vivo APAP exposure, we 
measured exosomal and protein-rich fractions of circulating miR-122.  A trend toward 
increased exosomal miR-122 was observed in APAP-treated animals at 8 h post-dose 
(Figures 3.3, 3.4).  This trend continued, with mean levels reaching 3- and 4-fold over 
controls in the low- and high-dose groups at 12 h, respectively.  At 24 h post-dose, mean 
exosomal miR-122 quantities in the low-dose group reached 9-fold that of vehicle-treated 
controls, despite a lack of hepatocellular toxicity.  miR-122 in the protein-rich fraction 
showed trends similar to exosomal miR-122 but was significantly elevated in the low-dose 
group after 24 h (Figures 3.3, 3.4).  Whereas the content of miR-122 in both exosomal and 
protein-rich compartments was increased by APAP exposure in our study, the distribution of 
miR-122 between these plasma compartments shifted over time.  In the high-dose group, the 
percentage of circulating miR-122 within HDE decreased over time and reached statistical 
significance at 12 h, prior to overt liver injury (Figure 3.4).   
Unexpectedly, we observed previously undocumented dose-dependent decreases in 
exosomal and protein-rich miR-122 fractions after 2 h of APAP exposure, which were not 
accompanied by decreases in exosomal ALB (Figure 3.4).  To determine whether the 
decreases in exosomal miR-122 reflected selective packaging of RNA into HDE or decreased 
hepatocyte miR-122 content, we quantified miR-122 in liver tissue obtained from the 2 h 
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post-exposure animals.  There was a trend toward increased hepatic miR-122 copy number 
coincident with statistically significant dose-dependent decreases in exosomal miR-122 
(Figure 3.4).  Exosomal ALB, however, was not significantly affected in circulating 
exosomes or liver tissue. 
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Figure 3.4. Alterations in exosomal and protein-rich fractions of miR-122 following in 
vivo APAP exposure.  Fold change in (A) exosomal and (B) protein-rich miR-122 plasma 
compartments relative to time-matched vehicle controls (n=5-6 rats/group). * p < 0.05, **** p 
< 0.0001; two-way ANOVA with Fisher’s LSD. (C) Percentage of circulating miR-122 in HDE 
from 1400 mg/kg APAP-treated rats. * p < 0.05, *** p < 0.001; one-way ANOVA with 
Dunnett’s post-test relative to t=1 h. (D) Relationship between liver-specific RNAs measured 
in exosomes and liver tissue at 2 h post-dose. * p < 0.05; one-way ANOVA with Dunnett’s 
post-test relative to vehicle. Data are presented as mean + SEM. 
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3.3.3  EV preparations from primary rat and human hepatocyte cultures are highly enriched 
for exosomes 
 We selected a well-characterized exosome enrichment method for our in vivo studies, 
and evidence suggests that most extracellular vesicles (EV) released by hepatocytes are 
exosomal in size (Giugliano et al., 2015; Koeck et al., 2014; Momen-Heravi et al., 2015a; 
Royo et al., 2013).  However, multiple cell types and tissues contribute to the population of 
circulating vesicles, and therefore we could not study the nature of hepatocyte-specific 
vesicles isolated from the in vivo samples.  To confirm the presence of exosomes in EVs 
isolated by ExoQuick, we analyzed the size, morphology, and protein enrichment of EVs 
produced in vitro by primary rat and human hepatocytes. 
EVs were isolated from conditioned medium of untreated primary rat or human 
hepatocytes by ExoQuick-TC polymer precipitation.  Nanoparticle tracking analysis of rat 
and human EV preparations revealed a majority of small exosome-sized particles less than 
200 nm in diameter, with the greatest concentration of particles being less than 100 nm in 
size (Figure 3.5).  These results were confirmed using a ZetaView® instrument 
(ParticleMetrix) (data not shown).  Cryo-electron microscopy verified exosome enrichment 
in precipitated rat and human EV preparations, which contained circular membrane-bound 
vesicles smaller than 100 nm (Figure 3.5).   
Western immunoblot analyses of rat EVs confirmed the presence of exosomal protein 
markers CD81 and CD63 (Figure 3.5).  Prohibitin-1, a mitochondrial membrane protein, was 
detected in rat hepatocytes but was not present in rat HDE, suggesting a lack of cellular 
contamination in exosomal samples (Figure 3.5).  Human EV preparations were positive for 
exosomal markers CD63 and Flotillin-1 and did not contain detectable cellular 
 90 
 
contamination, as measured by Prohibitin-1 and Grp78, a protein found in the endoplasmic 
reticulum (Figure 3.5).  These results confirm that our ExoQuick preparations contain mostly 
HDE.   
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Figure 3.5. Characterization of exosome enrichment in extracellular vesicles secreted by 
primary rat and human hepatocytes. Representative nanoparticle tracking analyses 
illustrating the average size distribution of EVs isolated from untreated (A) rat and (B) human 
hepatocyte-conditioned culture medium; red indicates SEM. Representative cryo-electron 
micrographs of (C) rat and (D) human hepatocyte-derived EV preparations. Bars indicate 100 
nm. Western blot analysis of exosomal and cellular markers in (E) rat and (F) human HDE 
(“Ex”) relative to hepatocytes (“Cell”).  
 92 
 
3.3.4 Sub-toxic APAP exposure elicits exosomal RNA elevations in primary rat hepatocytes  
 To further characterize HDE release from drug-treated hepatocytes, we explored 
whether APAP-dependent changes in exosomal RNA content observed in vivo could be 
reproduced in monocultures of primary rat hepatocytes.  Primary rat hepatocytes were 
exposed to a concentration range of APAP (0-30 mM) for 24 h.  Across 3 rat hepatocyte 
batches, statistically significant elevations in LDH leakage and decreases in cellular ATP 
were not observed at concentrations less than 30 mM APAP (Figure 3.6).  However, 
statistically significant increases in exosomal ALB mRNA were evident at concentrations as 
low as 1.1 mM APAP (Figure 3.6).  Hepatocellular ALB levels were not altered significantly 
at any APAP concentration, suggesting that increased exosomal ALB was not a result of 
increased expression at the cellular level.  In contrast to our in vivo findings, miR-122 was 
not elevated significantly in the exosome- or protein-rich fractions prior to the onset of overt 
cytotoxicity (Figure 3.6).   
We then tested the hypothesis that liver-specific exosomal RNA levels are indicative 
of HDE number, which cannot currently be assessed in vivo.  We performed nanoparticle 
tracking analysis on HDE from primary rat hepatocyte cultures exposed to 0, 10, or 30 mM 
APAP for 24 h (n=2 rats).  No statistically significant changes in HDE quantity were 
observed at any concentration (Figure 3.6). 
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Figure 3.6. APAP-induced 
alterations in exosomes 
released by primary rat 
hepatocytes. Data are 
presented as mean + SEM 
(n=3 rats) after 24 h APAP 
exposure. (A) Cytotoxicity, 
as indicated by cellular ATP 
and LDH activity in medium. 
(B) Exosomal and cellular 
levels of ALB in response to 
APAP. (C) miR-122 in 
exosomal, protein-rich, and 
cellular fractions in response 
to APAP. * p < 0.05, ** p < 
0.01, *** p < 0.001, **** p < 
0.0001; one-way ANOVA 
with Dunnett’s post-test 
relative to vehicle. (D) 
Nanoparticle tracking 
analysis on HDE 
preparations from primary 
rat hepatocytes (n=2 rats) 
following 24 h incubation 
with APAP. Data are 
presented as the mean + 
SEM of fold change in 
exosomes/ml relative to 
control. No statistically 
significant differences in 
exosome quantity between 
treated and untreated groups 
were observed; one-way 
ANOVA with Dunnett’s 
post-test relative to vehicle. 
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3.3.5  Increased secretion of exosomal RNA in the absence of overt APAP toxicity translates 
to primary human hepatocyte cultures 
 To determine whether primary human hepatocytes would respond to APAP exposure 
by increasing production of exosomal RNAs, we separately exposed individual batches of 
freshly isolated primary hepatocytes (n=7 donors) to a sub-toxic APAP concentration (10 
mM) for 24 h (Figure 3.7).  APAP treatment caused increases in mean exosomal ALB (not 
statistically significant) and miR-122 (p<0.001) levels in the absence of overt injury (Figure 
3.7).  Quantities of ALB and miR-122 in cells and protein-rich medium fractions were not 
affected by APAP exposure (Figure 3.7).   
To define the relationship between drug-induced changes in liver-specific exosomal 
RNA and HDE number in a human system, nanoparticle tracking analysis was performed on 
exosomes isolated from control and treated (0 vs. 10 mM APAP) primary human hepatocyte 
cultures (n=4 donors).  As observed in the rat experiments, APAP exposure did not cause 
statistically significant changes in exosome quantity (Figure 3.7).   
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Figure 3.7. Alterations in exosomes 
released by primary human 
hepatocytes with and without APAP 
exposure. (A) LDH leakage, (B) ALB 
mRNA, and (C) miR-122 after 24 h of 
exposure to APAP (10 mM). Data are 
presented as the mean + SEM across 7 
donors. *** p < 0.001; Student’s t-test 
comparing treatment and control. (D) 
Nanoparticle tracking analysis on HDE 
preparations from primary human 
hepatocytes (n=4 donors) after 24 h 
incubation with APAP. Data are 
presented as the mean + SEM of fold 
change in exosomes/ml relative to 
control. No statistically significant 
differences in exosome quantity between 
treated and untreated groups were 
observed; Student’s t-test. 
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3.3.6  Establishing baseline quantities of liver-specific RNAs in exosomes from primary 
human hepatocytes 
Individual lots of primary human hepatocytes (n=7) were cultured for 24 h with or 
without 10 mM APAP.  Substantial donor-to-donor variability in the exosomal quantities of 
ALB and miR-122 was apparent.  To identify donor characteristics that potentially influenced 
exosomal content, we related characteristics such as sex, age, BMI, and race to the quantity 
of liver-specific exosomal RNAs from medium control- and APAP-treated hepatocytes 
(Figure 3.8).  No association reached statistical significance, but we observed a relationship 
between exosomal ALB and BMI (p=0.074, regression analysis) in untreated hepatocytes 
(Figure 3.8).   
In an effort to establish healthy ranges of exosomal ALB and miR-122, we examined 
absolute copy numbers of these exosomal RNAs across hepatocyte donors (n=7) under 
control conditions.  We found that quantities of exosomal miR-122 generally corresponded 
with levels of protein-rich miR-122, although this relationship did not hold true for every 
donor (Figure 3.9).  We did not observe a consistent relationship between exosomal and 
cellular ALB.  Absolute copy numbers of exosomal miR-122 ranged from approximately 107-
109, while exosomal ALB ranged from approximately 103-106 (Figure 3.9).   
 97 
 
Figure 3.8. Relationships between human donor characteristics and HDE endpoints 
before and after in vitro APAP exposure. (A) Data are presented as p-values obtained by 
Student’s t-test (categorical variables) or regression (continuous variables); darker cells 
indicate lower p-values. The most significant relationship was observed between BMI and 
baseline exosomal ALB quantity (p=0.074). (B) High BMI (indicated by circle size) 
corresponded to lower exosomal ALB (indicated by circle color).  
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Figure 3.9. Quantification of miR-122 and ALB mRNA in HDE from untreated primary 
human hepatocytes. Absolute copy numbers of (A) miR-122 and (B) ALB mRNA in cellular, 
exosomal, and protein-rich (“protein”) fractions from 7 primary human hepatocyte donors. 
Data represent the mean + SEM of triplicate culture wells for each donor. Corresponding age, 
BMI, sex, and race are also presented. 
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3.3.7  Additional liver-enriched transcripts are present in human hepatocyte-derived 
exosomes 
 Finally we sought to confirm that additional liver-enriched mRNAs previously 
identified in rat EVs, and enriched in both rat and human liver, were packaged within human 
HDE (Miyamoto et al., 2008; Okubo et al., 2013; Royo et al., 2013; Yu et al., 2010).  
Exosomes were precipitated from the culture medium of untreated primary human 
hepatocytes (n=3 lots), and exosomal transcripts were quantified by absolute qRT-PCR.  All 
7 liver-enriched transcripts were detected in human HDE under control conditions, and 
although the absolute amounts varied, the relative proportions of each mRNA across donors 
were consistent (Figure 3.10).  
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Figure 3.10. Analysis of additional liver-enriched transcripts within exosomes released 
by untreated primary human hepatocytes. Bar color denotes different donors (n=3). Data 
represent the mean + SEM of exosomal mRNAs across triplicate culture wells for each donor. 
Transcript quantities are expressed as exosomal copy number per ml of culture medium used 
to isolate HDE. 
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3.4  Discussion 
 To determine whether HDE could mediate the immune reactions that occur without 
overt hepatotoxicity following drug exposure, we tested the hypothesis that HDE content 
and/or number would be altered by drug-induced hepatocellular stress in the absence of cell 
death.  We found that the RNA content of HDE was affected prior to, and in the absence of, 
overt hepatocellular injury in rats receiving both toxic and sub-toxic doses of APAP.  These 
results translated across experimental models and species as similar phenomena were 
observed in primary hepatocyte cultures from both rats and humans. 
APAP was selected for this work largely for its defined toxicity profile in vivo and in 
cultured hepatocytes from both rats and humans.  Although we are ultimately interested in 
the role of exosomes in immune signaling, the current study does not address the 
consequences of the immune component of APAP-induced hepatotoxicity, a topic that 
remains controversial.  Whether advantageous (Antoniades et al., 2012; Jaeschke et al., 
2012; Ju et al., 2002; Williams et al., 2014) or damaging (Fannin et al., 2015; Ferreira et al., 
2016; Huebener et al., 2015; Tujios and Fontana, 2011), there is no question that 
inflammatory and immune responses are associated with APAP-induced hepatotoxicity in 
humans.  In a study of recurrent therapeutic APAP dosing, activation of immune tolerance 
was evident in the peripheral blood transcriptome of healthy adults without APAP-induced 
ALT elevations (Fannin et al., 2015).  This suggests that immune responses after APAP 
exposure manifest prior to overt hepatocellular injury, a process that likely involves sub-toxic 
hepatocellular release of stress signals such as HDE.  
Although mouse models are generally considered to be more appropriate for the study 
of APAP-induced hepatotoxicity mechanisms (Jaeschke et al., 2014; McGill et al., 2012), the 
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goal of the current work was to evaluate early changes in HDE that occur during APAP-
induced stress, prior to hepatocellular injury.  Therefore, the rat was intentionally selected as 
a relatively resistant preclinical species to extend the duration of APAP-induced stress in vivo 
so that HDE alterations could be observed prior to overt DILI.  Evidence suggests that this 
latency may be more similar to humans than the latency to fulminant hepatotoxicity observed 
in mice (Jaeschke et al., 2014).  Because mouse hepatocytes are difficult to culture, selection 
of a rat model also facilitated comparisons of data collected from primary hepatocytes 
relative to in vivo data from the same species.   
In the current study, we selected liver-specific exosomal contents ALB mRNA and 
miR-122 as translational markers of HDE alteration that also elicit immunologically relevant 
responses when transferred to other cell types (Momen-Heravi et al., 2015a; Royo et al., 
2013).  Circulating ALB mRNA and miR-122 have been identified previously as more 
sensitive and specific biomarkers of liver injury in both preclinical species and humans 
(Antoine et al., 2013; Okubo et al., 2013; Starckx et al., 2013; Wang et al., 2009; Zhang et 
al., 2014).  In particular, the value of miR-122 in peripheral blood as a biomarker of APAP 
overdose is well established (Antoine et al., 2013).  Therefore, the biomarker potential of 
miR-122 and HDE was not a focus of the current work.   
In our in vivo rat model of APAP-induced liver injury, the proportion of plasma miR-
122 contained within exosomes decreased over time in the high dose group, presumably as a 
function of increased hepatocellular damage.  These data are in agreement with what is 
known about the active nature of exosome release and the passive, necrotic release of 
protein-rich miR-122 (Bobrie et al., 2011; Dear and Antoine, 2014; Kia et al., 2015; 
Turchinovich et al., 2013; Turchinovich et al., 2011; Villarroya-Beltri et al., 2014).  Similar 
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shifts in miRNA localization between protein-rich and exosomal fractions have been 
observed in DILI, and the nature of these shifts may reflect different mechanisms of liver 
injury (Bala et al., 2015; Bala et al., 2012).  We propose that shifts in miRNA localization, 
such as those shown here, may serve a biological signaling purpose.  For example, miR-122 
in HDE released by alcohol-treated hepatocytes can prime monocytes for activation, while 
biological activity has yet to be attributed to miRNA in the protein-rich form (Momen-Heravi 
et al., 2015a; Turchinovich et al., 2013).  Similarly, the effects of inflammatory mediators 
such as Hsp70 are amplified when they are delivered to recipient cells via exosomes (De 
Maio, 2011).  While it is unlikely that exosomal miR-122 is a driving factor or major 
inflammatory mediator in overt APAP hepatotoxicity, during which necrosis releases 
massive amounts of DAMPs, the present miR-122 results support the assertion that HDE 
alterations may be actively mediated and functionally relevant in the early stages of 
hepatocyte stress.   
In vivo, parallel increases in HDE-associated ALB mRNA and miR-122 were 
generally observed.  However, exosomal ALB mRNA did not decrease in vivo at early time 
points alongside exosomal miR-122, providing evidence for the selective packaging of RNA 
into HDE.  Selective mRNA packaging into exosomes has been observed in circulating 
vesicles from rats treated with APAP or D-(+)-galactosamine (DGAL), which contained 
distinct transcript profiles suggestive of compound-specific exosomal content (Wetmore et 
al., 2010).  We confirmed these results with HDE, as different trends in exosomal ALB 
mRNA and miR-122 were observed following APAP and DGAL exposures in primary rat 
hepatocytes (Figure 3.11).  While sub-toxic concentrations of DGAL elicited increases in 
both exosomal RNAs, neither reached statistical significance prior to overt cytotoxicity.  Our 
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nanoparticle tracking results also recapitulate the selective packaging hypothesis by 
indicating that the quantity of exosomal RNA does not correspond to HDE number.  As such, 
the APAP-induced exosomal ALB mRNA elevations observed in vivo and in vitro are likely 
the result of increased ALB packaging within a similar number of HDE rather than an 
increase in overall HDE production with constant ALB mRNA content.  While these findings 
are novel, it is important to note that exosome quantification could be affected by the stability 
of HDE in culture, which is currently unknown.  Future experiments to establish the half-life 
and clearance rate of HDE will be imperative for understanding the biological implications of 
HDE in DILI.   
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Figure 3.11. D-(+)-
galactosamine-induced 
alterations in exosomes 
released by primary rat 
hepatocytes. Data are 
presented as mean + SEM 
(n=3 rats) following 24 h 
DGAL exposure. (A) 
Cytotoxicity, as indicated 
by cellular ATP and LDH 
activity in medium. (B) 
Fold change in exosomal 
and cellular ALB in 
response to DGAL. (C) 
Fold change in miR-122 
within exosomal, protein-
rich, and cellular fractions 
in response to DGAL. * p < 
0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001; 
one-way ANOVA with 
Dunnett’s post-test relative 
to vehicle.  
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Although the intent of this work was not to study biomarkers, by defining the kinetics 
and dose-dependence of HDE release prior to overt DILI, the current study could help to 
validate HDE as sensitive, translational, and clinically relevant biomarkers of DILI.  We 
assayed 7 liver-enriched transcripts within primary human HDE from 3 separate donors.  To 
our knowledge, this is the first characterization of the mRNA content of HDE from primary 
human hepatocytes.  All 7 liver-enriched transcripts were measurable, and there was some 
consistency in the relative abundance of each transcript across the 3 donors, suggesting that 
these mRNAs, originally detected in rat HDE (Miyamoto et al., 2008; Okubo et al., 2013; 
Royo et al., 2013), may also be used to identify human HDE.  In addition, we have begun to 
define normal levels of exosomal ALB mRNA and miR-122 across donors.  Despite the small 
donor pool, potential relationships were identified between donor characteristics and 
exosomal content.  Continuing to study donor characteristics that influence HDE RNA 
content and to define a healthy range of HDE-based RNA levels will be important for 
interpreting biomarker data in the future.  These data will need to be considered in the 
context of disease, which is known to affect basal HDE quantity and content.  For instance, 
recent evidence suggests that high hepatocellular lipid content and non-alcoholic fatty liver 
disease correspond to increased extracellular vesicle production by hepatocytes (Hirsova et 
al., 2016; Kakazu et al., 2015). 
In summary, we detected significant alterations in the liver-specific RNA content of 
HDE at sub-toxic doses of the prototypical hepatotoxicant APAP in rats and in primary rat 
and human hepatocytes.  These alterations appear to reflect differential packaging of select 
RNAs in HDE rather than HDE number.  The changes in HDE content observed prior to and 
in the absence of overt hepatocellular injury, together with growing data on the role of 
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exosomes in stimulating immune responses, support the hypothesis that HDE released from 
drug-stressed hepatocytes may transmit signals that mediate critical early immune responses 
across multiple forms of DILI.  While this hypothesis was substantiated using an intrinsic 
hepatotoxicant, future work will address the release kinetics and signaling potential of HDE 
released by hepatocytes exposed to idiosyncratic DILI compounds.  
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CHAPTER 4. 
 
MECHANISTIC INTEGRATION OF HUMAN HEPATOCYTE-DERIVED 
EXOSOME CONTENT AND IMMUNOLOGIC ACTIVITY 
 
4.1  Introduction 
It is widely accepted that intrinsic and idiosyncratic drug-induced hepatocellular 
death are often mediated by immune responses (Adams et al., 2010; Ju and Reilly, 2012; 
Russmann et al., 2009).  For example, human leukocyte antigen (HLA) genotype is a strong 
risk factor for idiosyncratic DILI (I-DILI) associated with a wide range of drugs, suggesting 
a role for the adaptive immune system in drug-mediated hepatotoxicity (Urban et al., 2014).  
In addition, elevations in biomarkers that are suggestive of immune cell activation, including 
miR-155 and acetylated high mobility group box 1 (HMGB1), have been associated with 
intrinsic DILI (Antoine et al., 2014; Bala et al., 2012; Fontana, 2014).  Such immune 
reactions may be triggered in part by hepatocellular danger signals or damage-associated 
molecular patterns (DAMPs), which communicate to immune cells as part of a stress 
response (Uetrecht and Naisbitt, 2013).  Recent evidence indicates that hepatocytes can 
release these signals prior to overt cell death, suggesting that the first interaction between an 
injured hepatocyte and cells of the immune system may occur much earlier than previously 
thought.      
 Exosomes released by drug-stressed hepatocytes may constitute an early link between 
hepatocellular distress and the immune system.  The immunomodulatory activity of 
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hepatocyte-derived exosomes (HDE) has been validated in various models of liver disease.  
In the context of viral hepatitis, hepatitis C (HCV)-infected Huh7.5 cells release exosomes 
that transfer viral RNA to plasmacytoid dendritic cells (pDCs) and promote the release of 
interferon (IFN-α) as part of the body’s defense against HCV (Dreux et al., 2012).  HCV-
infected Huh7.5 cells alter monocyte secretion of the adaptive immune response mediator 
galectin-9, a process which is thought to be mediated by HDE (Harwood et al., 2016).  In  
hepatitis B viral infection (HBV), exosomes can actively transfer the virus to other 
hepatocytes and have a deleterious effect on natural killer (NK) cell proliferation (Yang et 
al., 2016).   
Exosome regulation of immune signaling in non-infectious liver disease has been best 
studied in models of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver 
disease (NAFLD).  Broadly, these diseases are characterized by lipid-induced hepatocyte 
toxicity, chronic inflammation, and compensatory wound healing leading to fibrosis.  
Evidence suggests that hepatocellular lipotoxicity is mediated by inflammatory signaling 
which has led to investigation of the link between hepatocyte lipoapoptosis and inflammatory 
response (Hirsova and Gores, 2015).  In a recent study by Hirsova et al, murine bone 
marrow-derived macrophages (BMDMϕ) were exposed to EV from mice fed a control or 
high-fat diet as well as EV from mouse hepatocytes exposed to control or toxic lipid 
treatment.  EVs from mice on a high-fat diet and from lipoapoptotic hepatocytes induced 
expression of the interleukins IL-6 and IL-1β in BMDMϕ relative to control EVs (Hirsova et 
al., 2016).  A similar study found that a mouse hepatocyte cell line exposed to palmitate 
produced greater quantities of ceramide-enriched EVs that chemotactically recruited more 
BMDMϕ than EVs from control-treated hepatocytes (Kakazu et al., 2015).  
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Few studies have focused on the role of HDE in xenobiotic-induced liver injury, 
although there is encouraging evidence from models of alcoholic liver disease.  A 
comparison of the immunomodulatory effects of control- versus ethanol (EtOH)-treated 
Huh7.5 cells revealed that EtOH EVs synergize with lipopolysaccharide (LPS) to promote 
increased production of the pro-inflammatory mediators tumor necrosis factor alpha (TNF-
α), IL-1β, and monocyte chemoattractant protein 1 (MCP-1) in THP-1 monocytes (Momen-
Heravi et al., 2015a).  Similarly, THP-1 cells, primary murine macrophages, and primary 
human monocyte-derived macrophages showed significant increases in pro-inflammatory 
cytokines following treatment with EVs from EtOH-treated, CYP2E1-overexpressing HepG2 
human hepatocyte-like cells (Verma et al., 2016).  Other xenobiotic studies have utilized the 
overt hepatotoxicant carbon tetrachloride (CCl4) to study the functional activity of EVs from 
injured hepatocytes.  For example, Simon et al co-cultured a subpopulation of bone marrow-
derived monocytes (BMDM) with primary rat hepatocytes isolated from a CCl4-induced 
acute liver failure (ALF) model or healthy rats (2015).  In the presence of ALF hepatocytes, 
BMDM internalized hepatocyte EVs and began to express hepatocyte progenitor markers 
(Simon et al., 2015).  However, whether hepatocyte EVs were involved in mediating the 
BMDM phenotypic changes in co-cultures was not examined.   
The molecular basis of exosome-mediated activity in recipient cells is not well 
defined.  One possible mechanism is the transfer of exosomal content (lipid, protein, and/or 
RNA cargo) into the recipient cell via fusion or endocytosis.  The transfer of RNA species 
like miRNA and mRNA by exosomes is well-established, an example being the transfer of 
viral RNA described previously.  An attractive argument for this mechanism is the fact that 
stress and toxicity influence the RNA content of exosomes from various cell types, including 
 111 
 
hepatocytes (de Jong et al., 2012; Eldh et al., 2010; Holman et al., 2016; Wetmore et al., 
2010).  Evidence supports the transfer of functional mRNA and miRNA by hepatocyte EVs.  
For example, following exposure to human liver stem cell-derived EVs, rat hepatocytes in 
vivo translate EV-delivered human AGO2 mRNA into protein (Herrera et al., 2010).  In the 
aforementioned study of EtOH HDE activating monocytes, a set of elegant and thorough 
experiments showed that hepatocyte-specific exosomal miRNA miR-122 was elevated in 
EtOH HDE over controls, and that this miRNA was responsible for the pro-inflammatory 
phenotype in recipient cells (Momen-Heravi et al., 2015a).   
 Surprisingly, despite convincing evidence of immune mediation by HDE, to our 
knowledge, no studies have examined the role of HDE in DILI reactions, representing a clear 
knowledge gap in this field.  Most exosome research related to DILI has focused on their 
biomarker potential, which is a promising area of study.  As a result, HDE are often studied 
in the context of drug overdose or drug-induced ALF.   
To better understand the biological activity of HDE in early immune-driven DILI 
events, we sought to establish that sub-toxic drug-induced HDE alterations could influence 
THP-1 human monocytes.  Acetaminophen (APAP) was selected as our model 
hepatotoxicant due to its well-defined in vivo and in vitro toxicity profiles.  We have already 
confirmed significant sub-toxic alterations in the albumin mRNA and miR-122 content of 
HDE released by rat and human hepatocytes following sub-toxic APAP exposures (Chapter 
3) (Holman et al., 2016), and both of these RNAs are implicated in the functional effects of 
HDE (Momen-Heravi et al., 2015a; Royo et al., 2013).  In addition, there is no doubt that 
immune responses play a role in APAP-induced liver injury.  For example, recent evidence 
from a healthy volunteer study revealed pro-inflammatory transcriptomic signatures in 
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subjects who developed ALT elevations following therapeutic doses of APAP (Fannin et al., 
2015).  While a consensus regarding the positive or negative impact of immune reactions is 
lacking, the human relevance is not.   
Based on this evidence, we sought to: (1) establish a role for HDE in the regulation of 
early DILI immune responses, (2) comprehensively profile the mRNA and miRNA content 
of exosomes released by control- and APAP-treated primary human hepatocytes, and (3) link 
HDE miRNA profiles to their biologic activity.  In addressing these goals, we provide the 
first next-generation sequencing (NGS) analysis of the RNA in primary human HDE.  This 
research is the first to report immunologic activity of primary human HDE in a model of 
DILI.  
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4.2  Materials and Methods 
4.2.1  EV pathway activation experiments with the potent Nrf2 activator 3H-1,2-dithiole-3-
thione (D3T) 
In vivo rat exposures 
Male Sprague-Dawley rats (Crl:SD), 10-12 weeks of age, were purchased from 
Charles River Laboratories and allowed to acclimate in-house for 10-15 days prior to study 
initiation.  Water and food (pelleted NIH-07 diet [Ziegler Brothers]) were available ad 
libitum during this time.  D3T (LKT labs) was administered once daily for 4 days in sterile 
saturated sucrose vehicle at 0, 0.1 mmol/kg, or 0.3 mmol/kg by oral gavage (n=14/group).  
The rats were not fasted at any point during this study.  Studies were conducted by Drs. 
Rusty Thomas, Barbara Wetmore, and Reetu Singh in accordance with the Guide for the 
Care and Use of Laboratory Animals, and were approved by The Hamner Institutes for 
Health Sciences Institutional Animal Care and Use Committee. 
At necropsy, blood was collected for circulating EV RNA analysis and liver tissue 
was collected for histology as well as gene expression analysis. Total RNA was isolated from 
plasma with a QIAmp Viral RNA Kit (Qiagen) according to the manufacturer’s instructions.  
Liver and plasma cDNA was generated with a High Capacity cDNA RT Kit (Applied 
Biosystems) and qRT-PCR was performed as described in previous chapters.  
In vitro exposures and analysis of hepatocyte-specific exosome content 
 Freshly isolated primary hepatocytes from male Sprague-Dawley rats were plated as 
previously described (Holman et al., 2016).  Cultures were treated with 0, 10, 50, or 100 µM 
D3T (LKT Labs) in 0.2% (v/v) dimethyl sulfoxide (DMSO) vehicle (Sigma).  These 
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concentrations are well below peak plasma concentrations observed in rats treated with high 
doses of D3T (0.4-4 mM) (Brown et al., 2000) but were the highest that could be achieved 
with the compound’s solubility limitations.  A concentration of 10 µM was previously used 
to induce Nrf2 in vitro and was deemed to be suitable for Nrf2 activation and down-stream 
gene target up-regulation (Kwak et al., 2002).   
 While D3T is widely considered non-toxic, we wished to confirm that the 
concentrations used to induce Nrf2 in rat hepatocytes over a 24 h period would not cause cell 
death.  To assess cytotoxicity, LDH in culture medium was assayed as described in earlier 
sections.  RNA was collected from hepatocytes and HDE precipitated by EQ to compare the 
content of Nrf2-regulated genes Gsta3, Nqo1, Hmox1, Gclc, and Ugt1a6 in both sample 
types.  TaqMan qRT-PCR was performed as stated earlier. 
 Given that the Nrf2 target genes being measured in HDE are not as abundant as the 
highly liver-enriched RNAs albumin or miR-122, we investigated the validity of isolating 
HDE from large volumes of conditioned rat hepatocyte culture medium via centrifugal 
concentration.  We compared quantities of exosomal albumin obtained by EQ precipitation 
from equal volumes of un-concentrated medium, medium processed using an Amicon Ultra 
3kDa molecular weight cutoff concentrator or a Centricon Plus 10 kDa concentrator.  Upon 
validating that no exosomal material was lost with medium concentration, rat hepatocyte 
cultures were scaled to the maximum feasible level to determine whether a larger quantity of 
exosomes would yield detectable Nrf2 target mRNAs.  
 
 115 
 
4.2.2  Generation of primary human HDE  
Primary human hepatocyte cultures 
Primary human hepatocytes from 5 donors were obtained from commercial sources 
(QPS Hepatic Biosciences and Triangle Research Labs) (Table 4.1).  Freshly isolated 
hepatocytes were used (n=3 donors) when available. Cryopreserved hepatocytes were also 
utilized (n=2 donors). Individual batches of hepatocytes were seeded into 10 cm dishes 
coated with collagen type I (Corning) at a density of 10 x 106 cells per dish in hepatocyte 
plating medium (William’s E medium, penicillin-streptomycin, GlutaMax™, HEPES, 
sodium pyruvate, fetal bovine serum [Thermo Fisher Scientific], insulin, and dexamethasone 
[Sigma-Aldrich]).  Culture plates were incubated at 37ºC with 5% CO2.  After attachment, 
non-adherent cells were removed and fresh plating medium was added.  Cultures were then 
transitioned to hepatocyte maintenance medium without fetal bovine serum within 6-12 h of 
plating.  Following a 24 h acclimation period, hepatocyte cultures were exposed to APAP (10 
mM) or a vehicle control (medium) for 24 h.   
Treatment-induced effects on cell health and function were determined by measuring 
cellular ATP, urea production, and LDH leakage.  Cellular ATP content was measured with 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) and urea production was 
assayed in cell culture supernatant with a Urea Nitrogen BUN kit (Stanbio) using modified 
methods. Briefly, a urea nitrogen standard curve of 2-fold serial dilutions from 100 to 1.56 
µg/ml was prepared in culture medium.  Clarified media supernatants and standards were 
added to a clear 96-well assay plate in 10 µl/well.  Working BUN reagent was prepared 
according to manufacturer’s instructions and added to the assay plate at 150 µl/well.  The 
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plate was incubated in an oven at 60 ºC for 90 min prior to data collection. LDH activity was 
determined as described previously (Kia et al., 2015).  Data for all cytotoxicity endpoints 
were collected using a SpectraMax® M3 microplate reader (Molecular Devices). 
Human HDE enrichment 
Hepatocyte-conditioned medium from control- or APAP-treated cells was collected 
after the 24 h exposure and clarified by centrifugation at 3000 x g for 15 min to remove 
cellular debris.  Medium supernatants were filtered at 0.45 µm and subsequently 
concentrated using Centricon-70 centrifugal filter units with a 10,000 Da cut-off (Millipore) 
per manufacturer’s instructions.  The resultant concentrates were subjected to a second 
filtration (0.22 µm) and processed under sterile conditions for the remainder of the 
preparation.  Exosomes for quantification, content analysis, and non-parenchymal cell 
exposure were precipitated from these concentrates with ExoQuick-TC™ (System 
Biosciences) following the protocol for tissue culture supernatants.  The use of ExoQuick-
TC™ for primary human hepatocyte-derived exosome enrichment has been previously 
validated by our group (Holman et al., 2016).   
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Table 4.1. Characteristics of primary human hepatocyte donors. 
 
  
Donor ID Age (yr) BMI Sex Race Cells Obtained
1 55 29 F Caucasian Cryopreserved
2 63 24 F Caucasian Freshly isolated
3 27 27 M Hispanic Freshly isolated
4 35 21 M Caucasian Freshly isolated
5 28 26 F Caucasian Cryopreserved
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4.2.3  Exosomal mRNA sequencing (RNA-seq) 
  
Preparation of RNA-seq samples 
Total RNA was isolated from exosomes using the miRCURY Cell & Plant Isolation 
Kit (Exiqon) according to the manufacturer’s instructions for RNA isolation from blood.  
Sample concentrations were obtained using an Experion RNA HighSens Analysis kit 
(BioRad). It is important to note that exosomal RNA cannot be quality controlled in the 
traditional manner using RIN numbers based on 18S and 28S peaks because exosomes do not 
carry significant levels of rRNA (Eldh et al., 2012; Royo et al., 2013).  cDNA was prepared 
with a SMART-Seq® v4 Ultra Low Input RNA Kit for Sequencing (Clontech Laboratories, 
Inc.) and libraries were created using the Nextera XT (Ilumina) library preparation workflow 
as previously described (Welch et al., 2016).  Libraries were QC’d as described above and 
pooled for 50 bp paired-end sequencing on a single lane of an Ilumina HiSeq system. 
RNA-seq data analysis 
 
 Two fastq files representing both paired-end reads were generated for each sample 
and Q scores were generated using FastQC (version 0.11.5).  Files were trimmed for adapter 
k-mers with BBDuk software and aligned to UCSC human genome build Hg19 (BBMap 
version 36.32).  Within R, the subread package and featureCounts command were used to 
generate count matrices, which were loaded into DESeq2 for differential expression analysis 
(Love et al., 2014).  Log2 fold change values were used to observe the most differentially 
expressed genes between HDE from APAP- versus control-treated human hepatocytes.  
Using raw counts, pathway enrichment analysis was performed to identify the best-
represented pathways within HDE from untreated human hepatocytes using Ingenuity 
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Pathway Analysis (IPA) software (Qiagen, version 28820210).  The 150 genes that exhibited 
the highest fold change in APAP HDE relative to control HDE were then cross-referenced 
with genes known to be differentially expressed in primary human hepatocytes following 10 
mM APAP exposure for 24 h.  These data were obtained from microarray analyses of 
primary human hepatocytes treated with 0 or 10 mM APAP (n=5 donors) from the NCBI 
GEO2R database (GSE13430).  Within the GEO2R microarray data set, DE analysis was 
performed via the limma R package using standard GEO2R parameters.   
 
4.2.4  Exosomal microRNA profiling 
HTG EdgeSeq miRNA Whole Transcriptome assay 
We selected the HTG EdgeSeq miRNA Whole Transcriptome Assay v2 Kit (HTG 
Molecular Diagnostics) for miRNA profiling. This kit was designed to measure all 2,083 
miRNAs currently annotated in miRbase version 20. Samples (isolated total RNA or intact 
exosomes) were washed 1x with PBS and centrifuged at 10,000 x g for 60 min at the UNC 
High Throughput Sequencing Facility. The supernatants were removed and 30 µl of HTG 
Lysis Buffer was added to each exosome sample. Lysates (25 µl) were loaded onto an 
EdgeSeq plate and processed according to the manufacturer’s instructions for cells. Briefly, 
libraries were prepared in two steps: nuclease protection on an HTG Edge processor followed 
by PCR labeling and amplification. Library concentration and quality were determined using 
a High Sensitivity DNA Assay Kit on an Agilent 2100 Bioanalyzer.  Libraries were pooled 
and sequenced in a single lane on an Ilumina MiSeq system for 50 bp single-end reads. Data 
were parsed using HTG EdgeSeq software.  
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Optimization of exosomal input for HTG miRNA assay 
Due to rapid advancement in the technologies available to analyze miRNAs many kits 
no longer require RNA extraction which can significantly bias results, allowing cells or 
exosomes to be used directly as input.  Use of exosomes as starting material is possible with 
the HTG technology, and we wished to ensure that the miRNA profiles obtained with this 
assay would be the same using intact exosomes versus total exosomal RNA.  We isolated 
exosomes from a single primary human hepatocyte donor with EQ and reserved an aliquot 
for direct miRNA profiling.  RNA, including mRNA and miRNA, was isolated using the 
miRCURY Cell & Plant kit (Exiqon) as described previously.  Duplicates of both sample 
types were analyzed to evaluate the technical variability inherent in this assay. 
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Profiling of differentially expressed miRNAs in HDE from primary human hepatocytes with 
and without APAP exposure 
Median-normalized counts for all 2,083 miRNAs were used for data analysis (Anders 
and Huber, 2010).  Results were filtered by liver expression, including only those miRNAs 
detected in 100% of 79 human liver samples in the analysis (Gamazon et al., 2013).  
ANOVAs were performed in Partek Genomics Suite (version 6.6) on these data to examine 
differential miRNA enrichment in HDE from APAP- and control-treated hepatocytes across 
4 human hepatocyte donors.  
4.2.5  In vitro HDE exposures 
 
Pilot studies to examine biological effects of human HDE across cell types 
 Exosome exposures were first conducted in human macrophage, monocyte, and 
sinusoidal endothelial cell (SEC) lines to evaluate HDE activity in representative non-
parenchymal cell (NPC) populations.   
Macrophages were generated from THP-1 human monocytes (TIB-202, ATCC) 
cultured in RPMI-1640 (ATCC) supplemented with 10% (v/v) Exosome-Depleted FBS 
(Gibco), penicillin-streptomycin (Gibco), and 0.05 mM β-mercaptoethanol (Sigma).  THP-1 
cells were differentiated in 24-well culture plates by incubation with 50 ng/ml phorbol 12-
myristate 13-acetate (PMA; Sigma) for 48 h (Park et al., 2007).  Upon differentiation, 
adherent macrophages were exposed to 20 µg/ml human HDE from hepatocytes that had 
been cultured with either 10 or 30 mM APAP for 24 h.  Exosomes were cultured with 
macrophages for 8 h followed by an 8 h wash-out period and a subsequent 6 h LPS-
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activation, according to a previously validated experimental design (Momen-Heravi et al., 
2015a).  Gene expression changes associated with stimulation were measured in control- and 
HDE-treated macrophages by relative RT-PCR.   
Immortalized human SECs, TMNK-1 cells (Japanese Cell Research Bank), were also 
exposed to HDE in initial studies.  TMNK-1 cells were maintained in MCDB-131 medium 
(Life Technologies) supplemented with 10% (v/v) Exosome-Depleted FBS (Gibco), 
penicillin-streptomycin (Gibco), and EGM-2 SingleQuot Kit (50% strength, Clonetics).  
Cells were subcultured with Accutase cell detachment solution and seeded in 96-well plates 
for 24 h HDE exposure experiments.  Human HDE at 200 µg/ml were co-incubated with 
TMNK-1 cells for 24 h prior to a 6 h activation period with or without LPS (50 ng/ml, 
Sigma) to induce validated activation markers such as cell adhesion molecules (Matsumura et 
al., 2004).  Expression of these markers was measured by relative RT-PCR using GAPDH as 
an internal normalization gene.  
THP-1 cells were cultured as above without PMA differentiation and were exposed to 
HDE (100 or 200 µg/ml) as monocytes in suspension culture to understand whether 
exosomes exert concentration-dependent effects on immune cells.  For these experiments, 
monocytes were co-cultured with HDE or medium alone for 24 h followed by a 6 h LPS 
activation to stimulate cytokine release.  Pro-inflammatory cytokines IL-8 and TNF-α were 
measured to determine whether HDE augmented monocyte cytokine secretion (see Cytokine 
and chemokine analysis section).   
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Mitigating potential biological effects of EQ polymer in HDE exposure studies 
Removal of EQ polymer 
Great care must be taken when assessing the biological functionality of exosomes 
prepared using EQ precipitation, because results may be confounded by effects of the 
polymer itself on recipient cells.  For activity studies, SBI recommends polymer removal via 
G-25 Sephadex resin desalting columns (GE Healthcare Life Sciences).  Prior to conducting 
HDE exposures, we attempted to remove EQ from HDE preparations according to the 
manufacturer’s instructions.  HDE with and without column-based polymer removal were 
visualized via cryo-electron microscopy according to published methods (Holman et al., 
2016). 
Preparation of mock controls to account for EQ matrix effects 
For each primary human hepatocyte exposure experiment used to generate HDE, 
portions of control and APAP dosing solutions were reserved.  A volume of unconditioned 
dosing solution equal to that of conditioned medium from each treatment was processed in 
parallel for mock “exosome enrichment” as described above.  Unconditioned dosing solution 
concentrates were brought to the same volume as true exosome samples with sterile PBS and 
EQ was added in equal amounts to both the unconditioned and conditioned samples.  
Unconditioned media samples did not contain HDE or any source of exogenous exosomes, 
and were used as an EQ vehicle or “mock” control in monocyte exposures.  In addition to 
controlling for the amount of EQ in each exosome preparation, these controls allowed us to 
examine the effect of residual hepatocyte maintenance medium and APAP that may have 
carried over from the hepatocyte dosing solutions to the monocyte cultures.  Following the 
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centrifugation step in our precipitation protocol, pellets of EQ polymer were seldom 
observed.  Whether a pellet was visible or not, the majority of supernatant was removed and 
a volume equivalent to the volume of the corresponding true HDE pellet was saved as the 
mock control.  This solution was diluted in monocyte culture medium exactly as the 
matching exosomes were diluted for monocyte treatment (see Monocyte HDE exposures 
section). 
 
Monocyte HDE exposures 
THP-1 human monocytes (TIB-202, ATCC) were cultured in suspension in RPMI-
1640 (ATCC) supplemented with 10% (v/v) Exosome-Depleted FBS (Gibco), penicillin-
streptomycin (Gibco), and 0.05 mM β-mercaptoethanol (Sigma).  Exposures were conducted 
in 96 well round-bottom plates (Corning) at a density of 1 x 105 cells per well.  THP-1 
monocytes were exposed to 200 µg/ml exosomes derived from control and APAP-treated 
hepatocyte cultures or matched EQ mock controls (described above) in separate experiments 
for each hepatocyte donor (Table 4.2).  In each well, monocytes were seeded at the desired 
density in 100 µl of medium and a 2x solution of exosomes in 100 µl medium was added for 
a total of 200 µl final volume.  Donor-specific exosome concentration for exosomes 
harvested from control- and APAP-exposed hepatocytes was determined using total 
exosomal protein measured by a BCA Protein Assay Kit (Thermo).  Normalizing exosome 
preparations for in vitro exposure based on total protein concentration is a common practice 
in mechanistic experiments (Chiba et al., 2012; Giugliano et al., 2015; Li et al., 2013). The 
final concentration of 200 µg/ml exosomal protein was modeled after total exosomal protein 
concentrations in human plasma (Momen-Heravi et al., 2015a; Muller et al., 2014). 
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Following 24 h of exosome co-culture, THP-1 monocytes were lysed in QIAzol (Qiagen) for 
gene expression analysis.  The effects of control- and APAP-treated hepatocyte-derived 
exosomes on human monocyte function were examined by quantifying pro-inflammatory 
cytokine release in co-cultures after incubating them for an additional 6 h following a spike-
in of 5 ng/ml LPS (E. coli 0111:B4; Sigma) or medium vehicle.   
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Table 4.2. Definition of THP-1 culture conditions in HDE exposure studies. 
 
 
  
Treatment Name Condition
Control HDE monocytes exposed to HDE from control-treated hepatocytes
APAP HDE monocytes exposed to HDE from APAP-treated hepatocytes
Mock Control mock HDE preparation containing ExoQuick for Control HDE matrix effects
Mock APAP mock HDE preparation containing ExoQuick and APAP for APAP HDE matrix effects
Medium monocytes exposed to medium alone
 127 
 
Cytokine and chemokine analysis 
Pro-inflammatory cytokines TNF-α, IL-8, IL-6, and IL-1β were measured in clarified 
culture supernatant using a multiplex MSD V-plex assay (Meso Scale Discovery) according 
to the manufacturer’s protocol for cell culture supernatant samples.  Release of the 
chemokine MCP-1 was quantified using an MSD Single Spot assay according to the 
manufacturer’s instructions. MSD plates were run on a Meso QuickPlex SQ 120 instrument 
and analyzed using Discovery Workbench 4.0 software (Meso Scale Discovery).  
4.2.6  Exosome uptake imaging 
Exosomes from control- and APAP-treated hepatocytes were stained using a PKH67 
dye kit (Sigma).  Exosomes were diluted to 200 µg/ml with Diluent C and were combined 
with an equal volume of 1:250 dye solution and incubated according to the manufacturer’s 
protocol.  Following incubation, 3 ml of complete exosome-free medium was added to 
terminate the labeling reaction.  Labeled exosomes were harvested and washed once with 1x 
PBS by centrifugation (100,000xg for 1 h at 4 ºC).  Exosomes were suspended in warm 
monocyte culture medium and were incubated with THP-1 cells for 8 h at 37 ºC.  Monocytes 
were then harvested and labeled for visualization of exosome uptake.  Monocytes were 
incubated with Alexa Fluor® 647 anti-human CD32 antibody (BioLegend) to define cell 
boundaries and permeabilized with Cytofix/Cytoperm Fixation and Permeabilization Kit 
(BD).  DAPI nucleic acid stain (BD Pharmingen) was added to delineate nuclei post-fixation. 
Image acquisition was performed on an Amnis ImageStreamX Mark II Imaging Flow 
Cytometer with INSPIRE® software at 60x magnification.  Focused, single, and DAPI 
positive cells were first gated and an internalization score (uptake of PKH67+ exosomes by 
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CD32+ cells) was generated with the IDEAS® software package (v6.2) as previously 
described (Ackerman et al., 2011). 
4.2.7  Monocyte gene expression analysis 
Gene expression microarrays 
Global gene expression from HDE-exposed THP-1 monocytes was evaluated using a 
microarray platform. Total RNA from THP-1 monocytes incubated for 24 h with control 
HDE, APAP HDE, treatment-matched EQ mocks, or medium alone was isolated with the 
miRNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Lysates from 
replicate wells were pooled and linear acrylamide carrier (Applied Biosystems) was added 
prior to RNA isolation. Total RNA samples were submitted to the UNC Functional 
Genomics Core for microarray analysis. All RIN values, assessed using an Agilent 2200 
TapeStation, were ≥ 9.7 using TapeStation Software (version A.01).   
An Affymetrix GeneChip® WT PLUS Reagent Kit (Afftymetrix) was used according 
to the manufacturer’s protocol to generate, fragment, and label sense-strand cDNA from total 
RNA.  Fragmented and labeled cDNA was used to prepare a hybridization cocktail with the 
Affymetrix GeneTitan Hybridization Wash and Stain Kit for WT Arrays.  Samples were 
hybridized onto a Clariom™ S HT Human peg plate (Affymetrix), washed, stained, and 
scanned using the Affymetrix GeneTitan MC Instrument. GeneChip Command Console 
Software (AGCC, version 4.3) was used for GeneTitan Instrument control.  Affymetrix 
Expression Console Software (version 1.4) was used for basic data analysis and quality 
control. 
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Differential gene expression (DE) analysis 
Normalized log2 probe intensities were analyzed in Partek Genomics Suite, version 
6.6.   Rather than adhere to a pre-determined intensity cutoff, data were filtered to include 
only probe sets whose maximum intensity across all samples was greater than the 25th 
percentile.  Analyses were batch-corrected for the greatest source of variability by defining 
HDE donor (n=5) as a random factor.  Treatment groups (Table 4.1) were compared by 
ANOVA.  To account for the potential biological activity of EQ, exosome treatments (APAP 
and mock APAP EQ control) were compared directly to their mock EQ controls by linear 
contrasts with false discovery rate (FDR) p < 0.05 and fold change (FC) > |1.5|.  Statistically 
significant DE genes were analyzed for enriched pathways using IPA software.  Linear 
contrasts were also performed on microarray data from monocytes exposed to APAP HDE or 
mock control from individual donors.  The top 100 genes most impacted by APAP HDE 
exposure from each donor were analyzed for pathway enrichment to identify the 
immunomodulatory influence of individual donor APAP HDE.  Pathway enrichment 
revealed two subsets of donors whose APAP HDE induced similar gene expression changes 
in monocytes.  Network analysis was performed on overlapping genes from these two 
subsets, respectively, to identify biological functions impacted by binding, activation, 
translocation, degradation, or biochemical reactions with these gene products.  Networks 
were generated using a curated database of interactions cross-referenced with NCBI, 
Ensembl, UniProt, UCSC Genome Browser, HapMap, KEGG, ChEBI, PubMed and GO 
resources (http://www.reactome.org; v58). 
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4.2.8  Integration of exosomal miRNA and recipient THP-1 cell gene expression patterns 
Reverse prediction of differentially expressed exosomal miRNAs 
miRNAs targeting the significant DE genes in exosome-treated THP cells were 
retrieved from the miRTarBase database (version 6.0), which is manually curated to include 
the most current experimentally validated miRNA-target interactions.  The miRNAs 
predicted from our list of DE THP genes was compared to the exosomal miRNAs enriched in 
APAP HDE versus vehicle HDE.  
Prediction of differentially expressed genes in exosome-exposed THP-1 cells 
 The 50 most differentially enriched exosomal miRNAs in APAP HDE relative to 
control HDE were used to generate a list of target genes predicted to be affected in exosome-
exposed THP cells.  Likely mRNA targets were inferred via the IPA microRNA Target Filter 
(IPA software), which retrieves results from 3 interaction databases: miRecords, TarBase, 
TargetScan.  IPA analysis was performed on these predicted gene targets to determine 
whether the over-represented pathways in exosome-exposed THP cell microarrays matched 
with the pathways inferred from exosomal miRNA profiling.  This process was performed 
using the top 50 most increased miRNA from the global data set (n=4 donors) as well as the 
top 50 most increased miRNAs on an individual donor basis.  Pathways predicted from 
individual donor analyses were compared to donor-specific pathway enrichment observed in 
monocytes. 
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4.3 Results 
4.3.1  Exosomal mRNA content and hepatocellular pathway activation 
 In vivo, rats treated with D3T to activate the Nrf2 oxidative stress response pathway 
demonstrated robust hepatic induction of Nrf2 target genes.  Expression of a representative 
target gene, Gsta3, is shown in Figure 4.1.   Gsta3 levels were also measured in plasma and 
were detectable due to their encapsulation within EVs.  While hepatic expression was dose-
dependently elevated by increasing D3T exposures, EV levels were dose-dependently 
decreased (Figure 4.1), suggesting an inverse relationship between liver and EV mRNA 
content.  Albumin mRNA was also measured as a control to ensure that D3T did not produce 
off-target gene induction.  Levels of albumin mRNA were not affected by D3T treatment in 
the liver or plasma samples (Figure 4.1).   As albumin mRNA is used as a surrogate marker 
of HDE, it was hypothesized that overall HDE release was unchanged while Gsta3 was 
selectively retained by stressed hepatocytes. 
Although D3T significantly up-regulates hepatic Nrf2-mediated gene expression, 
neither its effects nor the genes it influences are specific to the liver.  With the knowledge 
that many cell types contribute to the circulating population of exosomes in vivo, we used an 
in vitro model to directly investigate the relationship between hepatocellular Nrf2 activation 
and exosomal Nrf2 target gene content.  Primary rat hepatocytes were exposed to D3T across 
a range of concentrations and exhibited robust induction of all target genes analyzed (Figure 
4.2).  However, these same mRNAs were not detected in HDE at any concentration of D3T 
(Figure 4.2).  While D3T is considered non-toxic, we evaluated LDH leakage into medium at 
all concentrations in our culture system.  LDH was not increased relative to vehicle at any 
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D3T concentration; we observed a small but statistically significant decrease in LDH leakage 
at 100 µM D3T (p < 0.0001, Student’s t-test, data not shown). 
Experiments were then scaled-up to determine whether the lack of detection of these 
mRNAs was due to insufficient exosomal material.  First, HDE preparation from 
concentrated medium was validated for downstream RT-PCR.  Between unconcentrated 
medium and medium concentrated with 2 different methods, there were no differences in 
exosomal albumin mRNA recovery (data not shown).  We then employed these medium 
concentration techniques to 150 ml of rat hepatocyte-conditioned medium and measured 
Nrf2 target genes by RT-PCR.  It is important to note that the hepatocyte cultures were un-
stimulated with D3T.  We hypothesized that if the in vivo results held true, control exosomes 
would actually contain the highest levels of Nrf2 targets.  Therefore, if Nrf2 target genes 
could not be detected in control HDE, there was little chance they could be detected in D3T 
experiments.  Despite increasing culture scale, Nrf2 target genes remained undetectable in rat 
HDE (data not shown).  These data suggest that the decrease in circulating Nrf2 target genes 
observed in vivo following D3T exposure is unlikely due to hepatocyte EVs.  It is possible 
that these experiments were limited because we only measured a handful of targets via RT-
PCR, and supports a more global profiling approach to investigating lower abundance 
exosomal RNAs.  
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Figure 4.1. Relationship between Nrf2 target mRNA levels in liver and circulating 
exosomes. Male Sprague-Dawley rats were treated once daily for 4 days (p.o.) with non-toxic 
Nrf2 pathway activator D3T or saturated sucrose vehicle. Data represent mean + SEM (n=14-
15 rats). Transcripts detected in plasma are packaged within extracellular vesicles (EV). * p < 
0.05, ** p < 0.001; one-way ANOVA with Sidak’s test. 
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Figure 4.2.  Induction of Nrf2 target genes by D3T is apparent in rat hepatocytes but not 
rat HDE. Male Sprague-Dawley rat hepatocytes were treated once for 24 h with non-toxic 
Nrf2 pathway activator D3T or 0.2% DMSO vehicle.  Target genes were measured by RT-
PCR in hepatocytes (A) and HDE (B).  Data represent mean + SEM of triplicate reactions. * p 
< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; one-way ANOVA with Dunnett’s post-
test relative to vehicle.  
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4.3.2  RNA sequencing of primary HDE transcripts 
Earlier results from this research have confirmed that liver-enriched miRNAs and 
transcripts that are abundant in hepatocytes can be detected in primary rat and human HDE.  
The results of our earlier D3T studies suggest that certain mRNAs are not detectable in HDE 
with RT-PCR which is considered one of the most sensitive detection techniques.  In the 
present work, we employed an RNA sequencing approach to globally profile the mRNA 
content of primary human HDE under control conditions and following APAP exposure.  
Next-generation sequencing (NGS) approaches such as RNA sequencing have distinct 
advantages over microarray analysis.  RNA sequencing was pursued in the current research 
because it directly counts transcripts and provides a more quantitative dataset than 
microarrays, which is important for exosomes because they are not known to carry 
housekeeping genes.   With the knowledge that most exosomal RNA is non-coding as 
opposed to full length transcripts, we selected sequencing library preparations to select for 
mRNA specifically.  Exosomes are a challenging material for RNA profiling because they 
contain such small quantities of RNA, and little of the total RNA concentration is full-length 
mRNA (Hill et al., 2013; Huang et al., 2013; Nolte-'t Hoen et al., 2012).  Very few next-
generation sequencing (NGS) studies have been conducted using exosomes, and most are 
focused on miRNAs.  Only a single publication has examined the transcript content of HDE 
(Royo et al., 2013), and this was done using primary rat hepatocytes and gene expression 
microarray.  To our knowledge, our earlier measurements of mRNA within primary human 
HDE was the first study of its kind.  We sought to expand upon those findings with global 
mRNA sequencing. 
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Because there are no standardized techniques or precedents for exosomal RNA 
sequencing, we first assessed the quality of sequencing read alignments.  An early metric of 
quality is the Q score, which is a loose representation of base call accuracy.  It gives the 
probability that a given base was incorrect, such that a Q score of 30 for a region indicates 
that there is a 1:1000 chance a base was wrongly assigned.  Desirable Q scores are generally 
considered 25 or above, and our exosomal RNA sequencing Q scores did not fall below 27 
with the exception of one read (Table 4.3).  Another measure of data quality is the percentage 
of mated pairs, which is relevant for paired-end sequencing.  This metric quantifies 
concordance between sequencing reads from either end of the cDNA and demonstrates 
proportion of read 1 (R1) and read 2 (R2) sequences that aligned to the same genomic region, 
giving confidence in the identified gene.  Mated pairs above 80% are considered reliable, and 
all but 2 samples (control and treated samples from the same donor) met these standards 
(Table 4.3).  Overall, the technical quality of exosomal RNA sequencing was ideal.  Upon 
mapping the sequence alignments to the human genome, 2% of all sequences mapped to 
coding sequences.  While this mapping rate is low for traditional samples, it is not unusual 
for exosomes (Huang et al., 2013; Santangelo et al., 2016).  This result is not uncommon for 
HDE either: Bioanalyzer profiles on HDE from a mouse hepatocyte cell line have shown 
enrichment for small, likely non-coding RNAs (Momen-Heravi et al., 2015a).  It should be 
noted, however, that primary rat hepatocyte Bioanalyzer profiles and those from a different 
mouse hepatocyte cell line present much higher levels of large RNAs, suggesting that 
different hepatocyte lines may have unique RNA profiles (Royo et al., 2013).  Taking into 
consideration both the unique RNA profiles of exosomes and the high quality of our 
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sequencing data, we interpret the low mapping rate to be a true reflection of the abundance of 
coding sequences in human HDE.   
Due to the low proportion of coding sequence maps in our data set, robust statistical 
comparisons between the mRNA content of HDE from control versus APAP-treated human 
hepatocytes could not be performed.  However, we obtained sufficient data to perform 
pathway enrichment on control HDE and on APAP HDE relative to control HDE.  First, we 
used raw counts to identify the most abundant mRNAs in untreated (control) primary human 
HDE (Table 4.4).  Of these genes, many were also detected in rat HDE in vitro and in vivo, 
suggesting that these contents may be germane to hepatocyte EVs (Miyamoto et al., 2008; 
Okubo et al., 2013; Royo et al., 2013); they are marked in Table 4.4 with an asterisk.  These 
mRNAs are highly expressed in both rat and human liver (Yu et al., 2010) and were detected 
by qRT-PCR in our earlier analyses of primary human HDE mRNA (n=3 donors) (Holman et 
al., 2016).  IPA was used to define over-represented pathways in these data (Figure 4.3), 
some of which were also identified in rat HDE by Royo et al.  Shared pathways included 
acute phase response, clathrin-mediated endocytosis, LXR/RXR activation, and cholesterol 
metabolism.   
Statistical RNA-seq package DESeq2 was used to generate log2 fold change values 
for transcripts elevated in APAP HDE versus vehicle (control) HDE.  Given the small sample 
size and low mapping frequency, statistically significant differences were not observed.  
However, a shift in the exosomal mRNA enrichment was observed between HDE from 
APAP treated human hepatocytes (Figure 4.4).  Interestingly, many of the differentially 
enriched mRNAs in APAP HDE have been associated with APAP-induced stress at the 
hepatocyte level.  For instance, components of the electron transport chain (COX7B, ATP5, 
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UQCR, NDUFB) were differentially increased in APAP HDE and were significantly up-
regulated in HepG2 cells following exposure to the same concentration of APAP we 
employed (10 mM) (Jiang et al., 2015).  The abundance of multiple ribosomal mRNAs 
associated with EIF signaling also increased in APAP HDE, many of which were 
differentially regulated in HepG2 spheroids following APAP exposure (Wojdyla et al., 
2016).  These mitochondrial and ribosomal mRNAs are mechanistically relevant to APAP 
toxicity as they represent altered ATP production and protein production, respectively.  
Abundant transcripts in APAP HDE were then compared to genes that were significantly 
altered in primary human hepatocytes exposed to 10 mM APAP for 24 h relative to untreated 
controls.  Of the top 150 most increased mRNAs in APAP HDE, 99 overlapped with 
significant DE genes in APAP hepatocytes (Table 4.5).  Pathway enrichment analysis 
revealed that the overlapping genes from APAP HDE represent biological and toxicological 
processes that are mechanistically relevant in APAP DILI (Figure 4.5).  These data suggest 
that the mRNA contents of HDE following drug-induced stress may indeed reflect gene 
expression changes within hepatocytes.  
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Table 4.3. Sequence quality metrics from human exosomal RNA-seq samples  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Sample
R1 Minimum
Q-score
R2 Minimum
Q-score
Mated Pairs
(%)
Donor 1 Control 31 31 87.1
Donor 1 APAP 32 31 85.2
Donor 2 Control 16 27 60.7
Donor 2 APAP 27 31 71.8
Donor 3 Control 32 31 85.2
Donor 3 APAP 31 31 85.4
Donor 4 Control 31 31 86.8
Donor 4 APAP 31 31 85.5
Donor 5 Control 31 31 83.5
Donor 5 APAP 32 31 84.4
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Table 4.4. Top 50 most abundant mRNAs in control human HDE. * indicates mRNAs that 
overlap with the top 50 most abundant mRNAs in control rat HDE (Royo et al., 2013). 
  
Gene Symbol Gene Name Counts
FTL* ferritin light chain 13486
ALB albumin 13393
HP* haptoglobin 8775
SAA1 serum amyloid A1 7950
ORM1 α-1-acid glycoprotein 1 (orosomuscoid 1) 5704
APOA1 apolipoprotein A1 3991
SERPINA1* serpin family A member 1 3923
APOA2* apolipoprotein A2 3431
ROCK1P1 Rho-associated coiled-coil containing protein kinase 1 3137
FTH1* ferritin heavy chain 1 2782
AMBP* α-1-microglobulin bikunin precursor 2178
SAA2 serum amyloid A2 2145
APOC3* apolipoprotein C3 1964
GAPDH glyceraldehyde-3-phosphate dehydrogenase 1830
RBP4* retinol binding protein 4 1738
TAOK1 TAO kinase 1 1452
TTR* transthyretin 1443
APOC1* apolipoprotein C1 1267
APOE* apolipoprotein E 1256
TTN titin 1080
KCNQ1OT1 KCNQ1 opposite strand/antisense transcript 1 1064
ACTB* actin beta 987
TFPI tissue factor pathway inhibitor 966
CLU clusterin 943
DUX2 DUX4L8 double homeobox 4 like 8 831
CDC27 cell division cycle 27 818
ORM2 orosomucoid 2 805
UBC ubiquitin C 795
KNG1 kininogen 1 786
FGG fibrinogen gamma chain 698
SOD2 superoxide dismutase 2, mitochondrial 676
CCDC168 coiled-coil domain containing 168 669
REXO1L1 REX1, RNA exonuclease 1 homolog-like 1 pseudogene 657
SERPINA3 serpin family A member 3 631
APOH* apolipoprotein H 626
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Table 4.4. continued 
 
 
  
Gene Symbol Gene Name Counts
B2M* β-2 microglobulin 617
SH3KBP1 SH3 domain containing kinase binding protein 1 612
IL32 interleukin 32 595
VTN vitronectin 594
LOC100272216 uncharacterized LOC100272216 586
LOC388692 uncharacterized LOC388692 579
ANKRD20A9P ankyrin repeat domain 20 family member A9 pseudogene 576
HYDIN2 axonemal central pair apparatus protein pseudogene 574
FGL1 fibrinogen like 1 571
UBB ubiquitin B 569
LOC440297 chondroitin sulfate proteoglycan 4 pseudogene, discontinued 562
CLDN11 claudin 11 545
CFB complement factor B 529
FGB fibrinogen beta chain 514
AKR1C2 aldo-keto reductase family 1 member C2 512
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Figure 4.3. Top 10 pathways enriched in exosomal mRNA from untreated primary 
human hepatocytes.  Pathway enrichment was performed on the 100 most abundant exosomal 
mRNAs based on maximum count across donors (n=5). Canonical pathways (A) and toxicity-
related pathways (B) are represented. The dashed line indicates a –log(p) > 1.3 threshold for 
pathway significance.  
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Figure 4.4. Top 10 pathways enriched in exosomal mRNA from APAP-treated primary 
human hepatocytes.  Pathway enrichment was performed on the 100 most differentially 
expressed exosomal mRNAs across donors (n=5) relative to controls. Canonical pathways (A) 
and toxicity-related pathways (B) are represented. The dashed line indicates a –log(p) > 1.3 
threshold for pathway significance.  
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Table 4.5. Transcripts increased within APAP HDE that overlap with differentially 
expressed genes in APAP-exposed primary human hepatocytes.  
 
 
  
Gene Symbol Name
ACBD6 acyl-CoA binding domain containing 6
ACP1 acid phosphatase 1, soluble
ADH1A alcohol dehydrogenase class 1A, alpha polypeptide
ADH1C alcohol dehydrogenase class 1C, gamma polypeptide
AHSG alpha 2-HS glycoprotein
AIMP2 aminoacyl tRNA synthetase complex interacting multifunctional protein 2
ALDH1A1 aldehyde dehydrogenase 1 family member A1
APOH apolipoprotein H
APRT adenine phosphoribosyltransferase
ATP5A1 mitochondrial complex V: ATP synthase subunits
ATP5I mitochondrial ATP synthase, H+ transporting, mitochondrial F0 complex subunit E
ATPIF1 APTase inhibitory factor 1
BARHL2 BarH like homeobox 2
C9orf16 chromosome 9 open reading frame 16
CALM1 calmodulin 1
CBR1 carbonyl reductase 1
CFB complement factor B
CFH complement factor H
CHCHD2 coiled-coil helix coiled-coil helix domain containing 2
CNN3 calponin 3
COX4I1 mitochondrial complex IV: cytochrome C oxidase subunit 4I1
COX5A cytochrome c oxidase subunit 5A
COX5B cytochrome c oxidase subunit 5B
COX6C cytochrome c oxidase subunit 6C
COX7B cytochrome c oxidase subunit 7B
CYP2C9 cytochrome P450 family 2 subfamily C member 9
CYSTM1 cysteine rich transmembrane module containing 1
DAD1 defender against cell death 1
DCAF12 DDB1 and CUL4 associated factor 12
DCD dermicidin
DYNLL1 dynein light chain LC8 type 1
ECHS1 enoyl-CoA hydratase, short chain 1
EPHA4 EPH receptor A4
 145 
 
Table 4.5. continued 
 
 
  
Gene Symbol Name
ESD esterase D
FSHR follicle stimulating hormone receptor
FUCA2 fucosidase, alpha L2, plasma
GC vitamin D binding protein 
HMGN1 high mobility group nucleosome binding domain 1
IGBP1 immunoglobulin (CD79A) binding protein 1
ISCA1 iron-sulfur cluster assembly 1
ISG20 interferon stimulated exonuclease gene 20
KPNA3 karopherin subunit alpha 3
KRTCAP2 keratinocyte associated protein 2
LIPI lipase I
MOSPD1 motile sperm domain containing 1
MRGPRX2 MAS related GPR family member X2
MRPL37 mitochondrial ribosomal protein L37
MRPL39 mitochondrial ribosomal protein L39
MRPL54 mitochondrial ribosomal protein L54
MRPS5 mitochondrial ribosomal protein S5
NDUFB1 NADH:ubiquinone oxidoreductase subunit B1
NDUFB9 NADH:ubiquinone oxidoreductase subunit B9
NFIL3 nuclear factor, interleukin 3 regulated
NUDCD2 NudC domain containing 2
OAZ1 ornithine decarboxylase antizyme 1
OR10A7 olfactory receptor family 10 subfamily A member 7
OR10AD1 olfactory receptor family 10 subfamily AD member 1
OR1A1 olfactory receptor family 1 subfamily A member 1
OR4K17 olfactory receptor family 4 subfamily K member 17
OR51I1 olfactory receptor family 51 subfamily I member 1
OR7E5P olfactory receptor family 7 subfamily E member pseudogene
PABPC3 poly(A) binding protein cytoplasmic 3
PEBP1 phosphatidylethanolamine binding protein 1
PLSCR1 phospholipid scramblase 1
PQLC3 PQ loop repeat containing 3
PSMB6 proteasome subunit beta 6
PSMB7 proteasome subunit beta 7
PSMB9 proteasome subunit beta 9
PSMC1 proteasome subunit 26S, ATPase 1
PTGR1 prostaglandin reductase 1
RPL19 ribosomal protein L19
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Table 4.5. continued 
 
 
  
Gene Symbol Name
RPL31 ribosomal protein L31
RPLP1 ribosomal protein lateral stalk subunit P1
RPS12 ribosomal protein S12
RPS16 ribosomal protein S16
RPS18 ribosomal protein S18
SBDS SBDS ribosome assembly guanine nucleotide exchange factor
SEPP1 selenoprotein P1, plasma
SERF2 small EDRK-rich factor 2
SIGLEC1 sialic acid binding Ig like lectin 1
SLC35A1 solute carrier family 35 member A1
SNRPD2 small nuclear ribonucleoprotein polypeptide N
SNRPN SNRPN upstream reading frame-like (pseudogene)
TAAR6 trace amine associated receptor 6
TCEA3 transcription elongation factor A3
TCEB2 transcription elongation factor B subunit 2
TDO2 tryptophan 2,3-dioxygenase
TMEM117 transmembrane protein 177
TMEM199 transmembrane protein 199
TMEM99 transmembrane protein 99
TNFAIP8 TNF alpha induced protein 8
TP53TG1 TP53 target 1 (non-protein coding)
TPT1 tumor protein, translationally-controlled 1
TXNL1 thioredoxin like 1
UGT2B4 UDP glucuronosyltransferase family 2 member B4
UQCRB ubiquinol-cytochrome C reductase binding protein
UQCRQ ubiquinol-cytochrome C reductase complex III subunit VII
YBX1 Y-box binding protein 1
ZNF155 zinc finger protein 155
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Figure 4.5. Top 10 pathways represented by genes common to APAP HDE and APAP-
treated hepatocytes.  Pathway enrichment was performed on the 99 differentially enriched 
genes in APAP HDE that were significantly increased in primary human hepatocytes (n=5 
donors per data set). Canonical pathways (A) and toxicity-related pathways (B) are presented. 
The dashed line indicates a –log(p) > 1.3 threshold for pathway significance.  
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4.3.3 Cytotoxicity measurements in primary human hepatocytes following APAP exposure 
 At the end of each APAP exposure, medium was collected for exosome enrichment 
and cytotoxicity assays were conducted to measure urea production, cellular ATP, and LDH 
leakage.  Results from these assays across 5 donors are shown in Figure 4.6.  In 3 cases, 
LDH, a necrotic cell death marker, was significantly decreased following APAP treatment.  
When assessed in the context of mild urea and ATP decreases, these results suggest cellular 
stress rather than overt injury with 10 mM APAP for 24 h, which is consistent with prior 
findings (Holman et al., 2016; Kia et al., 2015).  The exception is donor 3, which appears 
uniquely sensitive to APAP.  
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Figure 4.6. Cytotoxicity measured in primary human hepatocytes used for HDE 
generation.  Data represent mean + SEM of biological replicates and duplicate assay wells 
from n=5 donors following 24 h of 10 mM APAP or vehicle exposure. * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001; Student’s t-test comparing vehicle to APAP for each donor. 
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4.3.4  miRNA profiling results are consistent across replicates and sources of exosomal RNA 
 
We compared HTG miRNA profiling results across replicates as well as across input 
types (whole exosomes and isolated exosomal RNA) and treatment groups (APAP and 
control).  We observed good concordance between data collected from whole exosomes and 
total RNA isolated from the same exosome sample (Figure 4.7), which confirmed that whole 
HDE were a viable input material for our purposes.  Elimination of RNA extraction is 
optimal because it eliminates excessive sample handling and any inherent bias introduced by 
the RNA isolation method.  Upon verifying HDE as an appropriate sample type, we 
evaluated the reproducibility of data by profiling the miRNA content of 2 identical HDE 
aliquots prepared from either control- or APAP-treated primary human hepatocytes.  
Replicates of both groups were highly correlated (Figure 4.7) suggesting low technical 
variability, and validated the use of the HTG miRNA profiling platform for global HDE 
miRNA analysis. 
 151 
 
  
Figure 4.7. miRNA profiling validation across sample types and replicates.  Exosomes or 
corresponding exosomal RNA from control-treated hepatocytes (A) and APAP-treated 
hepatocytes (B) were analyzed side-by-side to validate whole exosomes as a suitable input for 
HTG miRNA Whole Transcriptome profiling. Two identical replicates from control HDE (C) 
and APAP HDE (D) were profiled to ensure reproducibility. Black dots represent log2 
normalized counts and red lines show the data fitted with linear regression models. 
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4.3.5 Global miRNA profiles in human HDE shift as a result of APAP exposure 
Data from control and APAP HDE from Donor 4 did not pass quality control filters 
due to inefficient sample lysis and were discarded.  Median-normalized exosomal miRNA 
results from the remaining donors (n=4) were filtered by a list of miRNAs with consistent 
expression in human liver samples, obtained via personal communications with Dr. Wanqing 
Liu, a contributing author to the Gamazon et al manuscript.  Partek Genomics Suite (version 
6.6) was used for statistical analysis of differential miRNA enrichment between HDE from 
control- and APAP-treated human hepatocytes by linear contrast.  With a data set of this size 
and exposure to a sub-toxic APAP concentration, the power to detect statistically significant 
differences in miRNA profiles was limited.  As a result, no statistically significant 
differences between APAP and control HDE across all donors were observed.  This outcome 
may be due in part to the distinct differences in exosomal miRNA patterns observed between 
donors in response to APAP exposure (Figure 4.8).  Donor was the most significant source of 
variability, and global exosomal miRNA profiles following APAP-induced hepatocellular 
stress were donor-specific.  The cytotoxicity data collected from these same donors (Figure 
4.6) was not highly variable across individuals, and would suggest that hepatocyte responses 
to APAP did not differ greatly across donors, while the exosomal miRNA content reveals 
extensive donor-to-donor variation.  These results underscore the importance of integrating 
primary cells into exosome activity studies, as exosomes from immortalized cell lines fail to 
capture the extensive diversity of human donors.   
Although none of the miRNA changes were statistically significant, there were 
marked shifts in miRNA abundance between APAP HDE and control HDE.  Figure 4.9 
presents miRNAs with the highest and lowest fold changes in APAP HDE relative to control 
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HDE.  We compared the differentially expressed miRNAs in our exosomal data set to 
miRNAs that have been altered in plasma in at least 2 other studies of APAP DILI, either 
from published work (Krauskopf et al., 2015; Starkey Lewis et al., 2011; Vliegenthart et al., 
2015; Ward et al., 2014) or an in-house rat study (data unpublished).  The fold changes of 
miRNAs that were detected in our data set and also differentially expressed in at least 2 
additional studies of APAP DILI are shown in Figure 4.10.     
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Figure 4.8. Distinct donor-specific responses to APAP are captured by exosomal miRNA 
profiling.  Differential expression for each donor was determined by linear contrasts between 
the miRNA content of HDE from APAP-treated hepatocytes and control-treated hepatocytes. 
Coloration reflects directionality of log2 ratio of the contrast (green, down-regulated in APAP 
HDE; red, up-regulated in APAP HDE).  
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Figure 4.9. Top 10 up- and down-regulated miRNAs in human HDE as a result of APAP 
exposure.  Data represent fold changes in HDE from APAP-treated hepatocytes relative to 
control-treated hepatocytes across all donors.  
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Figure 4.10. Fold changes of exosomal miRNAs associated with APAP-induced liver 
injury.  Data represent fold changes in HDE from APAP-treated hepatocytes relative to 
control-treated hepatocytes across all donors. Candidate miRNAs were selected if they were 
differentially regulated in the circulation of treated subjects from 2 or more in vivo studies of 
APAP DILI.  
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4.3.6  Verification of HDE biological activity using models of non-parenchymal and immune 
cells 
The effects of exosomes from control- and APAP-treated human hepatocytes were 
initially investigated on multiple representative human non-parenchymal cell types: THP-1 
macrophages to mimic resident hepatic Kupffer cells, TMNK-1 immortalized SECs, and 
THP-1 monocytes to mimic infiltrating immune cells.  This work was conducted to 
substantiate the hypothesis that HDE exert biological activity on hepatic cell types prior to 
deeper mechanistic inquiries.   
 
Macrophages 
First, adherent macrophages were derived from THP-1 monocytes via PMA 
differentiation.  Macrophages were incubated with HDE from human hepatocytes exposed to 
vehicle, 10, or 30 mM APAP for 8 h to mimic baseline conditions, drug-induced stress, and 
overt cytotoxicity, respectively.  Following HDE incubation and an 8 h washout period, 
macrophages were transitioned to medium +/- LPS for a total experimental duration of 24 h.  
The addition of LPS served as a positive control to invoke NOX2 gene expression (Kim et 
al., 2010).   
Cells were then lysed for RNA isolation and the prototypical immune activation 
markers NADPH oxidase 2 (NOX2) and heme oxygenase 1 (HO-1) were measured in cells 
by RT-PCR.  Interestingly, in the macrophages that were exposed to HDE but were not 
stimulated with LPS, NOX2 expression was decreased (Figure 4.11).  Cells that were treated 
with the same HDE and were subsequently stimulated with LPS showed a reversal of this 
trend such that NOX2 levels were increased relative to medium alone.  HO-1 expression was 
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significantly affected by the addition of HDE but was not impacted by the addition of LPS 
(Figure 4.11).  HO-1 was induced most strongly by control HDE and this induction decreased 
in relation to the APAP concentration given to the hepatocytes. 
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Figure 4.11. Impact of primary human HDE on prototypical immune response genes in 
macrophages.  Data represent the mean + SEM of replicate culture wells and triplicate RT-
PCR reactions for NOX2 (A) and HO-1 (B). Statistical comparisons were made within each 
stimulation group (i.e. all treatments without LPS were compared to one another but not to the 
LPS-activated group). * p < 0.05, ** p < 0.01; one-way ANOVA with Tukey’s multiple 
comparisons test. 
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Sinusoidal endothelial cells  
 
Cells from the immortalized human SEC line TMNK-1 were also exposed to HDE 
from control- and APAP-treated human hepatocytes.  Following a 24 h incubation with HDE, 
SECs were stimulated with LPS to induce expression of cellular adhesion molecules, used as 
a physiologically relevant readout of SEC activation and possible HDE effects (Giugliano et 
al., 2015; Matsumura et al., 2004).  Expression of intracellular adhesion molecule 1 
(ICAM1), vascular endothelial cadherin (CDH5), and E-selectin (SELE) were measured by 
RT-PCR relative to GAPDH (Figure 4.12).  All three genes were down-regulated by HDE 
regardless of hepatocyte treatment (control or APAP) relative to medium + LPS.  Small but 
statistically significant decreases were observed for all genes, with the most pronounced 
down-regulation by HDE occurring for SELE.  SELE expression was not significantly 
affected by control HDE, but was greatly suppressed in the presence of APAP HDE. 
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Figure 4.12. Impact of primary human HDE on expression of cellular adhesion molecules 
in LPS-stimulated sinusoidal endothelial cells.  Data represent the mean + SEM of replicate 
culture wells and triplicate RT-PCR reactions for SELE (A), CDH5 (B), and ICAM1 (C). * p 
< 0.05, ** p < 0.01, **** p < 0.0001; one-way ANOVA with Dunnett’s post-test relative to 
medium.  
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Monocytes 
 
 Monocytes are the principal cell type of interest for HDE exposures because they are 
some of the first cells to be recruited to sites of injury such as hepatocellular necrosis 
(Antoniades et al., 2012).  For these initial experiments, we used cytokine secretion as a 
functional endpoint to indicate if HDE had any overt immune effects.  To accomplish this, 
we exposed THP-1 monocytes to medium, 100 µg/ml, or 200 µg/ml HDE from control- and 
APAP-treated human hepatocytes.  Monocytes were incubated with HDE for 24 h followed 
by a 6 h LPS stimulation to induce cytokine response.  The level of LPS (5 ng/ml) was 
selected from empirical concentration-response tests to produce sub-maximal cytokine 
release, allowing us to observe both increases and decreases in cytokine response induced by 
HDE exposure (Figure 4.13).   
To select cytokines of interest, we first performed a 10-plex analysis on LPS-
stimulated monocytes and found that IL-8 and TNF-α were most robustly affected compared 
to IL-1β which was poorly expressed and IL-6 which was almost undetectable (data not 
shown).  It has been established that THP-1 cells do not express IL-6 and IL-1β at the same 
levels as primary monocytes (Schildberger et al., 2013), but evidence is conflicting 
depending on the number of cells used and the stimulus (Bretz et al., 2013; Skazik-Voogt et 
al., 2016).   
Secretion of pro-inflammatory cytokines TNF-α and IL-8 was decreased in 
monocytes treated with control HDE relative to no-exosome (LPS alone) control (Figure 
4.14).  The reduction of cytokine secretion by control HDE-treated monocytes appeared to be 
dependent upon exosome concentration: suppression was slightly greater in the 200 µg/ml 
cultures than in the 100 µg/ml cultures (Figure 4.14).  Interestingly, THP-1 cells exposed to 
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APAP HDE produced higher levels of both cytokines than those exposed to control HDE, but 
quantities did not exceed LPS alone.  APAP HDE produced a concentration-responsive 
increase in IL-8, but not in TNF-α.  
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Figure 4.13. Selection of LPS concentration for monocyte stimulation using pro-
inflammatory cytokine responses.  Data represent the mean + SEM of triplicate culture wells 
and duplicate assay wells for TNF-α and IL-8.  Non-linear regression was performed on 
normalized data to illustrate minimum and maximum concentration responses. The dashed line 
indicates 5 ng/ml, the selected concentration for future in vitro LPS exposures. 
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Figure 4.14. HDE from control- and APAP-treated hepatocytes mediate pro-
inflammatory cytokine response in LPS-stimulated monocytes.  Data represent the mean + 
SEM of triplicate culture wells and duplicate assay wells for TNF-α (A) and IL-8 (B). * p < 
0.05, ** p < 0.01, Student’s t-test. 
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4.3.7  Accounting for the matrix effects of EQ polymer in HDE activity assays  
 Recognizing that EQ is an undefined synthetic matrix, we wished to separate EQ-
precipitated HDE from the reagent prior to examining the biological activity of exosomes.  
The manufacturer’s protocol was followed to remove EQ polymer via desalting columns and 
preparations with and without polymer removal were visualized using cryo-electron 
microscopy (EM) as previously described (Holman et al., 2016).  The desalting columns 
effectively removed most of the EQ polymer, which appears as clouds of granular particles in 
Figure 4.15.  However, in doing so, all of the HDE were also eliminated.  From these results, 
we ascertained that HDE are incorporated into a network of EQ polymer such that one cannot 
be removed without also removing the other.  It was clear that the potential confounding 
biological effects of EQ itself on recipient cells needed to be accounted for. 
 To ensure that HDE activity was not due to EQ, we prepared mock controls of control 
(medium vehicle) and APAP dosing solutions for every hepatocyte donor (n=5).  These mock 
controls were concentrated, precipitated with EQ, and applied to monocytes alongside the 
corresponding HDE preparations.  Adding these experimental conditions allowed us to 
control for potential activity of not only EQ, but also any residual APAP left in APAP HDE.  
EQ appeared to have inconsistent but potentially relevant effects on monocyte cytokine 
secretion induced by LPS (Figure 4.16).  Microarray data (described below) suggest that EQ 
exerts small but statistically significant effects on monocytes relative to medium alone, and 
that the gene expression changes induced by EQ largely overlap between control and APAP 
mock preparations (data not shown).  For analysis of significant HDE-induced gene 
expression changes, microarray results from monocytes exposed to exosomes were compared 
to monocytes exposed to the respective EQ mock (i.e. significance of APAP HDE effects 
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were determined via linear contrast to APAP mock control).  These findings represent 
valuable contributions because, to our knowledge, the gene expression effects of EQ have not 
previously been described or taken into account in previous functional studies of EQ-
precipitated exosomes.    
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Figure 4.15. Cryo-EM of ExoQuick-TC HDE preparations with and without polymer 
removal.  Representative electron photomicrographs of unprocessed HDE precipitated with 
EQ (left), arrows indicate HDE surrounded and obscured by clouds of granular EQ reagent. 
HDE preparations in which an attempt at EQ removal was made (right), showing some residual 
EQ (bottom left corner) and an absence of HDE.  The small circular shapes in the right-hand 
image are imperfections in the ice. Scale bar, 100 nm. 
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Figure 4.16. Cytokine release from monocytes may be affected by ExoQuick-TC. Data 
represent mean + SEM of triplicate culture wells assayed in duplicate for TNF-α (A-D) and 
IL-8 (E-H) from LPS-stimulated monocytes exposed to HDE or mock controls (n=4 donors).  
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4.3.8  HDE from control- and APAP-treated human hepatocytes are internalized by 
monocytes 
 To ensure that EQ-isolated HDE from both control- and APAP-treated human 
hepatocytes were taken up by recipient monocytes and to examine HDE subcellular 
localization, we performed uptake imaging and internalization analysis with an Amnis 
ImageStreamX Mark II Imaging Flow Cytometer.  Control and APAP HDE were diluted to 
the same concentration used for functional analysis (200 µg/ml) and stained using PKH67 
lipid dye.  Labeled HDE were incubated with monocytes for 8 h at 37 ºC prior to antibody 
staining for surface marker AF647-CD32 (FcɣR2), fixation/permeabilization, and DAPI 
staining.  Imaging was performed on monocytes exposed to labeled control or APAP HDE, 
as well as separate preparations of labeled monocytes and HDE alone (Figure 4.17).  
Monocyte uptake of both HDE types was confirmed and internalization scores calculated 
from approximately 10,000 cells in each treatment group indicated no significant difference 
between control HDE and APAP HDE uptake (Figure 4.17).  These results suggest that 
treatment-specific HDE effects on THP-1 cells are likely due to exosomal content alterations 
as opposed to differential uptake.  They also confirm that in this model system, HDE are 
capable of transferring cargo to the interior of recipient cells.  It is unlikely that areas of 
diffuse PKH67 (green) cytoplasmic staining in HDE-treated monocytes (Figure 4.17) are the 
result of non-specific PKH binding, given that its lipid intercalating properties would 
theoretically cause it to be localized to the outer membrane.  More plausible is the idea that 
diffuse green signal is caused by distribution of exosomal material within the recipient cells. 
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Figure 4.17. Monocytes internalize HDE from control- and APAP-treated human 
hepatocytes. Representative ImageStream-acquired brightfield (BF1), side-scatter (SSC), and 
fluorescent images of PKH67-stained HDE (green) within CD32+ THP-1 monocytes (red) 
counterstained with DAPI nuclear dye (violet) (A). Internalization scores generated from 
analysis of approximately 10,000 cells by IDEAS software for control HDE (B) and APAP 
HDE (C) in monocytes (continued on next page). 
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Figure 4.17. continued 
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4.3.9  HDE differentially regulate monocyte response to endotoxin 
 THP-1 monocytes were exposed to medium, mock controls, control HDE or APAP 
HDE (Table 4.2) from primary human hepatocytes for 24 h.  HDE activity was analyzed on a 
per-donor basis such that HDE preparations from individual donors (n=5; Table 4.1) were 
tested in separate THP-1 experiments.  To observe HDE-induced alterations in cytokine 
response, HDE-exposed monocytes were stimulated with LPS for 6 h prior to cytokine 
analysis.  As noted in HDE concentration-response studies (Figure 4.14), control HDE from 
all donors decreased TNF-α secretion relative to medium alone while APAP HDE reversed 
this trend (Figure 4.18).  The effects of HDE were similar for IL-8, although control HDE 
from Donor 5 uniquely increased IL-8 relative to LPS alone (no exosomes).  APAP HDE 
from Donors 2, 3, and 5 produced levels of IL-8 that exceeded the LPS alone group (Figure 
4.18).  These results indicate that exposure to control HDE suppresses the pro-inflammatory 
response of monocytes, suggesting that HDE from healthy human hepatocytes may in fact be 
anti-inflammatory.  Control HDE may confer some of the liver’s inherent immune tolerance 
for bacterial endotoxins from the gut to immune cells.  Conversely, HDE from APAP-treated 
hepatocytes do not have anti-inflammatory activity and appear to enhance LPS-induced IL-8 
secretion. 
 Levels of MCP-1 were also assayed in HDE-exposed THP-1 monocytes.  MCP-1, 
also known as CCL2, is a chemotactic cytokine that is produced by monocytes in response to 
inflammation by stimuli including LPS and pro-inflammatory cytokines like TNF-α and IL-
1β (Bossink et al., 1995; Chensue et al., 1996; Zisman et al., 1997).  MCP-1 mediates 
recruitment and infiltration of additional immune cells including monocytes, neutrophils, 
lymphocytes (natural killer [NK] and T cells), and to a lesser extent basophils and mast cells 
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(Bossink et al., 1995; Chensue et al., 1996; Zigmond et al., 2014).  MCP-1-recruited cells 
adopt pro- or anti-inflammatory properties depending on the stage of injury and tissue 
microenvironment (Shi and Pamer, 2011).  THP-1 monocytes increase MCP-1 production in 
response to exosomes from amniotic fluid, ascites, and EtOH-treated Huh7.5 hepatocyte-like 
cells (Bretz et al., 2013; Momen-Heravi et al., 2015a).  Our results demonstrate that HDE 
from control-treated primary human hepatocytes significantly increase LPS-induced MCP-1 
production in monocytes (Figure 4.19).  HDE from APAP-treated primary human 
hepatocytes promote greater elevations in MCP-1 that are significantly different from LPS 
alone and control HDE (Figure 4.19).  To support the assertion that the observed effects are 
exosome-related, we performed a concentration-response at 100 and 200 µg/ml HDE as 
described earlier.  MCP-1 release from LPS-stimulated monocytes was responsive to APAP 
HDE concentration such that the effects were significantly increased at 200 µg/ml relative to 
100 µg/ml (Figure 4.19).  Control HDE did not appear to elicit concentration-dependent 
effects.  HDE-induced MCP-1 elevations were also observed in un-stimulated monocyte 
cultures in the absence of LPS, albeit at much lower levels (Figure 4.19).  MCP-1-mediated 
monocyte recruitment is a well-established and integral part of  the “necroinflammatory” 
process in APAP DILI (Zigmond et al., 2014).  We present the first evidence that HDE 
released by APAP-treated hepatocytes mediate MCP-1 secretion in the absence of overt 
hepatocellular necrosis, and that the influence of HDE on monocyte-derived MCP-1 is 
enhanced by LPS.  
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Figure 4.18. HDE from control- and APAP-treated human hepatocytes alter monocyte 
response to endotoxin.  Data represent the mean + SEM of triplicate culture wells and 
duplicate assay wells for TNF-α (A) and IL-8 (B) released by LPS-stimulated monocytes 
following 24 h of HDE exposure (n=5 hepatocyte donors). Donor IDs correspond to those 
listed in Table 4.1. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; one-way ANOVA 
with Tukey’s multiple comparisons test. 
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Figure 4.19. HDE from control- and APAP-treated hepatocytes increase MCP-1 secretion 
by monocytes.  MCP-1 in HDE-treated LPS-stimulated cultures (A, n=3 HDE donors); APAP 
HDE induce concentration-responsive MCP-1 elevations (B, n=1 HDE donor); MCP-1 is 
increased by HDE in the presence and absence of LPS stimulus (C, n=1 HDE donor). Data 
represent the mean + SEM of triplicate culture wells and duplicate assay wells. Donor IDs 
correspond to those listed in Table 4.1. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; 
one-way ANOVA with Tukey’s multiple comparisons test. 
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4.3.10  HDE from drug-stressed hepatocytes significantly alter the monocyte transcriptome 
Gene expression microarrays were performed on THP-1 monocytes following 24 h 
exposure to medium alone, control HDE, control mock, APAP HDE, or APAP mock to 
assess the transcriptome-level effects of HDE on immune cells.  As previously described, the 
effects of EQ polymer in HDE preparations were taken into account by comparing HDE to 
their respective mock controls by linear contrast with FDR p < 0.05 and fold change > |1.5|.  
Performing the analysis in this manner allowed us to factor out the influences of residual 
APAP and EQ on monocyte gene expression.  Hierarchical clustering of significant probe 
sets revealed that control HDE influence monocyte gene expression in a different manner 
than APAP and that the expression profiles of EQ matrix controls are more closely related to 
each other than to HDE (Figure 4.20). 
There were 138 significantly DE genes from APAP HDE exposure relative to mock 
APAP control.  Control HDE relative to the mock EQ control produced 13 significantly DE 
genes, and 12 were common to APAP HDE as well (Table 4.6).  To analyze the genes 
uniquely affected by APAP HDE, we removed the 12 DE probe sets overlapping with control 
HDE to generate a list of 126 genes.  Of those, 7 were up-regulated (Table 4.7) and 119 were 
significantly down-regulated (top 50, Table 4.8).  IPA pathway enrichment analysis was run 
on significant genes to identify over-represented biological and pathological functions in 
monocytes that were influenced by APAP HDE.  The most prominent pathways uniquely 
affected by APAP HDE are those centered around cholesterol homeostasis and lipid 
metabolism, with connections to fatty liver disease (Figure 4.21).  These pathways were also 
enriched when we directly compared DE genes in APAP HDE versus control HDE (data not 
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shown), suggesting that the method we adopted to correct for EQ effects did not 
detrimentally affect or skew the results.  
Select up- and down-regulated genes that were significantly influenced by APAP 
HDE have been linked to enhanced pro-inflammatory response in the literature, thus 
providing a plausible explanation for the cytokine secretion patterns we observed in APAP 
HDE-treated monocytes following LPS stimulation (Figure 4.22).  APAP HDE also 
influenced a number of relevant innate and adaptive immune pathways falling into 2 broad 
categories: lymphoid tissue development (29 genes) and immune cell trafficking (25 genes) 
(Table 4.9).  While most of the DE genes were down-regulated, it is important to note that 
the pathways these genes participate in may be activated or repressed.   
While global analysis of gene expression changes induced by all APAP HDE 
treatments (n=5 donors) demonstrated an enrichment for cholesterol pathways, the effects of 
APAP HDE from individual donors revealed unique pathway trends.  For each donor, probe 
set fold changes between APAP HDE and APAP mock control were generated.  As the 
majority of monocyte genes were decreased due to APAP HDE exposure, the 100 most 
down-regulated genes were selected for pathway analysis.  Results demonstrated two groups 
within the donor pool: APAP HDE from two donors affected cholesterol-related pathways 
while APAP HDE from three donors influenced immune pathways (Figure 4.23).  These 
immune pathways were under-represented in the global data set and reveal that the 
immunomodulatory effects of APAP HDE on a gene expression level are more pronounced 
than initially thought.  Donors whose exosomes initiated cholesterol-related responses shared 
a number of significant pathways; the same was true of donors whose exosomes promoted 
immune-relevant gene expression changes (Table 4.10).  “Reactome” analysis was performed 
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on genes shared across donors within each subset to identify networks impacted by these 
gene products (Figures 4.24 and 4.25).  Reactome data were not available for 8 genes from 
the immune subset and 2 genes from the cholesterol subset.  The available donor 
characteristics (Table 4.1) do not reveal any obvious similarities between the donors in each 
group.  Regardless, these findings may be indicative of the donor-specific systemic immune 
responses to APAP that been observed in humans (Fannin et al., 2016).   
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Figure 4.20. Hierarchical clustering across treatments of the significant probe sets 
differentially regulated by APAP HDE. Signals indicate log2 ratios determined by linear 
contrasts between each treatment and medium alone. Coloration reflects directionality of the 
log2 ratio of the contrast (green, down-regulated; red, up-regulated). The probes clustered 
represent those that showed significant DE in APAP HDE versus mock APAP (FDR p < 0.05 
and FC > |1.5|).  
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Table 4.6. Differentially regulated genes in monocytes exposed to control HDE relative to control mock.   * indicates significant 
genes that were unique to control HDE.  
 
 
Gene Symbol Gene Name Gene FC p -value Relevant Gene Product Functions
ACSS2 acetyl-CoA synthetase short-chain family 
member 2
-3.62 0.0000012 acetate activation for lipid synthesis and energy production; "hub gene" for nutrient-
sensing transcript cluster in monocytes, within QTL associated with blood glucose and 
body weight (Martinez-Micaelo, et al. 2016)
SLCO4C1 solute carrier organic anion transporter 
family member 4C1
-2.68 0.0000379 sodium-independent organic ion transport, associated with cell differentiation; over-
expression decreases inflammation in models of chronic kidney disease (Toyohara, et 
al. 2009)
HSD17B7 hydroxysteroid (17-β) dehydrogenase 7 -2.66 0.0000021 participates in cholesterol and estrogen biosynthesis; down-regulated relative to 
healthy controls in models of cystic fibrosis and polycystic ovarian syndrome (Ogilvie, 
et al. 2011 & Salilew-Wondim, et al. 2015)
PNPLA3 patatin-like phospholipase domain 
containing 3
-2.18 0.0000152 glycerolipid metabolism; SNP associated with hepatic lipid accumulation and 
increased odds ratios for alcoholic and non-alcoholic liver disease in multiple patient 
cohorts (Awai, et al. 2016)
IDI1 isopentenyl-diphosphate delta isomerase 1 -2.14 0.0000252 isoprenoid and cholesterol biosynthesis; down-regulation associated with impaired 
regulatory T cell proliferation (Zeng, et al. 2013); expression altered by glucocorticoid 
receptor and NFĸB activation (Rao, et al. 2011)
CLCN6 chloride channel, voltage-sensitive 6 -2.08 0.0000114 voltage-gated chloride channel that functions in late endosomes as a chloride/proton 
antiporter; SNP associated with hypertension and renal damage in humans (Flister, et 
al. 2013)
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase -2.02 0.0000564 transmembrane glycoprotein that serves as a rate-limiting factor in cholesterol 
biosynthesis; auto-antibodies are directly related to peripheral immune myopathy 
(Alshehri, et al. 2015)
STARD4 steroidogenic acute regulatory (STAR) 
related lipid transfer domain containing 4
-1.87 0.0000210 intracellular sterol/lipid transport that is highly expressed in THP-1 cells, Kupffer cells, 
and hepatocytes (positive regulation of bile acid synthesis); localization and expression 
directly linked to sterol levels (Rodriguez-Agudo, et al. 2011)
SC5D sterol-C5-desaturase -1.78 0.0000279 cholesterol biosynthesis and lipid metabolism; knock-out models have altered protein 
synthesis and oxidative stress responses (Jiang, et al. 2010)
FDPS farnesyl diphosphate synthase -1.67 0.0000241 enzyme involved in isoprenoid biosynthesis and post-translational protein 
modifications; down-regulation associated with disruption of plasma membrane lipid 
rafts; mediates NK cell signaling and activation of ɣδ T cells (Ciaglia, et al. 2013)
C14orf1 chromosome 14 open reading frame 1 -1.62 0.0000555 probable ergosterol biosynthetic protein; assembles cholesterol biosynthetic complex 
that has been linked to lymphocyte development (Santori, et al. 2015)
ACACA acetyl-CoA carboxylase α -1.56 0.0000021 rate-limiting enzyme in long-chain fatty acid biosynthesis; inhibition of protein 
decreases Th17 cell formation and promotes anti-inflammatory Treg cell production 
(Berod, et al. 2014)
DLG5* discs, large homolog 5 1.63 0.0000443 role in signal transduction including receptor signaling complex scaffolds; SNP that 
reduces protein activity is a known risk factor for inflammatory bowel disease (Stoll, et 
al. 2004)
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Table 4.6. continued * indicates significant genes that were unique to control HDE.  
 
 
 
 
 
Gene Symbol Gene Name Gene FC p -value Relevant Gene Product Functions
STARD4 steroidogenic acute regulatory (STAR) 
related lipid transfer domain containing 4
-1.87 0.0000210 intracellular sterol/lipid transport that is highly expressed in THP-1 cells, Kupffer cells, 
and hepatocytes (positive regulation of bile acid synthesis); localization and expression 
directly linked to sterol levels (Rodriguez-Agudo, et al. 2011)
SC5D sterol-C5-desaturase -1.78 0.0000279 cholesterol biosynthesis and lipid metabolism; knock-out models have altered protein 
synthesis and oxidative stress responses (Jiang, et al. 2010)
FDPS farnesyl diphosphate synthase -1.67 0.0000241 enzyme involved in isoprenoid biosynthesis and post-translational protein 
modifications; down-regulation associated with disruption of plasma membrane lipid 
rafts; mediates NK cell signaling and activation of ɣδ T cells (Ciaglia, et al. 2013)
C14orf1 chromosome 14 open reading frame 1 -1.62 0.0000555 probable ergosterol biosynthetic protein; assembles cholesterol biosynthetic complex 
that has been linked to lymphocyte development (Santori, et al. 2015)
ACACA acetyl-CoA carboxylase α -1.56 0.0000021 rate-limiting enzyme in long-chain fatty acid biosynthesis; inhibition of protein 
decreases Th17 cell formation and promotes anti-inflammatory Treg cell production 
(Berod, et al. 2014)
DLG5* discs, large homolog 5 1.63 0.0000443 role in signal transduction including receptor signaling complex scaffolds; SNP that 
reduces protein activity is a known risk factor for inflammatory bowel disease (Stoll, et 
al. 2004)
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Table 4.7. Monocyte genes significantly up-regulated by exposure to HDE from APAP-treated human hepatocytes. Statistical 
significance was determined by linear contrast between APAP HDE and APAP mock control (FDR p < 0.05 and FC > |1.5|). Gene 
product functions were obtained from human UniProt annotations unless otherwise noted. 
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Table 4.8. Top 25 significantly down-regulated genes in monocytes exposed to APAP HDE. Gene product functions were obtained 
from human UniProt annotations or Ingenuity Knowledge Base unless otherwise noted.  
 
  
Gene Symbol Gene Name FC Relevant Gene Functions and Pathway Annotations
MVD diphosphomevalonate decarboxylase -4.64 isoprene biosynthesis
LIPG endothelial lipase -4.55 breakdown of triglycerides and HDL, heparin binding
HMGCS1 hydroxymethylglutaryl-CoA synthase -4.12 lipid metabolism, cholesterol biosynthesis, drug binding, liver 
TSC22D3 DSIP-immunoreactive peptide -3.95 inhibits inflammatory effects of glucocorticoids and IL-10 in 
macrophages, supresses NFĸB-mediated transcription, implicated in 
steatosis
LSS lanosterol synthase -3.64 steroid and cholesterol biosynthesis, protein aggregation
DHCR7 7-dehydroxycholesterol reductase -3.64 steroid and cholesterol biosynthesis
INSIG1 insulin-induced gene 1 -3.48 down-regulation of cargo loading into COPII-coated vesicles, steroid 
biosynthesis, implicated in steatosis
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Table 4.8. continued 
 
Gene Symbol Gene Name FC Relevant Gene Functions and Pathway Annotations
C6orf223 chromosome 6 open reading frame 223 -3.47 uncharacterized protein
BHLHE40 basic helix-loop-helix family member e40 -3.44 LXR/RXR co-repressor, implicated in steatosis, lymphocyte 
proliferation and activation
SCD stearoyl-CoA desaturase -3.26 phospholipid, cholesterol, and triglyceride biosynthesis, fatty acid 
oxidation, implicated in steatosis, down-regulated in non-responders 
in APAP healthy volunteer study (Fannin, et al. 2015)
LDLR low-density lipoprotein receptor -3.26 endocytosis (viral particles, LDL), lipid metabolism, clathrin and 
glycoprotein binding, implicated in hepatic fibrosis, steatosis, and 
cirrhosis; phagocyte and macrophage migration, leukocyte activation
CYTIP cytohesin-interacting protein -3.11 endosomal and cytoplasmic protein expressed in immune cells and 
regulating migration, extravasation, proliferation, adhesion (ICAM1), 
regulated by CD40L, IL-1β, TNF-α, etc.
ULBP2 retinoid acid early transcript 1H -2.95 MHC class I molecule involved in cytokine and chemokine release 
for immune cell recruitment, leukocyte and lymphocyte activation
  
 
1
9
0
 
Table 4.8. continued 
 
 
  
Gene Symbol Gene Name FC Relevant Gene Functions and Pathway Annotations
RHOB regualtor of G-protein signaling 2 -2.94 GPCR signaling, phospholipase activity, immune cell activation and 
migration (phagocytes, leukocytes, antigen-presenting cells)
SLC2A3 solute carrier family 2 facilitated glucose 
transporter member 3
-2.88 monosaccharide transmembrane transport, carbohydrate metabolism
LPIN1 phosphatidate phosphatase -2.87 fatty acid metabolism, PPAR co-activator, insulin response, known 
SNP associated with NAFLD (Valenti, et al., 2012); lymphocyte 
proliferation
BTG2 B-cell translocation gene 2 -2.80 proliferation and differentiation, up-regulated in hepatocellular 
carcinoma and following partial hepatectomy (Zhang, et al. 2009)
SCML1 sex comb on midleg-like protein 1 -3.74 transcription factor activity
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Table 4.8. continued 
 
 
 
Gene Symbol Gene Name FC Relevant Gene Functions and Pathway Annotations
MVK mevalonate kinase -3.61 cholesterol biosynthesis, down-regulation of inflammatory response, 
ATP binding
ALDOC fructose-biphosphate aldolase C -3.53 glycolysis, epithelial cell differentiation, fructose metabolism
SH2D3C SH2 domain-containing 3C -3.14 membrane modifications in cell migration, associated with leukocyte 
movement and lymphocyte proliferation, JNK signaling
TM7SF2 delta(14)-sterol reductase -2.99 sterol and cholesterol biosynthesis, oxidoreductase activity
ACAT2 sterol O-acetyltransferase 2 -2.89 lipoprotein particle assembly, macrophage-derived foam cell 
differentiation, dietary cholesterol absorption
SULF2 extracellular sulfatase 2 -2.84 calcium binding, positive regulation of Wnt signaling and VEGF 
production, involved in hepatocyte proliferation and liver regeneration
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Figure 4.21. Top pathways enriched among genes significantly associated with monocyte 
exposure to APAP HDE. Pathway enrichment was performed on the 126 significantly DE 
genes influenced by APAP HDE from primary human hepatocytes (n=5 donors). Canonical 
pathways (A), toxicity-related pathways (B), and pathologic associations (C) are represented 
(NAFLD: non-alcoholic fatty liver disease). The dashed line indicates a –log(p) > 1.3 threshold 
for pathway significance.  
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Table 4.9. Differentially expressed genes and related immune pathways represented in 
monocytes exposed to APAP HDE .  Pathways and significance were assigned by Ingenuity 
Knowledge Base.  
  
Diseases or Functions Annotation p -value Differentially Expressed Genes in Significant Pathway
Antigen Presenting Cell Migration 9.88E-05 CD38,IL10RA,LDLR,NDRG1,NPC1,PDPN,PTPN6,RHOB,S100A10,SREBF1, 
TRPM4
B Lymphocyte Proliferation 4.01E-04 ACLY,CD300A,CD38,CD72,FCGR2B,LPIN1,PTGER4,PTPN6,SH2D3C
CD4+ T-lymphocyte Proliferation 5.40E-03 BHLHE40,CYTIP,PPARD
Cellular Infiltration by Macrophages 6.48E-03 LDLR,NDRG1,NPC1,PTPN6,S100A10
Cytotoxic and Helper T Cells 6.23E-03 PTPN6
Dendritic Cell Migration 4.69E-03 CD38,IL10RA,PDPN,PTPN6,TRPM4
Leukocyte Activation 1.43E-03 BHLHE40,CD1D,CD300A,CD38,CD72,FCGR2B,LDLR,NDRG1,NPC1,PTGER4, 
PTPN6,RHOB,TRPM4,ULBP2
Leukocyte Migration 1.21E-04 CD1D,CD38,CYTIP,DPYSL2,FCGR2B,IL10RA,LDLR,NDRG1,NEDD9,NPC1, 
P2RX1,PDPN,PTPN6,RASGRP4,RHOB,S100A10,SH2D3C,SREBF1,TRPM4
Lymphocyte Activation 3.20E-03 BHLHE40,CD1D,CD38,CD72,FCGR2B,LDLR,PTGER4,PTPN6,RHOB,ULBP2
Lymphocyte Proliferation 7.84E-06 ACLY,BHLHE40,CD1D,CD300A,CD38,CD72,CYTIP,FCGR2B,JUND,LPIN1, 
NPC1,PPARD,PTGER4,PTPN6,RGS2,RRAS,SH2D3C,TSC22D3,ULBP2
Lymphoid Tissue Morphology 3.89E-03 ATP2B4,BHLHE40,BNIP3L,CD72,CYP51A1,FADS2,FCGR2B,FLVCR1, 
PDPN,PTPN6,TSC22D3
Macrophage Cell Movement 4.64E-03 LDLR,NDRG1,NPC1,PTPN6,RHOB,S100A10,SREBF1
Movement of Phagocytes 2.10E-03 CD38,IL10RA,LDLR,NDRG1,NPC1,PDPN,PTPN6,RASGRP4,RHOB,S100A10,SR
EBF1,TRPM4
Phagocyte Migration 5.11E-03 CD38,IL10RA,LDLR,PDPN,PTPN6,RHOB,S100A10
Quantity of Lymphatic System Cells 3.96E-03 BHLHE40,BNIP3L,CD1D,CD38,CD72,CYTIP,FCGR2B,IL10RA,LDLR, 
NEDD9,NPC1,POLR3E,PTPN6,SH2D3C
Quantity of Lymphocytes 5.04E-03 BHLHE40,CD1D,CD38,CD72,CYTIP,FCGR2B,IL10RA,LDLR,NEDD9,NPC1, 
POLR3E,PTPN6,SH2D3C
Quantity of Lymphoid Tissue 2.53E-03 BHLHE40,BNIP3L,CD1D,CD72,FADS2,FCGR2B,NEDD9,POLR3E,SH2D3C
Quantity of T Helper Lymphocytes 4.82E-03 FCGR2B,IL10RA,LDLR,PTPN6
Quantity of Th17 Cells 5.14E-03 FCGR2B,IL10RA,LDLR
Spleen Enlargement 4.98E-03 BNIP3L,FADS2,FCGR2B,PTPN6
T-lymphocyte Proliferation 3.11E-03 BHLHE40,CD1D,CD38,CYTIP,FCGR2B,JUND,PPARD,PTGER4,PTPN6, 
RGS2,RRAS,TSC22D3
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Figure 4.22. APAP HDE exposure causes gene expression changes in monocytes that may explain LPS response. Significant DE 
genes following APAP HDE exposure (red: up-regulated relative to mock; green: down-regulated relative to mock) that have been 
linked to increased pro-inflammatory response in databases and the literature. Associated inflammatory mediators expected to increase 
are indicated by red squares. Darker shading represents cytokines measured in this research. Stars indicate those genes whose activity 
has been directly associated with increased responsiveness to inflammatory activators such as LPS. MVK: (Cyster et al., 2014); ATF5: 
(Chuang et al., 2008); TSC22D3: (Koarai et al., 2012); FADS1: (Fan et al., 2012; Vij et al., 2008); POLR3E: Uniprot, (Chiu et al., 
2009); JUND: (Rahmani et al., 2001); NPC1: (Suzuki et al., 2007); LDLR: IPA, (Calkin et al., 2011); CD300A: (Nakahashi-Oda et al., 
2012); PPARD: (Adhikary et al., 2015); CD38: (Manjarrez-Orduno et al., 2007); BCL6: (Perez-Rosado et al., 2008).
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Figure 4.23. Top 10 pathways enriched among genes significantly associated with 
monocyte exposure to APAP HDE from individual donors. Pathway enrichment was 
performed on 100 of the genes most influenced by APAP HDE from each primary human 
hepatocyte donor. Pathways enriched as a result of APAP HDE exposure are presented in order 
of donor ID: Donor 1 (A), Donor 2 (B), Donor 3 (C), Donor 4 (D), Donor 5 (E). The dashed 
line indicates a –log(p) > 1.3 threshold for pathway significance. APAP HDE from donors 2 
and 3 induced alterations in cholesterol-related pathways while HDE from donors 1, 4, and 5 
modulated pathways related to immune responses.  
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Table 4.10. Common monocyte pathways associated with exposure to APAP HDE from 
individual donors.   Pathways were assigned by Ingenuity Knowledge Base.  
 
 
 
Shared Immune Pathways (Donors 1, 4, 5)
Acetate Conversion to Acetyl-CoA
Colorectal Cancer Metastasis Signaling
Communication between Innate and Adaptive Immune Cells
Hepatic Fibrosis / Hepatic Stellate Cell Activation
Interferon Signaling
Pathogenesis of Multiple Sclerosis
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses
TREM1 Signaling
Phagosome Formation
Shared Cholesterol Pathways (Donors 2, 3)
Acetate Conversion to Acetyl-CoA
Cholesterol Biosynthesis I
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol)
Cholesterol Biosynthesis III (via Desmosterol)
Estrogen Biosynthesis
FXR/RXR Activation
Ketogenesis
Lanosterol Biosynthesis
Mevalonate Pathway I
Oleate Biosynthesis II (Animals)
Sucrose Degradation V (Mammalian)
Superpathway of Cholesterol Biosynthesis
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate)
Triacylglycerol Degradation
Zymosterol Biosynthesis
  
 
1
9
9
 
 
 
Figure 4.24a. Reactome analysis of common genes differentially regulated by APAP HDE from Donors 1, 4, and 5.  Networks 
represent reactome data for 18 of 26 shared genes between donors in the immune subset. Red color saturation indicates greater 
enrichment of genes in a given network. 
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Figure 4.24b. Reactome analysis of common genes differentially regulated by APAP HDE from Donors 1, 4, and 5. Networks 
represent reactome data for 18 of 26 shared genes between donors in the immune subset. Red color saturation indicates greater 
enrichment of genes in a given network. Overrepresented pathways are labeled. 
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Figure 4.25a. Reactome analysis of common genes differentially regulated by APAP HDE from Donors 2 and 3.  Networks 
represent reactome data for 13 of 15 shared genes between donors in the cholesterol subset. Red color saturation indicates greater 
enrichment of genes in a given network. 
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Figure 4.25b. Reactome analysis of common genes differentially regulated by APAP HDE from Donors 2 and 3. Networks 
represent reactome data for 13 of 15 shared genes between donors in the cholesterol subset. Red color saturation indicates greater 
enrichment of genes in a given network. Overrepresented pathways are labeled.  
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4.3.11  miRNA in HDE from drug-stressed hepatocytes are linked to gene expression effects 
in monocytes 
 Finally, we sought to integrate the content of HDE from APAP-treated human 
hepatocytes with the exosome-induced transcriptional changes we observed in monocytes.  
We have demonstrated previously that both albumin mRNA and miR-122 within primary 
human HDE are significantly altered by sub-toxic APAP exposure (Holman et al., 2016), 
thus our interest was in the RNA content of HDE.  While a number of studies have 
demonstrated the ability of EVs to transfer full-length mRNA that can be translated in 
recipient cells (Herrera et al., 2010; Royo et al., 2013), exosomal RNA translation has not yet 
been connected with functional changes in recipient cells.  In addition, our RNA sequencing 
work and the research of others suggest that the majority of exosomal RNA is non-coding 
RNA (Huang et al., 2013; Santangelo et al., 2016).  Exosomes are well known for carrying 
inherently regulatory RNAs like miRNA, and it has already been established that hepatocyte-
like cells produce exosomes that can transfer functional miR-122 to monocytes (Momen-
Heravi et al., 2015a).  Therefore, we integrated our novel data set of primary human HDE 
miRNA profiles with the observed gene expression effects in recipient monocytes to test the 
hypothesis that the immunomodulatory activity of HDE is mediated in part by the delivery of 
functional miRNAs to immune cells. 
The 126 DE genes uniquely and significantly associated with APAP HDE across all 
donors were compared to miRNAs with the most marked fold changes in APAP HDE 
relative to control HDE in a 2-pronged approach.  First, we worked backwards from DE 
genes in monocytes and predicted which miRNAs should be differentially enriched in 
APAP HDE to cause the significant decreases observed in monocyte gene expression.  
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Experimentally-validated human miRNA-target interactions (MTIs) were obtained from 
IPA or miRTarBase.  The top 25 most significantly down-regulated monocyte genes were 
connected with differentially enriched miRNAs in APAP HDE (Table 4.11).  72% of the 
most down-regulated genes are known to be targeted by miRNAs whose levels increased in 
APAP HDE.  In addition, a number of these miRNAs have been significantly elevated in in 
vivo rat and human studies of DILI caused by APAP overdose (Table 4.11).  This 
concordance with previous APAP studies highlights the potential functional relevance of 
these miRNAs and the novelty of detecting increases in their abundance prior to overt 
hepatotoxicity.  
Next, we used differentially enriched exosomal miRNAs across all donors to predict 
which genes and pathways could be targeted in THP-1 cells.  Given that miRNAs typically 
have an inverse relationship with their target mRNA and that 94% of the genes significantly 
affected by APAP HDE were down-regulated, we predicted gene targets of the miRNAs 
with the greatest positive fold change.  The top 50 most increased miRNA from APAP HDE 
and their fold changes were imported into IPA microRNA Target Filter.  This software 
combined results from 3 different miRNA databases of experimentally observed MTIs to 
produce a list of known mRNA targets.  Enrichment analysis was performed on the mRNA 
targets to produce pathways that could be reasonably anticipated to change if functional 
APAP HDE miRNA were transferred to monocytes (Figure 4.26).  The most significant 
pathways predicted by APAP HDE miRNA content are almost identical to those actually 
affected in APAP HDE-treated monocytes (Figure 4.21).  In addition, miRNAs 
differentially enriched in APAP HDE target all but one differentially expressed gene 
directly tied to increased pro-inflammatory response in Figure 4.22.  These results suggest 
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that exosomal miRNA transfer may be one of the mechanisms used by drug-stressed 
hepatocytes to influence immune cell behavior. 
In addition to evaluating the degree to which miRNA within APAP HDE 
corresponded with the observed pathway alterations from the global data set, we also 
examined these relationships on an individual donor basis (n=4 donors).  The 50 most 
increased miRNA within APAP HDE relative to control HDE were determined for each 
donor.  These miRNAs were analyzed with IPA microRNA Target Filter to identify 
validated relationships with target genes.  Pathway enrichment was performed on predicted 
target genes for each donor and the results were compared to the pathway alterations 
observed in monocytes exposed to APAP HDE from that donor.  Of the observed pathways 
associated with APAP HDE exposure, 30-73% were recapitulated in the target gene set 
predicted by donor-matched APAP HDE miRNA (Table 4.12).  This degree of overlap 
provides additional evidence that exosomal miRNA may be mediating the gene expression 
changes observed in APAP HDE-treated monocytes.  It is important to note that the 
concordance between predicted and observed pathways was generated using limited miRNA 
target information.  Table 4.12 shows that of the 50 miRNAs used for target gene prediction, 
no more than 27 miRNAs from any donor had validated targeting information available.  
Therefore, the pathway overlap may have been considerably greater if additional MTI data 
were available. 
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Table 4.11. Enriched miRNAs in APAP HDE target a majority of the 25 most significantly down-regulated genes in monocytes 
exposed to APAP HDE. Annotation information was obtained from human UniProt, Ensembl, or Ingenuity Knowledge Base unless 
otherwise noted. MTI associations between miRNA and gene targets were obtained from Ingenuity Knowledge Base and bold miRNAs 
have also been elevated in at least 2 other rat and/or human APAP DILI models (Krauskopf et al., 2015; Starkey Lewis et al., 2011; 
Vliegenthart et al., 2015; Ward et al., 2014).  
 
Gene Target Gene Name
Top Up-regulated Exo miRNAs Targeting 
Down-regulated Gene
Gene FC
Relevant Gene Functions and Pathway 
Annotations
MVD diphosphomevalonate decarboxylase hsa-miR-26b-5p -4.64 isoprene biosynthesis
LIPG endothelial lipase hsa-miR-342-3p -4.55 breakdown of triglycerides and HDL, heparin binding
HMGCS1 hydroxymethylglutaryl-CoA synthase hsa-miR-19b-3p
let-7b-5p
-4.12 lipid metabolism, cholesterol biosynthesis, drug 
binding, liver development
TSC22D3 DSIP-immunoreactive peptide hsa-miR-19b-3p -3.95 inhibits inflammatory effects of glucocorticoids and IL-
10 in macrophages, suppresses NFĸB-mediated 
transcription, implicated in steatosis
LSS lanosterol synthase hsa miR-30a-5p
hsa-miR-125b-5p
-3.64 steroid and cholesterol biosynthesis, protein 
aggregation
DHCR7 7-dehydroxycholesterol reductase hsa-miR-34a-5p
hsa-miR-451b
-3.64 steroid and cholesterol biosynthesis
INSIG1 insulin-induced gene 1 hsa-miR-29b-3p -3.48 down-regulation of cargo loading into COPII-coated 
vesicles, steroid biosynthesis, implicated in steatosis
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Table 4.11. continued 
Gene Target Gene Name
Top Up-regulated Exo miRNAs Targeting 
Down-regulated Gene
Gene FC
Relevant Gene Functions and Pathway 
Annotations
C6orf223 chromosome 6 open reading frame 223 hsa-miR-192-3p -3.47 uncharacterized protein
BHLHE40 basic helix-loop-helix family member e40 hsa-miR-15a/b-5p, hsa-miR-16-5p, hsa-miR-
195-5p
-3.44 LXR/RXR co-repressor, implicated in 
steatosis, lymphocyte proliferation and 
activation
SCD stearoyl-CoA desaturase hsa-miR-125b-5p, hsa-miR-30a-5p, hsa-let-
7b-5p, hsa-miR-185-5p, hsa-miR-19/ba-3p, 
hsa-miR-142-5p ,hsa-miR-20a-5p, hsa-miR-
17-5p, hsa-miR-106a/b-5p
-3.26 phospholipid, cholesterol, and triglyceride 
biosynthesis, fatty acid oxidation, implicated in 
steatosis, down-regulated in non-responders 
in APAP healthy volunteer study (Fannin, et a. 
2015)
LDLR low-density lipoprotein receptor hsa-let-7b-5p, hsa-miR-106a/b-5p, hsa-miR-
17-5p, hsa-miR-19a/b-3p, hsa-miR-20a-5p, 
hsa-miR-27a/b-3p, hsa-miR-30a-5p, hsa-miR-
30C-5p, hsa-miR-30d-5p, hsa-miR-40e-5p
-3.26 endocytosis (virla particles, LDL), lipid 
metabolism, clathrin and glycoprotein binding, 
implicated in hepatic fibrosis, steatosis, and 
cirrhosis; phagocyte and macrophage 
migration, leukocyte activation
CYTIP cytohesin-interacting protein hsa-miR-26b-5p
hsa-miR-146b-5p
-3.11 endosomal and cytoplasmic protein expressed 
in immune cells and regulating migration, 
extravasation, proliferation, adhesion 
(ICAM1), regulated by CD40L, IL-1β, TNF-
α, etc.
ULBP2 retinoid acid early transcript 1H hsa-miR-34a-5p
hsa-miR-29b-3p
-2.95 MHC class I molecule involved in cytokine 
and chemokine release for immune cell 
recruitment, leukocyte and lymphocyte 
activation
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Table 4.11. continued 
 
  
Gene Target Gene Name
Top Up-regulated Exo miRNAs Targeting 
Down-regulated Gene
Gene FC
Relevant Gene Functions and Pathway 
Annotations
RHOB regualtor of G-protein signaling 2 hsa-let-7f-5p, hsa-miR-233-3p, hsa-miR-
let7b-5p, hsa-miR-let7c-5p, hsa-miR-21-
5p, hsa-miR-30a-5p, hsa-miR-19a/b-3p, 
-2.94 GPCR signaling, phospholipase activity, 
immune cell activation and migration 
(phagocytes, leukocytes, antigen-presenting 
cells)
SLC2A3 solute carrier family 2 facilitated glucose 
transporter member 3
hsa-miR-122-5p, hsa-miR-195-5p, hsa-miR-
34a-5p, hsa-miR-148a-3p, hsa-miR-106a-
5p, hsa-miR-16-5p, hsa-miR-15a/b-5p
-2.88 monosaccharide transmembrane transport, 
carbohydrate metabolism
LPIN1 phosphatidate phosphatase hsa-miR-17-5p
hsa-miR-27a/b-5p
-2.87 fatty acid metabolism, PPAR co-activator, 
insulin response, known SNP associated with 
NAFLD (Valenti et al. 2012); lymphocyte 
proliferation
BTG2 B-cell translocation gene 2 hsa-miR-21-5p, hsa-miR-101-3p, hsa-miR-
26b-5p, hsa-miR-16-5p, hsa-let7b-5p, hsa-
miR-15a/b-5p, hsa-miR-195-5p, hsa-miR-
125b-5p, hsa-miR-25-3p, hsa-miR-185-5p, 
hsa-miR-29b-3p, hsa-miR-20a-5p, hsa-miR-
17-5p, hsa-miR-106a/b-5p, hsa-miR-27a/b-
3p
-2.80 proliferation and differentiation, up-regulated 
in hepatocellular carcinoma and following 
partial hepatectomy (Zhang, et al. 2009)
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Table 4.11. continued 
 
 
Gene Target Gene Name
Top Up-regulated Exo miRNAs Targeting 
Down-regulated Gene
Gene FC
Relevant Gene Functions and Pathway 
Annotations
SCML1 sex comb on midleg-like protein 1 N/A -3.74 transcription factor activity
MVK mevalonate kinase N/A -3.61 cholesterol biosynthesis, down-regulation of 
inflammatory response, ATP binding
ALDOC fructose-biphosphate aldolase C N/A -3.53 glycolysis, epithelial cell differentiation, 
fructose metabolism
SH2D3C SH2 domain-containing 3C N/A -3.14 membrane modifications in cell migration, 
associated with leukocyte movement and 
lymphocyte proliferation, JNK signaling
TM7SF2 delta(14)-sterol reductase N/A -2.99 sterol and cholesterol biosynthesis, 
oxidoreductase activity
ACAT2 sterol O-acetyltransferase 2 N/A -2.89 lipoprotein particle assembly, macrophage-
derived foam cell differentiation, dietary 
cholesterol absorption
SULF2 extracellular sulfatase 2 N/A -2.84 calcium binding, positive regulation of Wnt 
signaling and VEGF production, involved in 
hepatocyte proliferation and liver regeneration
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Figure 4.26. Monocyte pathway enrichment is predicted by mRNA targets of 
differentially enriched APAP HDE miRNA.  Using experimentally validated targets of the 
top 50 miRNA with the highest FC in APAP HDE, monocyte gene targets were predicted. 
Pathway enrichment for top molecular functions (A) and toxicological mechanisms (B) was 
performed on the predicted target genes to confirm concordance with true DE pathways.
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Table 4.12. Concordance of observed monocyte pathway enrichment with pathways predicted using target genes of miRNA 
enriched within individual donor APAP HDE . Observed pathways were generated from the 100 monocyte genes most impacted 
(down-regulated) by APAP HDE exposure. IPA microRNA Target Filter was used to identify validated gene targets of the 50 most 
increased miRNAs in APAP HDE relative to control HDE. Observed and predicted pathways were included in the analysis if the pathway 
significance score exceeded a –log(p) > 1.3 threshold.  
 
 
 
 
 
Donor ID
HDE miRNAs with 
validated targets
Pathways predicted 
by miRNA target 
genes
Pathways observed 
Overlapping 
pathways
Observed pathways 
predicted by HDE 
miRNA
1 25 287 55 33 60%
2 27 29 27 18 67%
3 21 302 40 12 30%
4 19 234 70 51 73%
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4.4  Discussion 
The research presented here was performed to address knowledge gaps in the fields of 
HDE and DILI using primary human hepatocytes.  Foremost, we sought to establish a role 
for HDE released by drug-stressed cells in mediating early, sub-toxic immune responses in 
DILI.  In so doing, we profiled the mRNA and miRNA contents of HDE and linked the 
miRNA contents to the effects of HDE on immune cells, as we have already demonstrated 
sub-toxic APAP-induced alterations in mRNA and miRNA within HDE (Holman et al., 
2016). 
To assess the immunomodulatory capacity of HDE, we exposed THP-1 human 
monocytes to HDE harvested from cultures of control- and APAP-treated primary human 
hepatocytes (n=5 donors).  One set of THP-1 cells was stimulated with LPS to determine if 
HDE exposure affected prototypical immune responses such as cytokine (IL-8, TNF-α) and 
chemokine (MCP-1) secretion.  HDE from control hepatocytes suppressed the secretion of 
IL-8 and TNF-α relative to LPS alone, suggesting an inherently anti-inflammatory influence.  
HDE from APAP-stressed hepatocytes reversed this trend and in some donors, increased 
cytokine levels beyond those of LPS alone.  The IL-8 and TNF-α results indicate that the 
potential anti-inflammatory effects of HDE from healthy hepatocytes are lost upon drug-
induced hepatocellular stress.  Both control and APAP HDE stimulated MCP-1 release with 
and without LPS.  Taken together, these data revealed two key findings regarding HDE 
activity: (1) HDE from healthy and drug-stressed hepatocytes appear to have direct 
immunomodulatory activity; and (2) the effects of APAP HDE on the release of 
inflammatory mediators indicates that they may sensitize monocytes to LPS stimulation. 
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To better define the effects of primary human HDE on immune cells, transcriptomic 
analysis was conducted on HDE-exposed THP-1 monocytes via microarrays.  We present a 
novel method to account for the potential confounding effects of EQ precipitation reagent on 
gene expression analysis.  Briefly, mock EQ controls were prepared from hepatocyte dosing 
solutions (medium control and 10 mM APAP) that were not incubated with hepatocytes.  
These solutions were concentrated and precipitated with EQ in the same fashion as the 
conditioned hepatocyte medium containing HDE.  Application of these mock controls to 
monocytes alongside true HDE preparations enabled the isolation of gene expression effects 
due solely to HDE and not confounded by the potential influences of residual APAP or EQ.  
Differential gene expression (for global data set or individual donors) was determined by 
comparing the effects of HDE from control- and APAP-treated hepatocytes to monocytes 
treated with respective mock EQ controls.  In general, exposure to HDE from control- or 
APAP-treated hepatocytes caused down-regulation of genes. 
Inspection of genes with the greatest decreases induced by APAP HDE from 
individual donors revealed two distinct responses: APAP HDE from three donors (1, 4, 5) 
significantly affected genes in immune pathways while APAP HDE from two donors (2, 3) 
impacted genes associated with cholesterol metabolism pathways.  These results provide the 
first evidence of immunologically relevant gene expression changes occurring as a result of 
exposure to HDE from drug-stressed cells.  The present findings suggest that donor-specific 
hepatocellular responses to APAP—which were not apparent in cell viability and 
functionality data—are communicated to immune cells via HDE.  This hypothesis is 
supported by the outcome of a healthy volunteer study that examined the peripheral blood 
transcriptome following therapeutic doses of APAP.  Subjects were classified as responders 
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if they showed ALT elevations or non-responders if they did not.  In responders, peripheral 
blood transcriptomic signatures indicated a loss of immune tolerance and increased 
inflammatory response (Fannin et al., 2016).  Conversely, non-responders had tolerogenic, 
anti-inflammatory transcriptomic signatures.  The differential responses of monocytes to 
individual donor HDE observed here may represent the unique responses of hepatocytes to 
APAP. 
When data from all hepatocyte donors were pooled, thirteen genes were significantly 
altered by control HDE versus mock EQ control treatments, suggesting that under these 
experimental conditions, HDE from healthy cells do not exert a strong effect on monocyte 
gene expression.  However, 126 unique genes were differentially regulated by APAP HDE 
exposure in a statistically significant manner.  Pathway analysis of these data revealed 
extensive enrichment for genes involved in cholesterol homeostasis and lipid metabolism 
processes.  Most of the immune pathways affected by APAP HDE from donors 1, 4, and 5 
were not among the pathways enriched in the global data set.  There was, however, overlap 
of TREM1 signaling in both data sets.  TREM1 is a glycoprotein surface receptor on 
monocytes and neutrophils whose activation mediates pro-inflammatory cytokine production 
and phagocytosis (Arts et al., 2013).  However, the current data do not indicate whether the 
TREM pathway would be activated or inactivated as a result of the observed gene expression 
changes. 
There are a number of hypotheses that may explain why the majority of statistically 
significant transcriptomic alterations due to APAP HDE were related to cholesterol 
homeostasis, a process that is indirectly linked to immune response.  The simplest 
interpretation of these data is that APAP HDE deliver excessive lipids and cholesterol to 
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monocytes, resulting in a compensatory down-regulation of cholesterol biosynthesis and lipid 
breakdown.  The release of HDE carrying higher lipid loads following APAP exposure has 
been observed in rat models and may be adaptive for the hepatocyte (Royo et al., 2016).  
Utilization of exosomes to maintain cholesterol homeostasis is a known adaptive mechanism 
(Strauss et al., 2010) and is mechanistically plausible given that lysosomal accumulation of 
cholesterol is associated with increased susceptibility to APAP DILI (Baulies et al., 2015).  
Thus, hepatocytes may be ridding themselves of excess cholesterol as a precautionary 
measure against APAP toxicity. 
Exosomes are inherently enriched for cholesterol, sphingomyelin, ceramide, and 
phosphatidylserine externally but they can also carry bioactive lipids and lipid metabolizing 
enzymes as interior cargo (Kowal et al., 2014; Royo et al., 2016; Subra et al., 2010).  
Exosomes are structurally distinct from the major source of cholesterol for extrahepatic cells, 
low-density lipoproteins (LDL), but they are now becoming recognized as highly effective 
vectors for lipid transport between cells (Berg et al., 2002; Laulagnier et al., 2004; Record et 
al., 2014).  The fact that control HDE also caused down-regulation of a handful of 
cholesterol-related genes but to a lesser extent supports the hypothesis that APAP HDE may 
be enriched in lipids and cholesterol relative to controls.  In conjunction with our finding that 
monocytes do not differentially internalize control HDE and APAP HDE, these results 
suggest that the unique gene expression changes induced by APAP HDE are due to altered 
content rather than altered uptake.   
The differential packaging of lipids into APAP HDE may very well mediate some of 
the biological effects of HDE.  However, our data indicate that the differential gene 
expression in monocytes following APAP HDE exposure may be due to the transfer of 
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functional miRNA by APAP HDE.  Exosomal miRNA profiling revealed that APAP HDE 
are enriched for miRNA that target many of the down-regulated genes in monocytes.  Using 
experimentally validated miRNA-mRNA relationships, we predicted which monocyte genes 
would be targeted by the miRNA increased in APAP HDE across all donors.  Pathway 
enrichment analysis was performed on the predicted gene list to compare the monocyte 
functions that would be affected if functional exosomal miRNA were delivered by APAP 
HDE.  There was marked concordance between the most significantly affected predicted and 
observed pathways: 8 of 10 predicted canonical biological functions and 9 of 10 toxicity 
pathways were common to both data sets.  Common pathways included cholesterol 
metabolism, LXR/RXR activation, mitochondrial membrane permeability decrease, and liver 
steatosis.  There was also marked overlap between predicted and observed pathways on an 
individual donor basis.  Despite having limited gene target information, exosomal miRNA 
predicted up to 73% of the pathways altered by a given donor in monocytes. 
We propose that APAP HDE sensitized monocytes to LPS.  In this work, two sets of 
monocytes were treated with HDE from APAP- or control-treated hepatocytes for 24 h.  
After 24 h, one set of monocytes was harvested for gene expression analysis and the other set 
was stimulated with LPS for cytokine analysis.  Therefore, altered cytokine responses 
following LPS activation in HDE-treated monocytes reflect the influence of HDE on 
sensitivity to stimulus.  Similar results have been obtained from application of T-cell derived 
exosomes to THP-1 monocytes.  Exosome exposure resulted in cholesterol accumulation and 
enhanced TNF-α production (Zakharova et al., 2006).  In fact, many of the statistically 
significant genes affected by APAP HDE that are related to cholesterol homeostasis are also 
linked to LPS sensitization.  For example, 25-hydroxycholesterol synergizes with a TLR3 
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agonist to enhance IL-8 secretion (Koarai et al., 2012).  One of the significantly down-
regulated genes in our data set, TSC22D3, is responsible for this sensitization via negative 
regulation of NFĸB activity (Koarai et al., 2012).  Through mechanisms that are not yet 
defined, 25-hydroxycholesterol also promotes secretion of IL-6 and macrophage colony 
stimulating factor (Cyster et al., 2014).  Another significantly decreased gene, MVK, has 
been associated with pro-inflammatory responses.  In the genetic inflammatory disorder 
known as hyper IgD syndrome, low MVK expression is responsible for increases in the 
production of IL-1β (Cyster et al., 2014).  Usually considered a positive regulator, under 
certain conditions, down-regulation of ATF5 may enhance the release of pro-inflammatory 
cytokine production following T cell activation (Chuang et al., 2008).  While 94% of the 
genes whose expression was significantly different in the APAP HDE group were decreased, 
some of the increased genes also have ties to immune response.  For instance, POLR3E 
induces NFĸB, which could lead to potentiation of an NFĸB-mediated inflammatory response 
(Koarai et al., 2012). 
There is a well-recognized but poorly understood relationship between intracellular 
cholesterol levels and dysregulated immune response.  Observations from cholesterol-loaded 
monocyte-derived macrophages demonstrate that these cells are sensitized to LPS and that 
myeloid cells from a high-fat environment are pre-disposed to adopt a pro-inflammatory 
phenotype, a phenomenon called myeloid skewing (Murphy et al., 2014; Oiknine and 
Aviram, 1992).  The mechanisms of this sensitization have not been fully defined, but at least 
three processes have been described in the literature.  In the first process, cholesterol 
accumulation leads to formation of cholesterol crystals and excess LDL, which together can 
perform both of the priming steps required for inflammasome activation and pro-
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inflammatory cytokine release (Tall and Yvan-Charvet, 2015).  LPS sensitization may also 
occur as a result of failed compensatory mechanisms mediated by ABCG1 and ABCA1, 
which normally down-regulate toll-like receptor (TLR) signaling in response to cholesterol 
accumulation (Yvan-Charvet et al., 2008; Zhu et al., 2008).  Without the proper function of 
these cholesterol-mediated feedback mechanisms, the TLR4 signaling pathway remains 
highly responsive to LPS stimulation.  The facilitation of enhanced TLR and cytokine 
receptor-mediated signaling by increased density of lipid rafts is perhaps the most defined 
mechanism of cholesterol-mediated LPS sensitization.  Cellular cholesterol and lipid levels 
are directly tied to membrane remodeling, which is a key aspect of immune signaling.  For 
example, cholesterol accumulation increases the density of plasma membrane lipid rafts, 
which promote inflammatory receptor-mediated signaling, including that of TNFR, by 
serving as “platforms” for the assembly of signaling complexes (Fessler and Parks, 2011; 
Legler et al., 2003).  Cholesterol levels in the plasma membrane also mediate ligand-
independent activation of receptors such as EGFR (Chen and Resh, 2002), and cholesterol 
flux influences the levels of LPS recognition proteins CD14 and TLR4 (Fessler and Parks, 
2011).  Lastly, low cholesterol levels cause displacement and shedding of TNFR1, TNFR2, 
and IL-6R in immune cells including THP-1 monocytes (Matthews et al., 2003; Tellier et al., 
2008).  It is hypothesized that cholesterol stabilizes these receptors, increasing the 
responsiveness of cholesterol-loaded immune cells to inflammatory stimuli. 
It is difficult to conclude from these results whether the effects of APAP HDE on 
monocytes would exacerbate APAP injury, because cytokines play such varied roles in DILI 
depending upon the context of the injury.  For instance, TNF-α is known to exacerbate the 
toxicity of certain I-DILI drugs including trovafloxacin (Maiuri et al., 2015; Shaw et al., 
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2010), but may also promote hepatocyte regeneration after APAP injury (Chiu et al., 2003).  
Plasma levels of IL-8 and MCP-1 at presentation are correlated with the degree of injury in 
APAP overdose patients (James et al., 2001; James et al., 2005).  In human APAP-induced 
liver injury, classical CD14++/CD16- monocytes (the predominant circulating monocytes) are 
recruited to the liver in an MCP-1 dependent manner during the early phase of cell death, 
known as the “necroinflammatory” stage  (Geissmann et al., 2003; Shi and Pamer, 2011; 
Zigmond et al., 2014).  Once in the liver, these monocytes can differentiate into dendritic 
cells (DCs), macrophages, and possibly even hepatocyte stem-like cells (Shi and Pamer, 
2011; Simon et al., 2015).  In fact, monocytes recruited to the liver by APAP toxicity have 
been shown to differentiate into macrophages that aid in the resolution phase of injury 
(Zigmond et al., 2014).  It is important to note that in the current research, 4 out of 5 human 
hepatocyte lots did not experience overt APAP cytotoxicity.  Therefore, the observed 
alterations in monocyte cytokine response were produced by HDE released prior to fulminant 
necrosis.  While the current research cannot determine the ultimate influence of HDE on the 
outcome of APAP DILI, the results presented here substantiate HDE as a mechanism of sub-
toxic immune cell regulation by drug-stressed hepatocytes. 
 Although this work was not focused on the evaluation or HDE as biomarkers of DILI, 
the present RNA sequencing results suggest that global mRNA profiles in HDE may provide 
mechanistic information regarding cell stress.  Despite the fact that exosomal mRNA 
represented approximately 2% of all mapped reads, control HDE data were substantiated by 
concordance with results from rat HDE transcriptomics (Royo et al., 2013).  In addition, 
mRNAs representing genes known to be up-regulated in hepatocytes during APAP DILI 
were enriched in APAP HDE relative to control HDE.  These transcripts also showed 
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significant overlap with DE genes from APAP-treated primary human hepatocytes, and 
represented pathways that are mechanistically relevant in APAP DILI.  Therefore, the mRNA 
content of HDE may provide information regarding gene expression at the hepatocyte level, 
which supports the hypothesis that HDE may serve as a “liquid biopsy” of hepatic gene 
expression changes in patients, potentially eliminating the need for invasive measures.  
In summary, this research sought to verify the immunologic activity of HDE released 
by drug-stressed cells and evaluate HDE miRNA as potential mediators of said activity.  
HDE from APAP-treated hepatocytes induced different gene expression changes in 
monocytes depending upon the hepatocyte donor.  One subset of donors (n=3) produced 
HDE in response to APAP exposure that regulated many immunologically relevant 
pathways.  The second subset of donors (n=2) had the greatest impacts on cholesterol and 
lipid-related metabolic processes.  When examined as a whole, the data revealed statistically 
significant alterations in cholesterol pathways as a result of monocyte exposure to APAP 
HDE.  New evidence has identified differential lipid enrichment in HDE from APAP-treated 
cells, but the data presented here argue for a role of exosomal miRNA in the regulation of 
cholesterol pathways within monocytes.  We associated these gene expression changes with 
miRNA delivered by APAP HDE, and determined that there was significant overlap between 
the observed DE pathways and those predicted by HDE miRNA targets.  Control HDE 
appeared to induce compensatory and possibly even anti-inflammatory responses in 
monocytes.  However, gene expression changes induced by APAP HDE indicate major 
effects on cholesterol accumulation and metabolism, processes that are linked to the LPS 
sensitization of immune cells that we observed.  We conclude that exosomes from APAP-
stressed primary human hepatocytes sensitize monocytes to LPS activation, a process 
 221 
 
potentially mediated by exosomal miRNA regulation which may involve cholesterol 
homeostasis.  This research presents the first evidence of direct immunomodulation by 
primary human HDE and alteration of this activity by drug-induced hepatocellular stress, 
thereby substantiating the role of HDE in early immune-mediated DILI events.   
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CHAPTER 5. 
 
DISCUSSION 
 
5.1  Summary and conclusions 
The current research provided substantive evidence that hepatocyte-derived exosomes 
(HDE), a type of extracellular vesicle (EV), are directly involved in signaling to the immune 
system following drug-induced hepatocyte stress.  EVs are membrane-bound particles that 
carry RNA, protein, and lipid cargo to recipient cells as a means of communication.   It 
follows that EVs participate in myriad physiological processes including cell fate, 
regeneration, metastasis, and viral pathogenesis.  Exosomes represent the smallest class of 
EV (<150 nm) and are widely recognized as effective mediators of immune function.  Both 
innate and adaptive immune responses are key components of many intrinsic and 
idiosyncratic drug-induced liver injury (DILI) mechanisms.  Thus HDE are of great interest 
in the field of DILI.  
The field of HDE research is in its infancy, and the possibility that HDE form a link 
between hepatocytes and immune cells in the absence of overt hepatotoxicity had not been 
investigated prior to this research.  Multiple studies have demonstrated that HDE are 
immunologically active in models of viral hepatitis, fatty liver disease, and alcohol-induced 
liver injury.  Many of these experiments have utilized hepatocyte-like cell lines, which are 
characteristically dissimilar to primary hepatocytes.  In this work, we sought to establish a 
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role for HDE in early, sub-toxic immune responses to drug-induced hepatocyte stress that 
could ultimately influence the outcome of DILI.  With few methods or precedents in the 
literature, we intended to confirm the immunomodulatory capacity of HDE released by 
primary hepatocytes stressed with an intrinsic hepatotoxicant, acetaminophen (APAP).  
Although it was necessary to employ an intrinsic hepatotoxicant in this foundational work, it 
is fully anticipated that the findings presented here will be validated in models of 
idiosyncratic DILI (I-DILI) in the future. 
This research addressed the global hypothesis that HDE from drug-stressed cells 
carry bioactive signals of hepatocellular stress to the immune system.  We proposed that 
HDE could serve as functional regulators of early DILI events if the following conditions 
were met.  First, given that HDE are constitutively released, their content or quantity should 
be significantly altered prior to overt drug-induced hepatotoxicity.  Second, HDE content 
should be indicative of hepatocyte stress or of HDE function.  Lastly, immune cells should 
respond to HDE, and this response should be distinct between HDE from control- and drug-
treated hepatocytes.  These conditions were investigated in three Specific Aims using APAP 
as a model DILI compound.   
Chapter 2 of this work summarizes a year of extensive technique optimization and 
validation for the enrichment and analysis of primary rat and human HDE.  There are no 
standardized methods for the study of exosomes and it is vital that techniques are developed 
and substantiated for each individual research question.  In comparisons between 
ultracentrifugation (UC) and ExoQuick (EQ) polymer precipitation, EQ was selected as the 
ideal method for optimal HDE RNA and protein yields from rat plasma, rat hepatocyte 
cultures, and human hepatocyte cultures.  The use of EQ allowed us to decrease the scale of 
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hepatocyte experiments by 10 to 20-fold relative to published methods.  The absolute 
quantification of HDE mRNA was optimized by developing standard curves for quantitative 
real-time polymerase chain reaction (qRT-PCR) analysis of all rat and human targets.  In 
addition, the use of exogenous mRNA was validated as a means of qRT-PCR data 
normalization in the absence of traditional housekeeping genes.  Rarely in exosome literature 
are steps taken to generate absolute mRNA quantities and normalize qRT-PCR data.  
However, it is extremely important that these efforts be made because reliable housekeeping 
genes whose exosomal levels are unaffected by treatment have yet to be identified.  The 
procedures developed in this research represent higher throughput and reliable methods for 
the analysis of HDE from primary rat and human hepatocytes.  
In Chapter 3, the aforementioned techniques were employed to determine whether the 
content or quantity of HDE were altered prior to overt APAP hepatotoxicity.  In vivo, rats 
were exposed to a single APAP dose (0, 500, or 1400 mg/kg) for a total of 0, 1, 2, 4, 8, 12, or 
24 h (n=5-6/group).  At these time points, samples were collected for plasma exosome 
precipitation, clinical chemistry, liver histopathology, and liver gene expression analysis.  
HDE were isolated from plasma and examined via qRT-PCR for the liver-specific RNAs 
albumin mRNA and miR-122.  Currently available techniques cannot reliably separate 
exosomes released by a specific cell type from the heterogeneous mixture of exosomes in the 
circulation.  Therefore, in vivo HDE studies rely upon liver-specific RNAs to verify the 
presence of HDE.  For these studies, albumin mRNA and miR-122 were measured in 
exosomes as markers of HDE.  As it can exist outside of exosomes, miR-122 was also 
measured in the protein-rich (non-exosomal) fraction of plasma.  These data were compared 
to metrics of hepatic injury including liver histopathology scores and the plasma activity of 
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alanine aminotransferase (ALT), the gold-standard biomarker of hepatocellular necrosis in 
vivo.  Histopathology and ALT results indicated that APAP DILI only developed in the high 
dose group after 24 h.  Albumin mRNA in plasma HDE was significantly elevated in the 
high dose group at 12 h, prior to hepatocellular necrosis.  HDE albumin was also 
significantly elevated in the low dose group at 24 h, in the absence of hepatocellular necrosis.  
These data supported the hypothesis that the RNA content of HDE was altered before 
development of DILI in vivo.  Both the exosomal and protein-rich fractions of miR-122 were 
elevated prior to DILI, but these changes were not statistically significant.  However, when 
exosomal miR-122 was plotted as a percentage of total circulating miR-122 (exosome + 
protein-rich), time-dependent decreases in the proportion of exosomal miR-122 relative to 
total were observed.  These decreases were apparent as early as 2 h post-dose, and reached 
statistical significance at 12 h, before development of APAP DILI.  These results confirmed 
that the majority of miR-122 released by hepatocytes as a function of APAP exposure is 
protein-rich, and also revealed that following exosomal miR-122 as a percent of total 
provided earlier indication of toxicity than measuring protein-rich miR-122 alone.  Finally, 
the unique profiles of miR-122 and albumin mRNA within HDE support the assertion that 
RNAs are selectively and differentially packaged into HDE. 
Corresponding in vitro studies were conducted using primary rat hepatocytes exposed 
to 0, 0.37, 1.1, 3.3, 10, or 30 mM APAP for 24 h.  These experiments confirmed that in vivo 
HDE dynamics could be recapitulated in vitro.  They were also used to evaluate the effect of 
drug stress on HDE quantity because, as mentioned previously, it is not yet possible to 
reliably separate HDE from other circulating exosome populations.  Therefore, any 
investigation of changes in HDE quantity must be performed in an isolated monoculture 
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system.  From these studies, we observed significant increases in HDE albumin mRNA 
beginning at 1.1 mM APAP, while cytotoxicity was not apparent until 30 mM APAP.  
Quantification of albumin mRNA in the hepatocytes themselves revealed that increases in 
exosomal albumin were not simply a passive reflection of increased transcription at the 
hepatocyte level.  No statistically significant increases in HDE or protein-rich miR-122 were 
detected prior to overt hepatocellular injury.  The unique increases in albumin mRNA that 
were not observed for miR-122 indicated a selective packaging of albumin mRNA into HDE 
following APAP exposure.  Despite increases in albumin mRNA content, HDE number was 
not affected by any APAP concentration.  Taken together, these results suggest that the 
significant alterations in HDE RNA observed in vivo and in vitro were caused by an increase 
in selective packaging of albumin mRNA as opposed to an increase in total HDE release.  
The translational relevance of these findings was assessed using freshly isolated 
primary human hepatocytes (n=7).  Cultures were exposed to 10 mM APAP for 24 h, after 
which samples were harvested for cytotoxicity, cellular and HDE RNA analysis, and HDE 
quantification.  Across all donors, 10 mM APAP did not significantly increase LDH leakage, 
suggesting that 10 mM APAP was not overtly toxic.  APAP-induced elevations in HDE 
albumin mRNA were observed but did not reach statistical significance.  However, exosomal 
miR-122 showed statistically significant increases across all donors in response to APAP 
stress.  In keeping with the rat hepatocyte results, HDE quantity was not affected by APAP 
exposure.  These results confirmed that the RNA content, but not quantity, of HDE is altered 
by sub-toxic drug stress in rats, rat hepatocytes, and human hepatocytes.  As these were the 
first studies to quantify mRNA in primary human HDE, baseline levels of additional liver-
enriched mRNAs were measured across donors, and the influence of donor characteristics on 
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baseline HDE content were also examined.  We observed a potential relationship between 
donor BMI and baseline quantities of albumin mRNA in HDE.  These results may have 
implications for the role of HDE in fatty liver disease and related liver disorders. 
In Chapter 4, we sought to comprehensively profile the mRNA and miRNA content 
of HDE from control- and APAP-treated primary human hepatocytes (n=5) (Aim 2).  Next-
generation sequencing techniques were employed to generate the first profiles of mRNA and 
miRNA in primary human HDE.  Analysis revealed that mRNA and miRNA enrichment 
within HDE are influenced by sub-toxic APAP stress.  RNA sequencing indicated that the 
most abundant transcripts in primary human HDE overlap with those identified as the most 
prevalent in primary rat HDE.  Relative to control HDE, the mRNA enriched in APAP HDE 
represented pathways including oxidative phosphorylation and mitochondrial dysfunction, 
that are not only mechanistically relevant in APAP DILI but are also altered at the hepatocyte 
level.  These results suggest that global alterations in HDE mRNA content may be indicative 
of hepatocellular gene expression, as we had originally hypothesized.  Similarly, the 
miRNAs that were enriched in APAP HDE relative to control HDE have been associated 
with response to APAP in both rat and human in vivo studies. 
HDE were then incubated with THP-1 human monocytes to address the hypothesis 
that HDE from drug-stressed hepatocytes are capable of immunomodulation in the absence 
of cell death (Aim 3).  Gene expression profiling of monocytes revealed that exposure to 
control HDE and APAP HDE may alter cholesterol metabolism and lipid homeostasis 
pathways, with APAP HDE promoting the differential expression of 10 times more genes 
than control HDE.  Depending on the hepatocyte donor, monocyte pathway enrichment 
indicated overrepresentation of immunologically relevant genes or those involved in 
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cholesterol metabolism.  Analysis of the global data set revealed statistically significant 
effects on cholesterol homeostasis.  In an effort to relate HDE content to this activity, 
miRNAs enriched in APAP HDE were used to predict the pathways anticipated to be 
differentially regulated in monocytes for individual donors as well as pooled data.  Notably, 
the pathways known to be targeted by the miRNA in APAP HDE largely overlapped with the 
pathways actually affected in monocytes.  These results strongly suggest that HDE regulation 
of monocyte gene expression may be caused by the horizontal transfer of functional 
miRNAs, a mechanism that has been substantiated for miR-122 delivery to monocytes via 
Huh7.5 HDE (Momen-Heravi et al., 2015a).   
We also provided evidence to suggest that the gene expression changes caused by 
APAP HDE may predispose monocytes to activation.  Monocytes pre-treated with control or 
APAP HDE were stimulated with LPS to examine effects on cytokine response.  Results 
demonstrated that control HDE caused a mild increase in MCP-1 secretion and generally 
decreased release of pro-inflammatory cytokines IL-8 and TNF-α.  In contrast, APAP HDE 
promoted a pro-inflammatory phenotype with increases in all measured cytokines.  We 
proposed that the gene expression changes induced by APAP HDE exposure promoted 
sensitization of monocytes to LPS stimulus, and provided evidence to support this claim.  For 
the first time, this research demonstrates the immunomodulatory capacity of exosomes 
released by drug-stressed hepatocytes.  The activity of HDE prior to overt cytotoxicity 
strongly suggests that through direct interactions with immune cells, HDE may be critical 
mediators of DILI outcomes. 
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5.2  Limitations 
 In the field of exosomes, there are several inherent limitations that must be 
considered, not the least of which is the inability to truly purify exosomes from other EVs.  
In any biofluid, exosomes are part of a heterogeneous mixture of other EVs, lipoproteins, 
protein aggregates, and protein-miRNA complexes.  Current technologies for exosome 
isolation rely on separation by size, buoyant density, or specific protein markers.  Many 
variations of size- and density-based methods exist, and none can truly isolate exosomes due 
to size and density overlap with non-exosomal particles.  Selection for exosomes using 
immunoprecipitation via protein markers of the endolysosomal pathway such as CD9, CD63, 
CD81, or TSG101 is an attractive option.  However, there is no single protein that has been 
unequivocally detected in all exosomes, therefore, immunoselection of this kind 
automatically creates a bias by ignoring exosome populations that are not positive for the 
marker of interest.  It follows that the outcome of individual exosome investigations is highly 
dependent upon the enrichment method and functional endpoints.  The current research 
employed a polymer precipitation reagent, which enriches for exosomes by size.  Like all 
size-exclusion methods, this approach may co-precipitate miRNA-protein complexes and 
lipoproteins in exosome preparations.  This limitation is particularly important when 
measuring miRNAs in the exosomal fraction, as we have done, because some of the miRNA 
signal may be due to extra-exosomal molecules.  For this reason, we also measured exosomal 
mRNA such as albumin, which was not detected outside of exosomes and serves as a 
confirmatory marker.  It is also important to note that standardized methods for exosome 
enrichment and analysis do not currently exist.  It is for this reason that so much time and 
effort was invested in confirming that the approaches developed here were appropriate and 
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optimized for the research query.  To ensure reproducibility, it is paramount to report all 
pertinent methods in exosome studies and work towards standardization in the field.   
An area that will require significant optimization specifically for exosomes is the 
analysis of exosome content by RNA sequencing.  RNA sequencing has become a popular 
approach for global profiling because it allows for more direct quantification of RNAs and 
can detect novel RNA species.  Sample preparation is relatively simple, but there is a 
significant bottleneck in the data analysis stage that limits the feasibility for RNA sequencing 
for many purposes.  In addition to the inherent complications of RNA sequencing, exosomes 
contain RNA profiles that are often distinct from those within their parent cell.  RNA 
sequencing results have demonstrated that the majority of exosomal RNAs are miRNAs and 
other non-coding RNA species (Huang et al., 2013; Nolte-'t Hoen et al., 2012).  This posed a 
challenge for the current research, which sought to identify coding mRNAs within HDE that 
could be reflective of hepatocyte gene expression. With such a low proportion of mappable 
reads, statistical comparisons between mRNAs in control HDE and APAP HDE could not be 
performed reliably.  RNA sequencing is a strong analytical tool, but requires further 
optimization of specialized sample preparation and bioinformatics techniques before it can be 
readily applied to exosomes. 
 When conducting in vitro hepatotoxicity studies, it is important to recognize the 
limitations of each model system.  In the present research, experiments were conducted on 
primary rat or human hepatocytes in monoculture on a collagen substratum, without the 
overlay applied in traditional sandwich culture.  Sandwich culture of hepatocytes has 
remained the gold standard model for in vitro hepatotoxicity testing because the 
configuration supports metabolic function, canalicular development, and cell viability 
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(LeCluyse et al., 1994; Swift et al., 2010).  However, evidence indicated that the sandwich 
culture overlay could impede exosome release and detection, and existing work using rat 
HDE did not utilize an overlay (Conde-Vancells et al., 2008; Royo et al., 2013).  Since the 
current research was attempting to significantly scale down experiments relative to published 
methods, it was imperative to culture without an overlay to ensure maximal exosome 
collection.  In the absence of an overlay, it is possible that the hepatocytes used in the present 
studies were experiencing stress at the time that they were exposed to APAP.  Conversely, 
the cells were likely to have experienced more stress had they been cultured longer without 
an overlay. 
While primary hepatocytes constitute an inherently more physiologically relevant 
system than hepatocyte-like cell lines, their biology is not ideally modeled in monocultures.  
In the liver, hepatocytes are surrounded by non-parenchymal cells that support and regulate 
their function, as well as their responses to toxicants, as our earlier work has shown (Rose et 
al., 2016) (Appendix).  The inability to separate HDE from other exosomes necessitated that 
hepatocytes be studied in monoculture to ensure that the exosomes being harvested and 
analyzed were hepatocyte-derived.  Improvements on the methods available today would 
allow for the study of HDE in complex, multi-cellular models that more accurately 
recapitulate in vivo liver physiology. 
5.3  Future directions 
 The current research presents the first evidence that immune cells are directly 
influenced by exosomes from primary human hepatocytes in response to sub-toxic drug 
treatment.  These findings have exciting implications for the future study of DILI 
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mechanisms, as they implicate HDE as an early regulator of the immune system following 
drug-induced stress.  A natural progression of this work would utilize the approaches 
described here to investigate the role of HDE in early responses to I-DILI drugs.  I-DILI 
frequently involves the immune system, and HDE may be used to study the mechanisms of I-
DILI or to identify and predict I-DILI in patients.  The present work may also implicate HDE 
as mediators of inflammatory responses in other organs and underscores the importance of 
contextualizing the systemic effects of HDE release.  For example, an as-yet undefined 
relationship exists between immune responses in the liver and the lung (Hilliard et al., 2015).   
This axis, and others like it, may be mediated in part by the immunomodulatory functions of 
HDE. 
Near-term future directions would be to further investigate the potentially bioactive 
exosome components identified here, namely miRNA.  We reported increases in exosomal 
miRNAs that corresponded to regulation of targeted pathways in monocytes.  Many of the 
potential miRNA regulators differentially enriched in APAP HDE have known associations 
with APAP DILI.  To support the hypothesis that these miRNAs are responsible for the 
activity of APAP HDE on monocytes, molecular biology techniques should be employed to 
individually manipulate those miRNAs in monocytes and establish a causal relationship.  
First, the most abundant miRNAs in APAP HDE should be measured in monocytes by qRT-
PCR before and after HDE exposure to confirm transfer.  Ideally, miRNAs that are 
hepatocyte-specific and not expressed in monocytes, like miR-122, would be selected to 
strengthen the argument for exosomal transfer.  Similar to the work of Momen-Heravi and 
colleagues, recipient monocytes should be treated with mimics and RNAi inhibitors of a 
given miRNA to examine the influence of that miRNA on the phenotype (Momen-Heravi et 
 233 
 
al., 2015a).  Recent evidence from primary rat HDE suggest that lipid profiles and metabolic 
enzymes within HDE are altered by APAP exposure (Royo et al., 2016).  These findings 
should be confirmed in primary human HDE, as exosomal lipid content may influence the 
activity of HDE and have implications for diseases involving lipid accumulation and 
inflammation, such as fatty liver disease.   
While not the focus of the current work, HDE-mediated gene expression changes 
were also observed in SECs and macrophages.  The activity of HDE demonstrated here 
warrants further investigation of these interactions, and provides justification for exposing 
primary monocytes and elutriated hepatic NPCs to HDE.  The effects of HDE on primary 
NPCs would have implications for intrinsic and idiosyncratic DILI, especially for those drugs 
whose toxicity is known to involve NPCs (Rose et al., 2016)(Appendix).  In addition, 
application of HDE to non-immune NPCs such as SECs and stellate cells could reveal 
mechanisms by which HDE indirectly mediate immune responses.  Lastly, to fully 
understand the complex dynamics between the cells of the liver, exosomes from NPCs 
should be applied to hepatocytes.  Results from such experiments would be valuable in the 
field of DILI but also for understanding the mechanisms of exosome-mediated cell 
communication in liver disease as a whole. 
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APPENDIX. 
 
CO-CULTURE OF HEPATOCYTES AND KUPFFER CELLS AS AN IN VITRO 
MODEL OF INFLAMMATION AND DRUG-INDUCED HEPATOTOXICITY2 
 
Overview 
 
Immune-mediated drug-induced hepatotoxicity is often unrecognized as a potential 
mode of action due to the lack of appropriate in vitro models.  We have established an in 
vitro rat donor-matched hepatocyte and Kupffer cell co-culture (HKCC) model to study 
immune-related responses to drug exposure.  Optimal cell culture conditions were identified 
for the maintenance of co-cultures based on cell longevity, monolayer integrity and cytokine 
response after LPS exposure.  Hepatocyte mono-cultures and HKCCs were then used to test a 
subset of compounds associated with hepatotoxic effects with or without LPS.  Cytokine 
levels and metabolic activity (Cyp3A) were measured after a 48 hr exposure to monitor 
endotoxin-induced changes in acute phase and functional endpoints. LPS-activated HKCCs, 
but not hepatocyte mono-cultures, treated with trovafloxacin (TVX) or acetaminophen 
(APAP), compounds associated with immune-mediated hepatotoxicity, showed LPS-
dependent decreases in IL-6 production with concomitant increases in Cyp3A activity. 
Differential endotoxin- and model-dependent alterations were observed in cytokine profiles 
and Cyp3A activity levels that corresponded to specific compounds. These results indicate 
                                                 
2 This chapter has been published as an original research article in the Journal of Pharmaceutical Sciences and is 
presented according to journal convention. The original citation is as follows: Rose K., Holman N., et al. 2016. 
Co-culture of hepatocytes and Kupffer cells as an in vitro model of inflammation and drug-induced 
hepatotoxicity, Journal of Pharmaceutical Sciences, 105:950-964; Epub 2015 Nov 17.   
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the utility of the HKCC model system to discern compound-specific effects that may lead to 
enhanced or mitigate hepatocellular injury due to innate or adaptive immune responses. 
Introduction 
Unexpected and unexplained hepatotoxicity continues to be one of the main adverse 
outcomes observed in humans during clinical trials and after-market withdrawals (Corsini et 
al., 2012; Kaplowitz, 2005; Sunman et al., 2004).  Drug-induced hepatotoxic modes of action 
(MOA) are often complex, involving metabolic activation, multiple cell types and 
perturbation of biochemical pathways involving both hepatocytes and resident macrophages 
(i.e. Kupffer cells [KCs]) (DeLeve et al., 1997; Evers et al., 2013; Kmiec, 2001; Sunman et 
al., 2004).  Many complex, immune-mediated hepatocellular responses such as reactive 
metabolite formation, infectious disease, circulating cytokines, and gut-derived endotoxin 
inflammation require interactions between hepatocytes, endothelial cells and KCs (DeLeve et 
al., 1997; Evers et al., 2013; Liu and Kaplowitz, 2006; Sunman et al., 2004).   
KCs constitute the largest resident macrophage population in the body, and are 
crucial for the regulation of immune-mediated hepatotoxicity and liver injury (Dixon et al., 
2013).  In their primary scavenger role, KCs endocytose foreign particles and bacterial 
endotoxins, which causes their activation and production of a number of cell signaling and 
stress pathway modulators, such as reactive oxygen species and cytokines, including TNF-α 
and IL-1 (Kolios et al., 2006).  Cell damage and soluble stress signals during drug-induced 
hepatocellular injury cause a similar KC activation, which modulates hepatocyte and non-
parenchymal cell death by apoptosis (Dixon et al., 2013; Kolios et al., 2006; Roberts et al., 
2007).  In addition, cytokines and chemokines secreted by KCs during injury modulate the 
metabolic activity of hepatocytes and induce the expression of acute phase proteins, such as 
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C-reactive protein and NOS2, while causing the suppression of genes involved in the 
metabolism and clearance of xenobiotics, including cytochrome P-450 enzymes, uridine 5'-
diphospho(UDP)-glucuronosyl transferase systems and uptake and efflux transporters 
(Higuchi et al., 2007; Hoebe et al., 2001; Morgan, 2009; Sunman et al., 2004; Wu et al., 
2006).   
KCs constitute the largest resident macrophage population in the body, and are 
crucial for the regulation of immune-mediated hepatotoxicity and liver injury (Dixon et al., 
2013). In their primary scavenger role, KCs endocytose foreign particles and bacterial 
endotoxins, which causes their activation and production of a number of cell signaling and 
stress pathway modulators, such as reactive oxygen species and cytokines, including TNF-α 
and IL-1 (Kolios et al., 2006).  Cell damage and soluble stress signals during drug-induced 
hepatocellular injury cause a similar KC activation, which modulates hepatocyte and non-
parenchymal cell death by apoptosis (Dixon et al., 2013; Kolios et al., 2006; Roberts et al., 
2007).  In addition, cytokines and chemokines secreted by KCs during injury modulate the 
metabolic activity of hepatocytes and induce the expression of acute phase proteins, such as 
C-reactive protein and NOS2, while causing the suppression of genes involved in the 
metabolism and clearance of xenobiotics, including cytochrome P-450 enzymes, uridine 5'-
diphospho(UDP)-glucuronosyl transferase systems and uptake and efflux transporters 
(Higuchi et al., 2007; Hoebe et al., 2001; Morgan, 2009; Sunman et al., 2004; Wu et al., 
2006).   
These complex and dynamic cellular interactions are not adequately captured in 
traditional hepatocyte mono-cultures.  As such, indirect hepatocellular toxicity caused by 
immune cell activation and hepatic inflammation is often overlooked as a potential mode of 
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action (Evers et al., 2013).  Development of an optimized co-culture system that incorporates 
KCs will be imperative to study these events. In addition, there is a growing body of 
evidence for the role of genetic variability and adaptive immune responses within the human 
population that accounts for some idiosyncratic drug-induced liver injury and its severity in 
some patients (Corsini et al., 2012).  This also becomes even more important when using 
inbred strains of rodents or animal models with rare or unique genetic backgrounds (Harrill et 
al., 2009a). 
Clearly, to better assess the potential of compounds to cause immune-mediated 
hepatotoxicity, more reliable and predictive culture models that incorporate donor-matched 
cell types are needed.  Previously, we developed a rodent-based co-culture model using a 
commercial source of cryopreserved KCs and observed enhanced drug-induced 
hepatotoxicity under glucocorticoid-free medium conditions (Bonzo et al., 2015).  In the 
current study, we present a more metabolically competent in vitro rat hepatic co-culture 
system that incorporates donor-matched primary hepatocytes and KCs (HKCC) to assess 
immune-mediated hepatotoxicity over an extended culture period.  The effects of different 
medium formulations and glucocorticoid levels were investigated to define suitable 
experimental conditions prior to compound testing (Waxman et al., 1990).  Validation 
studies were conducted under predefined culture conditions using a set of hepatotoxic 
compounds, including trovafloxacin (TVX), an antibiotic associated with immune-related 
hepatotoxicity, and acetaminophen (APAP), an analgesic and antipyretic agent associated 
with reactive metabolite formation and oxidative stress.  As part of these studies, we 
determined the concentration-dependent responses of a set of test compounds on functional 
endpoints (Cyp3A activity) and cytokine profiles (IL-6, TNF-α) in the presence and absence 
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of lipopolysaccharide (LPS).  Our results indicate that this enhanced co-culture model system 
provides a more stable and physiologically relevant platform by which to investigate drug-
induced, immune-mediated reactions that can lead to acute hepatotoxic effects.   
Materials and methods 
Reagents 
Trovafloxacin, levofloxacin, allyl alcohol and acetaminophen were purchased from 
Sigma-Aldrich (St. Louis, MO).  Triclosan (Irgacare MP) was obtained from Ciba-Geigy AG 
(Basel, Switzerland).  Propiconazole and Acetochlor were purchased from Chem Service (West 
Chester, PA).  All other compounds were purchased from Sigma-Aldrich and were of the 
highest grade available.  Compound stocks were prepared in dimethyl sulfoxide (DMSO, 
Sigma-Aldrich) so that the final concentration did not exceed 0.1%. Lipopolysaccharide (LPS) 
from E. coli strain 0127:B8 (Sigma-Aldrich, Cat # L4516) was dissolved in sterile phosphate 
buffered saline (PBS).  
Isolation of Primary Hepatocytes and KCs   
Donor-matched hepatocytes and Kupffer cells (KCs) were co-isolated from individual 
adult (200-300g) male Sprague-Dawley rats (Charles River Laboratories) using differential, 
density gradient and counter-flow elutriation centrifugation methods (LeCluyse et al., 1996; 
Valatas et al., 2003).  Briefly, in situ perfusions were performed following a modified two-
step digestion method using a collagenase/protease enzyme blend according to the 
manufacturer’s recommendations (Vitacyte, Indianapolis, IN).  After digestion, the liver 
tissue was dissected, placed in a sterile 150-mm petri dish containing HBSS supplemented 
with 1% BSA, 15 mM HEPES and 1 g/L glucose (Thermo-Fisher/Life Technologies, Grand 
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Island, NY), and transferred to a sterile biosafety cabinet.  After removing the outer 
membrane (Glisson’s capsule) with sterile forceps, the digested liver tissue was gently 
shaken to remove the parenchymal cells from the vascular tree without direct mechanical 
manipulation.  The crude cell slurry was poured through a mesh filter (105-µm) into 50 mL 
tubes and centrifuged at 70 g for 3 min, which enriched for the mature hepatocytes in the 
pellet and NPCs in the supernatant.  Supernatants were collected for KC isolation and the 
hepatocyte pellets were further subjected to Percoll density gradient centrifugation (GE 
Healthcare, Marlborough, MA) which yielded >99% pure population of hepatocytes 
(LeCluyse et al., 1996).  Final hepatocyte yields and viabilities were determined using a 
Vision CBA Image Cytometry System (Nexcelom Bioscience, Lawrence, MA), and seeded 
as described below.   
For the isolation of KCs, the liver remnant with residual parenchymal and non-
parenchymal cells (NPCs) was placed in a 250-mL specimen cup containing 100 mL of 
supplemented HBSS with 1% BSA and 100 g/mL DNase and further dissociated by gentle 
stirring for 5 min.  Afterwards, the cell slurry was filtered through a 297-micron mesh and 
centrifuged, along with the supernatants from the initial hepatocyte low-speed spin, at 500 g 
for 6 min at 4ºC (DeLeve et al., 2006).  Crude NPC pellets were resuspended in 
supplemented HBSS, filtered using a 70-micron snap-cap filter, and loaded into a sterile 10-
mL syringe.  KCs were then further separated from other NPCs by a combination of Optiprep 
(Sigma-Aldrich) density gradient and counterflow elutriation centrifugation using an Avanti 
J-26XP centrifuge (Beckman-Coulter, Brea, CA) and a JE-5.0 rotor equipped with a 5-mL 
standard chamber following a modified version of the methods described by Valatas et al 
(Valatas et al., 2003).  Adjustments were made to the elutriation protocol as necessary until 
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KC purity was determined to be greater than 90% based on flow cytometry results (see Flow 
Cytometry). 
Plating of Primary Cell Co-cultures  
Hepatocyte-Kupffer cell co-cultures (HKCC) were plated at a 2:1 ratio onto 48-well 
Type I collagen-coated plates. The ratio of KC and hepatocytes was initially optimized as 
part of the development of the co-culture system with the goal to achieve maximum cytokine 
production in the presence of LPS (Bonzo et al., 2015).  Whereas normal KC:hepatocyte 
ratios are on average closer to 1:4 across the liver acinar structure, the 1:2 ratio that was 
utilized for the co-culture model does represent a near physiological condition when 
considering their enrichment in the periportal region under inflammatory conditions in vivo 
(Adams et al., 2010). 
For initial studies exploring effects of dexamethasone, co-cultures were plated in 
Advanced DMEM supplemented with penicillin-streptomycin, GlutaMax and 10% fetal 
bovine serum (Life Technologies, Grand Island, NY).  For later studies investigating effects 
of hydrocortisone and screening compounds, co-cultures were plated in DMEM-HG 
supplemented with MEM Non-Essential Amino Acids, penicillin-streptomycin, 10% fetal 
bovine serum (Life Technologies) and insulin (10 mg/mL; Sigma-Aldrich).  Hepatocytes 
were plated at 375,000/well and allowed to attach for ~ 1 h at 37C/5% CO2 with manual 
gentle shaking every fifteen minutes.  After hepatocyte attachment, medium with unattached 
cells was removed and donor-matched KCs in supplemented plating medium were added at 
187,500/well.  KCs were allowed to attach for approximately 1 hr in the incubator with 
gentle shaking every 15 min and transferred into maintenance medium prior to use.  
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Flow Cytometry  
Cell sample preparation and flow cytometry measurements were performed using a 
modification of methods described previously (Hanna et al., 2011).  Small aliquots of NPC 
fractions were collected from the final cell pellets after elutriation and density gradient 
separation as described above.  Cells were then washed with PBS containing 2.5mM EDTA 
and pelleted by centrifugation at 300 g for 5 minutes.  Cells were then resuspended at 1x106 
per 100µl staining buffer (BD Biosciences, San Jose, CA) containing 2.5mM EDTA.  To 
measure viability, cells were stained with a fixable LIVE/DEAD stain (ThermoFisher, 
Waltham, MA) according to the manufacturer’s recommendations.  Cells were then blocked 
with Fc  receptor (BD Biosciences) for 15 min and stained with AlexaFluor 488-conjugated 
CD163 (AbD Serotec, Raleigh, NC) for 30 min at 4ºC.  For intracellular staining of CD68, 
cells were fixed and permeabilized using BD IntraSure Kit (BD Biosciences).  AlexaFluor 
647-conjugated CD68 antibody (AbD Serotec) was added in 100µl of staining buffer and 
incubated for 30 min at 4ºC.  
Flow cytometry and cell fluorescence measurements were performed using a BD 
Cantos II flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star, 
version 10.0.6).  Samples were analyzed using 100,000 events based on NPC population.  
Parameters for FSC/SSC were set to include all cell types potentially present in liver cell 
isolation and elutriation fractions (i.e., endothelial cells, stellate cells, KCs, and hepatocytes).  
Populations were first interpreted using relative cell size and complexity in FSC/SSC, 
viability, and the presence or absence of cellular markers.  Calculations for the percentage of 
each cell type were based on live cell populations as determined by viability analysis.  KCs 
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were identified as CD68+, with CD163 determining maturation.  Mature KCs were defined 
as CD68+/CD163+.  Liver sinusoidal endothelial cells were identified by exclusion.   
Immunocytochemistry 
To visually confirm KC enrichment in elutriated fractions and KC localization within 
HKCCs, KC mono-cultures and HKCCs were stained with antibodies against CD68 and 
CD163. Cultures were activated with LPS (1 μg/mL) for 48 hr after 24 hr acclimation. Cells 
were fixed and permeabilized with ice-cold methanol.  Cultures were washed 2x with DPBS 
and blocked using BSA Stain Buffer (BD Pharminogen) containing diluted Hoechst 33342 
nuclear dye (ThermoFisher).  Individual wells were probed for CD68 or CD163 using mouse 
anti-rat primary antibodies (AbD Serotec) incubated for 6 hr at 4°C.  Cultures were washed 
and incubated with a goat anti-mouse AlexaFluor 488 secondary antibody (ThermoFisher) 
for 1 hr at room temperature.  After washing, cells were visualized with the EVOS FL Cell 
Imaging System (ThermoFisher,).   
Comparison of Maintenance Media  
To extend HKCC longevity, four different maintenance medium formulations were 
evaluated: Advanced DMEM (A-DMEM) (Life Technologies), Modified Chee’s Medium 
(MCM) (Life Technologies), Williams’ E Medium (WEM) (Life Technologies), or Hepatocyte 
Maintenance Media (HMM) (Lonza, Walkersville, MD).  HKCCs were plated as previously 
described above, and transitioned to one of four maintenance media formulations supplemented 
with ITS+ and penicillin-streptomycin (ThermoFisher) 30 min after KC attachment.  After a 24 
hr acclimation period, cultures were exposed to LPS (1 µg/mL) for 48 hr.  Cell viability after 48 
hr LPS exposure was assessed by measuring cellular ATP levels as described below. 
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Glucocorticoid Effects on LPS-mediated Responses 
To identify a plating and treatment regimen that would provide HKCCs with sufficient 
glucocorticoids to sustain hepatocytes over a 3-4 day culture period with minimal suppression of 
LPS-induced cytokine production, pre-treatment of hepatocytes and/or KCs with normal and 
reduced levels of dexamethasone (Dex) and hydrocortisone (HC) were evaluated.  Pretreatment 
with Dex was initially evaluated by exposing both hepatocytes and KCs during the respective 
attachment stages to supplemented Advanced DMEM containing 1 µM Dex. After attachment, 
the cells were washed, medium replaced with Dex-free MCM, and HKCCs were treated with 
LPS (1 µg/mL) for a 48 hr period followed by assessment of cytokine production levels and 
morphological integrity.  Additional experiments in which only the hepatocyte fraction was 
initially plated in Advanced DMEM containing Dex (20 nM) were conducted. Prior to adding 
KCs in Dex-free medium, hepatocyte monolayers were washed with Dex-free medium.  
HKCCs were then treated with LPS in Dex-free MCM as described in the previous section 
followed by evaluation of cytokine production levels and morphological integrity. 
To ensure appropriate KC-mediated events were recapitulated in HKCCs exposed to 
HC, effects of TVX and LVX, a toxic and non-toxic fluoroquinolone antibiotic, respectively, 
on cytokine release and HKCC viability were determined.  Hepatocytes were allowed to attach 
(approximately 1 hr) in plating medium containing  1µM HC before addition of KC. HKCC 
were maintained in MCM as described above, and co-exposed to TVX or LVX (0-200 µM) in 
the presence of absence of LPS on culture day 1 for 48 hr.  
In a separate set of experiments, the concentration- and time-dependent effects of 
hydrocortisone (HC) on LPS-mediated cytokine production in HKCCs were examined by 
exposing hepatocytes and KCs to plating medium containing 1 or 10 µM HC for a 2 hr or 24 hr 
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duration, prior to changing cells into Dex-free maintenance medium (MCM).  HKCCs were 
then treated with LPS (1 µg/mL) and samples were collected for determination of cytokine 
production, Cyp3A activity, and gene expression as described below.  
Measurement of Cytokine Production  
Cytokine levels were measured as described previously (Bonzo et al., 2015).  Briefly, 
cell culture supernatant samples were collected at indicated time points after treatment with 
compounds in the presence or absence of 1 µg/mL LPS and stored at -80°C until analysis.  
Individual cytokine levels were measured using rat IL-6 and TNF-α ELISA kits according to 
the manufacturer’s recommendations (Life Technologies/ThermoFisher) and quantified using 
a SpectroMax M5 plate reader and utilizing SoftMax Pro software (Molecular Devices, 
Sunnyvale, CA).  Additional multiplex measurements were performed on select medium 
samples using the Cytokine Rat 10-Plex Panel (ThermoFisher) for the Luminex® platform. 
Data were collected and analyzed using the Bio-Plex System (Bio-Rad, Hercules, CA). 
Measurement of Cytochrome P450 3A (Cyp3A) Activity 
Cyp3A metabolic activity was measured in intact cultures as described previously 
(Bonzo et al., 2015).  Briefly, HKCCs were cultured and treated with compounds in the 
presence or absence of LPS for 48 hours as indicated above. Cytochrome P450 3A (Cyp3A) 
activity was measured directly in wells using the P450-Glo™ CYP3A4 Assay with 
Luciferin-IPA (Cat # V9001, Promega, Madison, WI) according to the manufacturer’s 
instructions for cultured cells, and utilizing a Luciferin standard curve (Beetle Luciferin, Cat 
# E1601, Promega).  Plates were analyzed using a SpectroMax M5 plate reader and utilizing 
SoftMax Pro software. Values are reported as units of Luciferin (nM).  
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Gene Expression Profiling  
At the end of the 48 hr treatment period, RNA was extracted from HKCCs using the 
RNeasy Miniprep Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. 
RNA samples were reverse transcribed with the High Capacity RNA-to-cDNA Kit following 
the manufacturer’s instructions (Applied Biosystems/Life Technologies, Grand Island, NY).  
Quantitative PCR reactions (technical duplicates) were performed with 10 ng of cDNA per 
well using TaqMan® Universal PCR Master Mix (Applied Biosystems) and manufacturer 
recommended “best coverage” TaqMan® Gene Expression Assays for Crp, Nos2, Tat, and 
Alb (Applied Biosystems).  Reactions were carried out using an ABI 7900HT Fast Real-Time 
PCR System with sample analysis performed using Sequence Detection Systems software 
(version 2.4; Life Technologies).  Relative quantities (RQ) were calculated for each gene of 
interest by normalizing to Hprt1 and are presented as a percent of the respective HC vehicle 
control group for each set of treatments.  
ATP Content 
For measurement of ATP levels as a representation of overall cell viability, the 
CellTiter-Glo® Luminescent Cell Viability Assay was performed on cell cultures maintained 
with different medium conditions according to manufacturer’s instructions and utilizing an 
ATP standard curve (Promega).  Plates were analyzed using a SpectroMax M5 plate reader 
and utilizing SoftMax Pro software.  Values are reported as µM ATP.  
Screening with Test Compounds 
After a 24 hr post-plating acclimation period in MCM with 1 µM HC, HKCC or 
corresponding mono-cultures of hepatocytes were treated with several compounds associated 
with liver injury over a range of concentrations in the presence or absence of LPS (1 µg/mL) for 
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an additional 48 hr.  Effects on cytokine production (IL-6, TNF-α and Cyp3A activity were 
determined as described in previous sections.  Compounds tested were TVX, APAP, triclosan 
(TCS), acetochlor, propiconazole, and allyl alcohol.   
Data Analysis  
Each treatment condition was performed in a minimum of two replicate culture wells.  
The average or mean  SD was calculated from the data for each treatment group unless 
otherwise specified.  Statistical tests and significance levels utilized are described in 
individual figure legends where applicable.  
Results 
Establishment of HKCC Model with Donor-matched Hepatocytes and KCs  
The main goal of this project was to extend and expand upon our previous efforts to 
develop a robust co-culture model of primary rat hepatocytes and liver-derived macrophages 
(KCs) that would ultimately lead to a corresponding human cell-based system for drug and 
chemical screening purposes (Bonzo et al., 2015).  In this work, we developed novel methods 
to produce donor-matched primary hepatocyte and KC fractions from the same liver tissue 
that, under optimized culture conditions, allow an extended compound exposure period 
compared to our previous culture system (DeLeve et al., 2006; LeCluyse et al., 1996; Valatas 
et al., 2003).  The inherent sequence of events during the isolation process allowed for the 
rapid preparation of hepatocyte fractions first, which were pre-plated at the appropriate 
density and allowed to attach while the NPC fractions were processed using modified density 
gradient and elutriation centrifugation methods.   
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Confirmation of the identity and purity of the KC fractions was performed using a 
combination of flow cytometry and immuno-fluorescence microscopy.  The isolated cells 
were stained for CD68 and CD163, which indicate monocyte lineage and mature macrophage 
phenotype, respectively, and purity was assessed using flow cytometry (Fig. 1).  Flow 
analysis confirmed the enrichment of KCs (>90%) with very small amounts of contaminating 
cell types (Fig. 1D).  The ratio of KCs and hepatocytes was previously optimized as part of 
the development of a rodent-based co-culture system with the goal to achieve maximum 
cytokine production after treatment with LPS (Bonzo et al., 2015).  Phase-contrast and 
fluorescent images of HKCCs illustrated the localization of KCs relative to hepatocytes in 
these co-cultures (Supplementary Fig.1) (Bonzo et al., 2015).  KCs were well-distributed 
around and amongst the hepatocyte chords that formed as a result of the seeding conditions 
described in the Materials and Methods section.  LPS treatment did not appear to have an 
impact on the localization or distribution of the KCs among the hepatocytes (Supplementary 
Fig. 1B,D). 
Effect of Medium Formulation on HKCC Integrity and Viability 
As part of our model development strategy, we further explored the effects of four 
commercially available cell maintenance media (Advanced DMEM [A-DMEM], Modified 
Chee’s Medium [MCM], Williams’ E Medium [WEM], or Williams’ E-based Hepatocyte 
Maintenance Media [HMM]) on HKCC viability and morphological integrity over a 72 hr 
period in the presence and absence of LPS.  In keeping with previous study conditions, no 
glucocorticoids were utilized during these media comparison experiments (Bonzo et al., 
2015).  The results showed that MCM maintained the greatest overall ATP levels in HKCCs 
on culture day 3, representing contributions from both hepatocytes and KCs, followed by A-
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DMEM, regardless of LPS stimulation (Fig. 2A,B).  Corresponding photomicrographs 
depicting the unstimulated HKCCs at 72 hours confirmed that the overall health and integrity 
of the co-cultures was best supported using MCM (Supplementary Fig. 2).  As a result of 
these experiments, all subsequent experiments were performed using glucocorticoid-free 
MCM as the basal maintenance medium formulation. 
Effects of Glucocorticoids on LPS-induced Responses 
In order to develop a more physiologically relevant medium formulation that included 
glucocorticoids to support native hepatocyte metabolic function, the impact of Dex or HC 
exposure on cell morphology and LPS-induced inflammatory cytokine responses in HKCCs 
was explored.  Initial experiments were performed using Dex because of its prevalent use and 
acceptance as a potent synthetic glucocorticoid for hepatocyte cell culture experimentation in 
the pharmaceutical and chemical industries.  The impact of Dex on HKCC monolayer 
integrity and cytokine response was investigated after brief exposure (2 hr) to medium 
containing 1 µM Dex during the post-isolation hepatocyte and KC attachment phase.  As has 
previously been shown, the presence of 1 µM Dex enhanced the overall appearance of the 
monolayers and the cuboidal architecture of the hepatocytes (data not shown) (LeCluyse et 
al., 1999; LeCluyse et al., 1996).  However, the LPS-induced production of TNF-α was 
reduced by ~80% from no LPS levels and IL-6 was completely eradicated in Dex-treated 
HKCCs (Fig. 3A, C).  
We further explored the tenacity of the Dex-mediated effects on LPS-induced 
cytokine response by exposing only the hepatocytes during the attachment step to an even 
smaller amount of Dex (20 nM).  Upon hepatocyte attachment, the Dex-containing medium 
was removed and cultures were washed with fresh Dex-free medium prior to addition of KCs 
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to the hepatocyte monolayers.  Photomicrographs of HKCCs with and without 20 nM Dex in 
the plating medium during hepatocyte and KC attachment showed minor effects on cell 
morphology after day 1 (Supplementary Fig. 3A,C).  However, there were marked 
differences in the overall monolayer integrity and cuboidal structure of the hepatocytes by 
day 3 in the absence of Dex (Supplementary Fig. 3B).  LPS-induced TNF-α levels were 
reduced ~33% of those without Dex while IL-6 production was reduced ~70% (Fig. 3B,D).  
The results from an expanded list of cytokines as represented in Table 1 confirmed that the 
major pro-inflammatory cytokines, e.g. IL-6, IL-1α, IL-12, GM-CSF, and IFN-ɣ, were 
drastically reduced, whereas the anti-inflammatory cytokines, e.g. IL-10 and IL-4, were 
minimally affected.  The combined results from these experiments indicated that Dex would 
not be a suitable glucocorticoid supplement for subsequent use in experiments to investigate 
compound-induced effects on adaptive immune responses, even if only employed at low 
levels during the cell attachment stage.    
Hydrocortisone as a Substitute Glucocorticoid in HKCCs for Immune-based Toxicity Testing 
Given the tenacity of Dex pretreatment on cytokine response to LPS exposure in 
HKCCs, we explored whether brief exposure to low concentrations of hydrocortisone (HC), a 
glucocorticoid with lower in vitro stability and potency, would serve as a suitable substitute.  
For these experiments, hepatocytes and KCs were seeded in attachment medium containing 1 
µM HC, which was subsequently replaced with HC-free maintenance medium.  Cultures 
were then treated with trovafloxacin (TVX) over a range of concentrations (0-200 µM) 
known to cause differential effects on cytokine profiles and cytotoxicity in the presence of 
LPS after a 48 hr exposure period (Shaw et al., 2007; Waring et al., 2006).  As a negative 
control, the experiments were run in parallel using HKCCs treated with the non-toxic analog 
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levofloxacin (LVX) with or without LPS.  As anticipated, the results showed statistically 
significant increases in both TNF-α and IL-6 production levels in LPS-activated HKCCs 
compared to those that were not (Fig. 4A,B).  TVX caused decreased ATP levels with LPS 
co-treatment (Fig. 4C), while no significant decreases in ATP levels were observed in LVX-
treated HKCCs under any condition (Fig. 4D).  TVX produced concentration-dependent 
increases in TNF-α production (Fig. 4A) and corresponding decreases in IL-6 production 
(Fig. 4B) at 22 µM prior to overt toxicity at the highest concentration tested (200 µM).  TVX 
and LPS co-exposure significantly impacted both TNF-α and IL-6 production (interaction 
term p<0.0001).  LPS and LVX co-exposure caused significant increases in TNF-α that were 
independent of LVX concentration (Fig. 4A).  In contrast, LPS and LVX interact (interaction 
term p<0.05) to increase IL-6 at 66 µM with respect to LVX vehicle control.  These data 
recapitulate previous data collected from rat co-culture systems without HC (Bonzo et al., 
2015).   
As a result of these initial outcomes, we further expanded on these findings by 
exploring the effects of low levels of HC on Cyp3A metabolic activity and cytokine levels in 
LPS-activated HKCCs.  Inflammatory cytokines, such as IL-6, are known to reduce the drug 
metabolizing capacity of the liver in both animal models and isolated primary hepatocytes 
(Abdel-Razzak et al., 1993; Ashino et al., 2004; Poüs et al., 1990).  Therefore, cells were 
exposed to either 1 or 10 µM HC during attachment (~2 hr) or continuously for the first 24 hr 
in culture, followed by treatment for an additional 48 hr with LPS and TVX (50 μM), which 
causes well-defined alterations in IL-6 and Cyp3A activity levels without overt 
hepatocellular injury in the previous experiments.  Under all HC treatment conditions tested, 
the expected suppression of Cyp3A activity was observed in the absence of TVX as a result 
 251 
 
of the corresponding increases in IL-6 and TNF-α production in LPS-activated HKCCs (Fig. 
5).  Moreover, the corresponding reversal of this suppressive effect was observed in activated 
co-cultures treated with 50 μM TVX regardless of the HC concentration or exposure period.  
These outcomes were further confirmed by the concomitant LPS-induced changes in the pro-
inflammatory cytokine profiles of IL-6 and TNF-α in the presence and absence of TVX (Fig. 
5BC,E,F).  
The corresponding morphological effects of short-term (2 hr) versus long-term (24 
hr) exposure to HC prior to LPS stimulation were also examined on HKCCs using phase-
contrast microscopy.  The results indicated that treatment with 1 or 10 µM HC sustained or 
improved the over morphological integrity and longevity of the cultures compared to those 
maintained in HC-free medium over the course of the study period (Supplementary Fig. 4).   
HC Effects on LPS- and TVX-induced Gene Expression in HKCCs 
To further elucidate the impact of brief versus prolonged exposure of HKCCs to 1 or 
10 µM HC on liver-specific gene expression, we investigated the changes in the mRNA 
levels of two glucocorticoid receptor-dependent genes (Alb, Tat) and two oxidative-stress and 
acute phase-response (OSAR) genes (Crp, Nos2).  The results, represented as a percentage of 
respective HC-free controls, indicate that brief exposure to 1 µM HC did not cause 
significant changes in the expression levels of the four genes under any treatment condition 
(Fig. 6A-D).  However, 24 hr exposure to 1 µM HC caused a decrease in the acute-phase 
response gene Crp in the absence of LPS, whereas it caused an overall decrease in the 
expression of Nos2 under all treatment conditions (Fig 6A,B).  Addition of LPS reversed Crp 
suppression brought about by 24 hr of 1 µM HC exposure. HKCCs exhibited a global 
increase for all four genes when exposed to 10 µM HC at plating, regardless of LPS or TVX 
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treatments (Fig. 6E-H).  As seen with 24hr 1 µM HC, LPS-induced Crp expression increased 
with 24hr of 10 µM HC (Fig. 6E).  Another similarity to 24 hr of 1 µM HC results is the 
overall decrease in expression of Nos2 under all treatment conditions when combined with 
24 hr of 10 µM HC (Fig. 6F).  While no differences in Tat expression were observed between 
the different 10 µM HC exposure times tested, a trend in the up-regulation of Alb was 
observed in HKCCs exposed to 10 µM HC for 24 hr (Fig. 6G, H).   
Immune-mediated Toxicity Testing Using the Modified HKCC System 
Overall, the combined results from the previous experiments demonstrated that 
HKCCs exposed to HC in the first 24 hr of culture exhibited better viability, morphology and 
hepatic gene expression profiles while successfully recapitulating the in vitro changes in 
metabolic function, cytokine profiles and hepatotoxic effects known to occur under 
glucocorticoid-free conditions (Bonzo et al., 2015).  As a result of these findings, MCM 
medium supplemented with 1 µM HC for a 24 hr period prior to treatment with LPS was 
selected as our system of choice for screening additional compounds for immune-mediated 
changes in cytokine profiles and hepatocellular functions.  For these experiments, a subset of 
compounds with known associations with liver injury and inflammation was selected from a 
list of hepatotoxic compounds published previously (Rodrigues et al., 2013).  After a 24 hr 
post-plating acclimation period, mono-cultures of hepatocytes and matching HKCCs were 
treated with compounds over a range of concentrations in the presence or absence of LPS to 
assess effects on cytokine production and metabolic (Cyp3A) activity. These experiments 
were designed to show the impact of KC activation in the presence of LPS on the 
concentration-dependent effects of 6 hepatotoxic compounds (Fig. 8).  Matching mono-
cultures of hepatocytes alone (Fig. 7) were treated in an identical fashion to discriminate 
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between intrinsic compound-dependent hepatocellular injury in the absence of a KC-
mediated inflammatory response.   
The results are represented in Figures 7 (mono-cultures) and 8 (co-cultures) as a 
percent change in each endpoint at each concentration compared to the initial vehicle control 
value from the corresponding groups treated with or without LPS.  Corresponding actual 
values for each endpoint in mono-cultures and co-cultures treated with each compound are 
included as supplementary tables (Suppl. Tables 1 and 2).  In mono-cultures of hepatocytes, 
TVX caused a 2-fold increase in Cyp3A activity at the highest concentration tested but no net 
change in cytokine production regardless of LPS treatment (Fig. 7A,B).  This same overall 
pattern was observed in HKCCs in the absence of LPS (Fig. 8A).  However, in the presence 
of LPS (i.e. KC activation), TVX caused a concentration-dependent decrease in IL-6 levels 
that was concomitant with a pronounced ~ 5-fold increase in Cyp3A activity and enhanced 
hepatotoxicity (at the highest concentration) compared to the other treatment groups (Fig. 
8B).  Little or no concentration-dependent effects were observed on TNF-α levels.  Upon 
closer inspection of the absolute values of the endpoint data for the HKCCs with and without 
LPS, it was apparent that the activation of KCs in the vehicle control HKCCs treated with 
LPS caused a 50% reduction of Cyp3A activity concomitant with a marked increase in both 
IL-6 and TNF-α levels (Suppl.Table 2A).  The data also showed that the TVX-mediated 
increase in the Cyp3A activity correlated with a concentration-dependent decrease in IL-6 
production without effect on the corresponding production of TNF-α.     
APAP also caused a concentration-dependent increase (~3-fold) in Cyp3A activity in 
mono-cultures of hepatocytes relative to the vehicle controls without a major change in the 
corresponding cytokine levels regardless of LPS treatment (Fig. 7C,D).  This pattern of 
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effects also occurred on Cyp3A and cytokine profiles in APAP-treated HKCCs in the 
absence of LPS (Fig. 8C).  In APAP-treated HKCCs in the presence of LPS, there was a 
concomitant concentration-dependent reduction in IL-6 levels and >5-fold change in Cyp3A 
activity at the highest concentration without a corresponding effect on TNF-α levels (Fig. 
8D).  The shift in Cyp3A activity was again associated with the reversal of IL6-mediated 
suppression of Cyp3A similar to what was observed with TVX (Suppl Table 2A).   
TCS caused no significant changes in Cyp3A activity or cytokine levels in mono-
cultures of hepatocytes regardless of LPS treatment prior to observing overt toxicity, which 
occurred at the highest concentration tested (100 µM) (Fig. 7E,F).  In HKCCs treated with 
LPS, TCS also did not cause a significant change in Cyp3A activity or cytokine levels at 
subtoxic concentrations.  A slight reduction in IL-6 levels was observed in the presence of 
LPS, but it was less pronounced compared to TVX and did not result in reversing the IL-6 
suppression of Cyp3A activity levels (Suppl. Table 2A).  Acetochlor also did not cause 
marked changes in Cyp3A activity or cytokine levels in mono-cultures of hepatocytes 
relative to vehicle controls prior to overt toxicity, which also occurred at the highest 
concentration tested (100 µM) (Fig. 7G,H).  In HKCCs, acetochlor caused a slight increase in 
TNF-α which resulted in a slight decrease in Cyp3A activity, but no net effect on IL-6 levels 
until the highest concentration (Fig. 8G).  By contrast, it caused a reduction in IL-6 levels in 
HKCCS treated with LPS, without concomitant effects on TNF-α or Cyp3A (Fig. 8H), which 
was not observed in corresponding mono-cultures of hepatocytes (Suppl. Tables 1,2).  
Notably, the overt cytotoxicity observed in acetochlor-treated mono-cultures at the highest 
concentration was attenuated in HKCCs (data not shown).   
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Propiconazole treatment of mono-cultures caused a large ~10-fold increase in Cyp3A 
activity at the lowest concentration tested; followed by a complete inhibition of Cyp3A 
activity at the higher concentrations (Fig. 7I,J).  By contrast, it had minimal effects on 
cytokine levels that were related to the LPS treatment (Suppl. Table 1A).  Propiconazole-
treated HKCCs in the absence of LPS exhibited a reduced 4-fold increase in Cyp3A activity 
at the lowest concentration followed by complete inhibition of metabolic activity at the 
higher concentrations (Fig. 8I; Suppl. Table 2A).  However, the induction of Cyp3A activity 
at the lower concentration was nearly completely attenuated in LPS-activated HKCCs (Fig. 
8J).  Little or no effects were observed on the cytokine levels in HKCCs regardless of the 
LPS treatment with the exception of LPS-treated co-cultures at the highest propiconazole 
concentration tested, where reduced IL-6, but not TNF-α, and enhanced cytotoxicity were 
observed (Suppl. Table 2A).  
Allyl alcohol (AA) caused little or no changes IL-6 or TNF-α levels in mono-cultures 
of hepatocytes in the absence of LPS (Fig. 7K).  However, there was a slight concentration-
dependent increase in IL-6 in LPS-treated mono-cultures (Fig. 7L).  Regardless of the LPS 
treatment, a marked reduction in Cyp3A activity was observed in mono-cultures at 
concentrations 100 µM, which coincided with the onset of overt cytotoxicity (Fig. 7K,L; 
Suppl. Table 1B).  Treatment of HKCCs with AA caused more pronounced changes in 
cytokine levels in the presence of LPS at concentrations 100 µM (Fig. 8K,L).  Notably, 
there were more-pronounced concentration-dependent decreases in Cyp3A activity at the 
lower concentrations of AA in HKCCs compared to mono-cultures, but less-pronounced 
decreases in Cyp3A activity at higher AA concentrations (Fig. 8K,L).  Upon closer 
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inspection of the separate endpoint values, AA caused a concentration-dependent decrease in 
Cyp3A activity that was independent of LPS treatment (Suppl. Table 2B).  
Discussion 
Drug- and chemical-induced hepatotoxicity continues to be a major concern for 
during development and compound prioritization in the pharmaceutical and agrochemical 
industries, despite the scientific advancements in our understanding of the clearance, 
disposition and exposure for most compounds.  Many hepatotoxic responses are caused or 
exacerbated by an immune system component, which cannot be mimicked in simple mono-
cultures of hepatocytes (Evers et al., 2013; Kaplowitz, 2005).  More advanced, multicellular 
models incorporating both primary adult hepatocytes and resident immune cells, i.e. KCs, 
recapitulate the interaction between parenchymal and immune cells under controlled 
conditions (LeCluyse et al., 2012).  LPS- and treatment-mediated KC activation also has 
been shown to contribute to a number of adverse effects produced by hepatotoxic compounds 
(Jaeschke, 2007; Jaeschke et al., 2002; LeCluyse et al., 2012).  Hypotheses for the key 
molecular events and cellular pathways that may be involved in the mechanisms of action 
and progression of the hepatotoxic effects in vivo have been elegantly described and 
illustrated previously (Roberts et al., 2007; Shaw et al., 2010).  Accordingly, the direct as 
well as indirect effects of compounds on important cell-cell interactions, shifts in cytokine 
levels and changes in metabolic clearance can only be examined more systematically in vitro 
using more sophisticated co-culture systems that incorporate the key cell types that possess 
biochemical pathways. 
In a previous study, we described an in vitro co-culture model using rat primary 
hepatocytes and cryopreserved KCs (Bonzo et al., 2015).  We established conditions that 
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facilitated short-term culture of both cell types while maintaining responsiveness to LPS 
activation and TVX-dependent hepatocellular injury.  TVX is one of the most highly studied 
and best described examples of immune-mediated enhanced hepatoxicity (Beggs et al., 2014; 
Shaw et al., 2009).  Previous work has shown that TNF-α is a key mediator of TVX effects 
on caspase-dependent hepatocellular injury by direct effects on resident macrophages (e.g. 
KCs) and increasing its biosynthesis and slowing its elimination (Poulsen et al., 2014; Shaw 
et al., 2010).  LVX, a structural analog of TVX, does not exhibit the direct effects on KCs 
nor the corresponding hepatotoxic properties in vivo or in vitro.  
In our previous work, we employed KCs from a commercial source (Life 
Technologies/ThermoFisher) and avoided the use of glucocorticoids due to their known anti-
inflammatory effects.  As an extension of our previous work, our goal was to establish 
methods of isolating donor-matched hepatocytes and KCs from the same tissue specimen in 
order to establish a model for studying the role of innate and adaptive immunity in 
idiosyncratic drug-induced liver injury (IDILI).  The ability to isolate and culture donor-
matched cell types also would allow studies to be performed using the matched cell types 
from knock-out animals and specific strains from murine genetic diversity panels (Harrill et 
al., 2009a; Harrill et al., 2009b).  Moreover, we are exploring the genetic variability that 
accounts for the idiosyncratic drug-induced liver injury and its severity in some patient 
populations (Corsini et al., 2012).  In order to conduct these studies it is important to 
eliminate any artifactual immune response that could be due to HLA/MHC differences or 
mismatches across donors.  This becomes even more important when using inbred strains of 
rodents or precious human tissue samples from patients that have very rare or unique genetic 
backgrounds.  In addition to having donor-matched liver cells, we also intended to identify a 
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more suitable medium formulation incorporating low levels of glucocorticoids, if possible, in 
order to prolong the useful life-span of HKCCs and to better understand drug-induced 
hepatotoxic events under more physiologic conditions.   
In order to isolate liver cells from the same tissue, we combined methods from the 
literature that had been originally designed to isolate individual cell types and modified them 
until we were able to obtain suitable quantities of hepatocytes and KCs with acceptable 
purity and viability (DeLeve et al., 2006; LeCluyse et al., 1996; Valatas et al., 2003).  As 
demonstrated in Figure 1, we were able to obtain relatively pure populations of KCs that 
exhibited >90% enrichment of macrophage-specific markers, CD68 and CD163.  Further 
examination by phase-contrast and immuno-fluorescence microscopy confirmed the presence 
of KCs that stained positive for these same markers.  We also established a protocol for 
plating the hepatocytes and KCs sequentially, which followed the natural progression of the 
isolation stages, such that the hepatocytes were isolated first and allowed to attach for 45-60 
min while the KCs were purified from the NPC-enriched supernatant fractions.  Freshly-
isolated KCs were then added to the attached hepatocyte monolayer, after which they became 
integrated in between individual hepatocytes, as illustrated in Figure 2. 
Following the establishment of our isolation protocols, we explored different 
formulations of culture media that had been employed for the maintenance of primary 
hepatocytes (LeCluyse et al., 1999; LeCluyse et al., 1996).  The results from the medium 
experiments indicated that modified Chee’s medium (MCM) provided greater support for 
optimal co-culture morphology and viability over a 72 hr culture period, which was deemed 
suitable for investigating compound effects on immune-related responses and hepatocellular 
injury.  Notably, MCM had been identified previously as a ‘preferred’ medium for 
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maintaining primary hepatocyte function and viability over longer culture periods, but this is 
the first report to show evidence of its beneficial effects on maintenance of HKCC monolayer 
integrity and functionality (LeCluyse et al., 1999; Waxman et al., 1990). 
We then attempted to identify suitable conditions under which we could incorporate 
glucocorticoids to sustain hepatocyte gene expression and metabolic capacity, while retaining 
the HKCC cytokine response to LPS (LeCluyse et al., 2012; Waxman et al., 1990).  Our 
initial experiments confirmed that the use of potent and stable glucocorticoids, such as Dex, 
completely abolish the activation of KC by LPS in both KC mono-cultures and co-cultures 
even after limited exposure during the initial attachment phase.  However, subsequent results 
suggest that HKCCs, exposed to low levels of HC (1 M) for up to 24 hr after plating, could 
still respond normally to LPS treatment, recapitulating key events such as TNF-  and IL-6 
cytokine production and concentration-dependent TVX toxicity.  Importantly, cytokine 
production directly resulted in the down-regulation of CYP activity, which was reversed by 
TVX treatment, a benchmark result from a prototype compound that is known to elicit 
adverse effects in vitro and in vivo, especially under inflammatory conditions (Bonzo et al., 
2015; Morgan, 2009; Roberts et al., 2007; Shaw et al., 2007).  Moreover, gene expression 
levels of liver-specific and OSAR genes were maintained at higher levels in HKCCs with HC 
pretreatment compared to those without it.   
After establishing the culture conditions for maintaining cell longevity and improved 
hepatocyte functionality while retaining LPS responsiveness, a subset of known 
hepatotoxicants was tested using the modified HKCC model system (Borlak et al., 2013; 
Rodrigues et al., 2013).  The compounds were tested over a 48 hr exposure period at several 
concentrations that were relevant to their exposure in vivo or that had been shown to cause 
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hepatocellular injury in vitro.  We then examined their immune-mediated (LPS-induced) and 
direct effects (without LPS) on the production of key cytokines, namely TNF-α and IL-6, as 
well as metabolic capacity as represented by Cyp3A activity.  Cytotoxicity was monitored 
either visually by phase-contrast microscopy and/or biochemically by measuring changes in 
intracellular ATP levels.   
Firstly, the data confirmed the fidelity of the modified HKCC model to recapitulate 
the key events exhibited by the benchmark compound TVX, including the concentration-
dependent alteration in IL-6/TNF-α ratios and corresponding shift in Cyp3A suppression that 
has been described previously (Bonzo et al., 2015).  HKCCs treated with APAP also 
exhibited a similar trend in LPS-mediated effects on cytokine profiles and CYP activity.  In 
addition, APAP caused a greater cellular ATP decrease in LPS-treated HKCCs relative to co-
cultures not exposed to LPS, which was similar to what was observed with TVX (data not 
shown).  Notably, APAP is another compound known to be associated with immune-
mediated enhanced hepatotoxic events leading to severe liver injury and liver failure in some 
individuals (Borlak et al., 2013).  Although it is well established in the literature that APAP 
is metabolically activated to a reactive metabolite (NAPQI), which depletes GSH as a key 
initiating event leading to oxidative stress and hepatocellular injury, our results provide 
confirmation that there may be secondary pathways involved in its hepatotoxic mechanism, 
such as changes in cytokine profiles and metabolic capacity, that may be responsible for 
enhancement of toxicity in LPS-activated HKCCs, outside the classical APAP-induced 
cytotoxic effects from NAPQI formation. Notably, the ‘idiosyncratic’ nature of the severity 
of APAP toxicity in some patients has been linked to the patient’s adaptive immune 
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responses, suggesting that it too may fall into a category of a ‘TVX-like’ mechanism (Borlak 
et al., 2013; Harrill et al., 2009b).  
Other hepatotoxic compounds that were tested using the enhanced HKCC system 
exhibited unique trends in their effects on either cytokine profiles and/or CYP activity that 
seemed to lead to exacerbated or attenuated cytotoxicity.  For the most part, the compound-
induced effects observed in the HKCC model system are likely to be a reflection of their 
mode of action on KC activation and/or hepatocellular functions.  For example, it’s been 
shown that TCS causes LPS-independent perturbations in thyroxine disposition (Paul et al., 
2012).  Chloroacetanilide pesticides, such as acetochlor and alachlor, exhibit metabolism-
dependent hepatoxicity (Kale et al., 2008; Rodrigues et al., 2013).  Many antifungals, such as 
propiconazole, are known to be potent inhibitors and inducers of liver cytochrome P450 
enzymes and nongenotoxic tumor promoters, events which are exacerbated by inflammatory 
responses (Wolf et al., 2006).  Allyl alcohol has been shown to exhibit selective 
hepatocellular damage around the periportal region that was shown to be related to localized 
gradients in oxygen and inflammatory responses (Przybocki et al., 1992).   
Taken together these results suggest that the HKCC model could provide additional 
information and insights into the true potential of compounds in development to cause 
hepatocellular injury and toxicity.  We propose that the HKCC model system could 
potentially be utilized to stratify toxic compounds into sub-categories of immune-mediated 
hepatotoxic responses as observed in this study, for example: 1) compounds that caused KC-
mediated decreases in IL-6 levels with concomitant in metabolic activity leading to enhanced 
cytotoxicity, e.g. TVX, APAP; 2) compounds that caused hepatocellular effects and 
cytotoxicity that were independent of inflammatory mediators, e.g. TCS; 3) compounds 
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exhibiting KC-mediated attenuation of hepatocellular effects and cytotoxicity, e.g. 
acetochlor; allyl alcohol; and 4) compounds that cause marked changes in metabolic capacity 
(i.e. induction, inhibition of Cyp3A), with enhanced KC-mediated cytotoxicity in the absence 
of distinct cytokine effects, e.g. propiconazole.  Moreover, our findings underscore the need 
for more biologically relevant, multicellular culture models to study these complex biological 
and toxicological events.  Further research is warranted in order to explore the mechanisms 
of the LPS-enhanced and KC-mediated secondary and adaptive events leading to enhanced or 
diminished hepatocellular injury.  
 
Conclusion 
We have demonstrated the utility of an optimized donor-matched HKCC model for 
exploring possible mechanisms of immune-mediated drug responses.  Our HKCC system 
responds to prototype effector molecules of inflammation and toxicity and corresponds 
closely with results observed previously in vitro and in vivo for prototype hepatotoxic 
compounds.  Application of this model system to screening a limited set of compounds 
associated with liver injury indicated that APAP displayed enhanced immune-mediated 
effects similar to that of TVX, a known IDILI compound.  Other compounds had unique 
direct or indirect effects on cytokine levels and metabolic capacity that appeared to reflect 
known in vitro and in vivo effects or modes of action (Borlak et al., 2013; Liu et al., 2015; 
Rodrigues et al., 2013; Rotroff et al., 2010).  Overall, these findings support the use of 
HKCCs, with proper medium formulation, as a valuable in vitro tool to evaluate and stratify 
compounds with hepatotoxic liability that would otherwise be overlooked using hepatocytes 
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alone. Moreover, this novel approach can be extended to development of a human-based co-
culture model to explore population diversity in innate immunity and its role in IDILI. 
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Figure 1.  Flow cytometric analysis of freshly isolated rat NPC- and KC-containing 
fractions.  A, Representative fluorescent images of cells analyzed by flow cytometry and 
counter-stained with antibodies against CD68 and CD163 for visual verification of cells with 
macrophage lineage (i.e. KCs). Original magnification, 100x.  B, FSC/SSC plot representing 
entire population present after elutriating liver cells for KC.  Counts were recorded for 100,000 
events within the population of interest.  All cells are shown in FSC/SSC to ensure maximum 
collection of KC during elutriation.  C, Cell viability is represented by dye exclusion. Only 
viable cell populations were utilized for subsequent cell marker analysis.  D, Flow analysis of 
cell fractions using CD68 and CD163 as markers of cell lineage and relative fraction purity 
with corresponding gating strategy. Representative plots for unstained control sample, SEC 
fraction, and KC fraction are shown.  Quadrants display cells that are both CD68- and CD163-
, single CD68+, single CD163+, and double CD68+/CD163+. Data are representative of three 
separate elutriations.  
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Figure 2. Effect of maintenance medium formulation on intracellular ATP levels in 
HKCCs. Hepatocyte mono-cultures and HKCC were cultured for 48 hr with or without LPS 
in four different types of maintenance media.  A, cell viability across medium formulations 
without LPS stimulation.  B, cell viability across medium formulations with LPS stimulation.  
An (*) denotes a significant difference between ATP values for a given medium and those for 
MCM, after a Bonferroni post-test (p<0.001).  
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Figure 3. Effects of Dex supplementation in hepatocyte and KC plating medium on 
HKCC cytokine release. TNF-α and IL-6 release from HKCCs in which Heps and KCs were 
plated in media containing Dex (A,C, 1 µM; B, D, 20 nM) (†, values from biological singlet 
wells). Significance of Dex treatment on cytokine release in LPS stimulated HKCC was 
determined by two-tailed Student’s t-test (****, p<0.0001); (***, p<0.001); (**, p<0.01); 
(BLQ, below limit of quantification).  
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Figure 4. Validation of immune-mediated biology in HKCC with prototypical positive 
and negative control compounds. HKCCs were exposed to a concentration range (0-200 µm) 
of TVX or LVX in the presence and absence of LPS. Levels of TNF-α (A) and IL-6 (B) in 
collected medium samples were assayed by ELISA after 48 hr of compound exposure. 
Combined effects of LPS and compound were analyzed for each cytokine by two-way 
ANOVA with Dunnett’s post-test and compared to compound vehicle control (*: p<0.05);( **: 
p<0.01); (***; p<0.001); (****: p<0.0001). Matching data for levels of ATP in HKCC after 
treatment with TVX (C) or with LVX (D) in the presence or absence of LPS found that relative 
to no LPS control, LPS significantly increases ATP levels for LVX and significantly decreases 
ATP for low TVX concentrations. ATP statistics were done by 2-way ANOVA with 
Bonferroni’s post-test to compare no LPS to LPS (*: p<0.05); (**: p<0.01) ;( ***, p<0.001); 
(****: p<0.0001). 
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Figure 5. Effects of 1 µM and 10 µM HC on Cyp3A activity and IL-6/TNF-α levels in 
HKCCs. HKCCs were exposed to 1 or 10 µM HC briefly (~2 hr) at plating or for 24 hr, and 
then were treated with 1 μg/mL LPS, 50 μM TVX and/or respective controls for 48 hr. Cyp3A 
activity was assessed (A, 1 µM HC; D, 10 µM HC) and media was collected and frozen for 
IL-6 (B, 1 µM HC; E, 10 µM HC) and TNF-α (C, 1 µM HC; F, 10 µM HC) analyses as 
described in Materials and Methods.  
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Figure 6. Gene expression in HKCC after exposure to 1 or 10 µM HC. HKCC were 
exposed to 1 or 10 µM HC briefly (~2 hr) at plating or for 24 hr, and then were treated with 1 
μg/mL LPS and 50 μM TVX and/or respective controls for 48 hr. Panels A-D represent levels 
of gene expression after 1 µM HC exposure, E-H after 10 µM HC exposure. Crp expression is 
shown in panels A and E,  Nos2 in B and F, Tat in C and G,  and  Alb in D and H.  
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Figure 7. Effects of known hepatotoxic compounds on Cyp3A activity and IL-6/TNF-α 
levels in mono-cultures of hepatocytes with or without LPS. Data expressed as % +/- LPS 
controls. 24 hr post-plating, hepatocytes were treated with varying doses of TVX (A,B), APAP 
(C,D), TCS (E,F), acetochlor (G,H), propiconazole (I,J), or allyl alcohol (K,L)  with or without 
1 μg/mL LPS for 48 hr. Cyp3A activity was assessed  and media was collected and frozen for 
IL-6 and TNF-α analyses as described in Materials and Methods. Data are representative of a 
single experiment and expressed as a percentage of the respective LPS-free or LPS-containing 
vehicle controls as shown on y-axis. * = toxicity evident in in photomicrographs or ATP studies 
for this compound (data not shown). 
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Figure 8. Effects of known hepatotoxic compounds on Cyp3A activity and IL-6/TNF-α 
levels in HKCCs with or without LPS. Data expressed as % of +/- LPS controls. HKCC were 
treated with varying doses of TVX (A,B), APAP (C,D), TCS (E,F), acetochlor (G,H), 
propiconazole (I,J), or allyl alcohol (K,L)  with or without 1 μg/mL LPS for 48 hr. Cyp3A 
activity was assessed  and media was collected and frozen for IL-6 and TNF-α analyses as 
described in Materials and Methods. Data are representative of a single experiment and 
expressed as a percentage of the respective LPS-free or LPS-containing vehicle controls as 
shown on y-axis. * = toxicity evident in in photomicrographs or ATP studies for this compound 
(data not shown). 
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Supplementary Figure 1. Immunofluorescent imaging of HKCCs. Representative HKCCs 
(1:2 KC to hepatocyte) on day 3 of culture in the absence (A,C) and presence (B,D) of LPS 
stimulation for 48 hr. A, No LPS control: CD68 positive KC (green) and nuclei (blue). B, LPS-
treated: CD68 positive KC (green) and nuclei (blue); C, No LPS: Overlay of phase contrast 
and GFP channel; D, LPS-treated: Overlay of phase contrast and GFP channel, demonstrating 
LPS-induced KC localization to hepatocyte junctions. 
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Supplementary Figure 2. Effect of maintenance medium formulation on hepatocyte 
morphology in HKCCs. Hepatocyte mono-cultures and HKCC were cultured for 48 hr 
without LPS in four different types of maintenance media. Photo-micrographs depict the 
corresponding non-stimulated HKCCs on culture day 3 in various medium formulations:  A, 
MCM; B, A-DMEM; C, WEM; D, HMM (original magnification, 100x).  Arrows indicate 
areas of cell morphology distortion and lack of proper attachment.  
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Supplementary Figure 3. Effects of Dex supplementation in hepatocyte and KC plating 
medium on HKCC morphology. Photo-micrographs (A-D) depict the long-term effects of 
Dex (20 nM) in hepatocyte plating medium only (original magnification, 100x).  Arrows 
indicate areas of cell distortion and lack of proper attachment. 
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Supplementary Figure 4. Effects of HC supplementation on HKCC morphology. Co-
cultures were plated in 1 µM HC for ~ 2 hr (A) or 24 hr (B), or in 10 µM HC for ~2 hr (C) or 
24 hr (D), or no HC (E). HCCCs shown were not treated with LPS or other compounds. 
Cultures are shown 48 hr after initiation of treatment, and therefore are 72 hr post-plating. 
Original magnification, 200x.  
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Table 1. Effects of dexamethasone (20 nM) in hepatocyte plating medium on subsequent 
HKCC cytokine release.  
 
 
 
- Dex + Dex - Dex + Dex
16.6 ± 6.5 3.0 ± 2.0
a TNF-α 547.65 ± 311.3 16.0 ± 5.2
384.25 ± 47.6 ND IL-6 1981.1 ± 130.9 ND
5.7 ± 0.9
a
6.6 ± 1.4
a GM-CSF 115.9 ± 12.1 ND
1.0 ± 3.8
a ND INF-γ 12.2 ± 34.4 ND
ND ND IL-1α 148.78 ± 38.0 ND
20.3 ± 1.4
a
6.4 ± 3.1
a IL-1β 135.1 ± 26.1 7.0 ± 0.7a
93.2 ± 2.1 41.6 ± 0.9
a IL-2 381.5 ± 11.6 48.4 ± 1.4
a
0.4 ± 1.3
a
0.4 ± 0.5
a IL-4 0.4 ± 0.9
a
0.4 ± 0.6
a
55.2 ± 1.3
a
65.6 ± 2.7
a IL-10 162.83 ± 5.1 117.3 ± 2.1
23.3 ± 1.1
a
22.0 ± 0.8
a IL-12 203.1 ± 8.9 6.0 ± 0.5
a
No LPS Activation LPS ActivationAnalyte
(pg/mL)
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Supplementary Table 1. Use of hepatocyte monocultures for screening effects of compounds 
on Cyp3A activity and IL-6/TNF-α levels, data expressed as units of luciferin (nM), IL-6 or 
TNF- α (both pg/ml). 24 hr post-plating, hepatocytes were treated with varying doses of 1A, 
TVX, APAP, TCS , Acetachlor, propiconazole, or 1B, allyl alcohol  with or without 1 μg/mL 
LPS for 48 hr. Cyp3A activity was assessed and media was collected and frozen for IL-6 and 
TNF-α analysis as described in Materials and Methods.  
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Supplementary Table 1A. 
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Supplementary Table 1B. 
 
  
Conc LPS Mean SD Mean SD Mean SD
0 - 10.72 0.69 489.22 28.17 71.73 10.31
0 + 9.50 1.50 521.23 21.94 75.80 1.50
6.25 - 10.76 0.83 492.94 27.05 66.61 10.54
6.25 + 9.88 1.23 586.44 18.09 66.83 4.81
12.5 - 11.96 1.05 513.80 72.95 68.25 6.64
12.5 + 10.02 0.73 540.52 5.80 58.50 1.74
25 - 11.33 0.94 548.32 7.10 61.65 0.25
25 + 9.01 0.00 551.86 35.50 78.98 16.09
50 - 10.69 1.50 495.40 92.43 67.47 2.07
50 + 8.26 0.64 575.69 44.40 67.47 2.07
100 - 1.61 1.64 534.00 82.61 70.04 3.40
100 + 0.19 0.00 599.53 57.16 73.87 2.23
200 - 0.19 0.00 489.52 40.42 65.92 19.19
200 + 0.00 0.00 665.25 152.67 58.96 12.59
400 - 0.23 0.27 453.39 97.05 70.46 10.27
400 + 0.26 0.04 480.43 7.08 60.94 11.72
IL-6 TNF-α
Allyl Alcohol
(Luciferin, nM) pg/ml pg/ml
CYP3A
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Supplementary Table 2. Use of HKCC for screening effects of compounds on Cyp3A activity 
and IL-6/TNF-α levels, data expressed as units of luciferin (nM), IL-6 or TNF- α (both pg/ml). 
24 hr post-plating, HKCC were treated with varying doses of 2A, TVX, APAP, TCS , 
Acetachlor , propiconazole, or 2B, allyl alcohol  with or without 1 μg/mL LPS for 48 hr. Cyp3A 
activity was assessed and media was collected and frozen for IL-6 and TNF-α analysis as 
described in Materials and Methods. 
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Supplementary Table 2A. 
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Supplementary Table 1B. 
 
 
Conc LPS Mean SD Mean SD Mean SD
0 - 7.66 0.44 632.41 21.63 67.48 0.21
0 + 4.21 0.83 1645.39 500.35 145.77 3.46
6.25 - 7.01 0.91 653.20 4.90 77.70 24.91
6.25 + 3.68 0.05 1682.78 221.82 156.58 7.61
12.5 - 6.39 1.12 680.58 110.09 59.70 0.80
12.5 + 3.25 1.01 1663.95 383.13 150.40 23.43
25 - 6.04 0.31 623.34 83.60 71.35 0.92
25 + 3.32 0.56 1730.74 264.13 140.37 12.46
50 - 5.49 0.42 645.36 52.95 72.80 1.21
50 + 2.47 0.32 1959.00 216.86 146.42 4.08
100 - 2.54 0.00 557.21 60.85 83.61 14.29
100 + 1.85 2.02 635.66 125.48 86.77 28.82
200 - 0.19 0.00 500.11 9.07 61.62 3.73
200 + 0.08 0.06 566.31 95.58 67.39 5.64
400 - 0.14 0.03 453.80 13.04 57.61 5.67
400 + 0.17 0.07 596.27 74.90 52.32 2.91
(Luciferin, nM) pg/ml pg/ml
CYP3A
Allyl Alcohol
IL-6 TNF-α
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